



# **STIC Search Report**

## **Biotech-Chem Library**

**STIC Database Tracking Number:** 104777

**TO: Rita Mitra**  
**Location: CM1/9B03/9B01**  
**Art Unit: 1653**  
**Monday, September 29, 2003**

**Case Serial Number: 09/887855**

**From: Alex Waclawiw**  
**Location: Biotech-Chem Library**  
**CM1-6A02**  
**Phone: 308-4491**

**Alexandra.waclawiw@uspto.gov**

### **Search Notes**

## SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name RITA MITRA Examiner # 77995 Date: 9/23/03  
An Unit 1653 Phone Number 301 605-1211 Serial Number 09/887855  
Mail Box and Bldg/Room Location 9801 CMI/ Rm 9803 Results Format Preferred (circle) PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. ME

\*\*\*\*\*  
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention "Lectin SS3939 DNA and Polypeptides"  
Inventors (please provide full names): ANDERSON, DIRK M.

Earliest Priority Filing Date: December 23, 1998

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

I would request an expedited literature search (Patent and Non-patent both) on above application because this is a date case. No Seq Search

The search should cover a polypeptide termed "SS3939" that can be used as has use for peptide fragmentation study, molecular weight measurement and for use in protein sequencing using tandem mass spectrometry.

Keywords:Lectin, sugar-binding protein, Lectin domainElected claims: claims 3, 4, 5 & 12

C. Chan  
[Signature]

STAFF USE ONLY  
Point of Contact:  
Alexandra Wacławiw  
Technical Info. Specialist  
CM1 8A02 Tel: 308-4491

Searcher Phone # \_\_\_\_\_

Searcher Location \_\_\_\_\_

Date Searcher Assigned 9-29-03Date Entered 9-29-03

Searcher Prep &amp; Review Time \_\_\_\_\_

Client Prep Time 8On Hold Time 21

## Type of Search

NA Sequence (#) \_\_\_\_\_

AA Sequence (#) \_\_\_\_\_

Structure (#) \_\_\_\_\_

Bibliographic ☒

Litigation \_\_\_\_\_

Fulltext \_\_\_\_\_

Patent Family \_\_\_\_\_

Other \_\_\_\_\_

## Vendors and cost where applicable

STN \$ 135.00

Dialog \_\_\_\_\_

Questel Orbit \_\_\_\_\_

On Line \_\_\_\_\_

Lexis Nexis \_\_\_\_\_

Sequence Systems \_\_\_\_\_

WWW Internet \_\_\_\_\_

Other (specify) \_\_\_\_\_

=> fil hcaplus wpids biosis medline embase  
 FILE 'HCAPLUS' ENTERED AT 07:45:10 ON 29 SEP 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 07:45:10 ON 29 SEP 2003  
 COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 07:45:10 ON 29 SEP 2003  
 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 07:45:10 ON 29 SEP 2003

FILE 'EMBASE' ENTERED AT 07:45:10 ON 29 SEP 2003  
 COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

=> d his l1-l12

(FILE 'HCAPLUS, WPIDS, BIOSIS, MEDLINE, EMBASE' ENTERED AT 07:36:20 ON 29 SEP 2003)

L1 4 S SS3939 OR SS 3939  
 L2 1 S (SS3939 OR SS 3939)/AB  
 L3 4 S L1 OR L2  
 L4 3 DUP REM L3 (1 DUPLICATE REMOVED)  
 L5 25589 S CHROMOSOME (3A) 11  
 L6 33 S L5 AND LECTIN#  
 L7 2744383 S (DNA OR NUCLEIC ACID# OR CDNA)  
 L8 22 S L6 AND L7  
 L9 579390 S PROTEIN (2W) SEQUEN? OR POLYPEPTIDE#  
 L10 13 S L8 AND L9  
 L11 12 DUP REM L10 (1 DUPLICATE REMOVED)  
 L12 11 S L11 NOT L4

~~=> d bib abi it 14 1-3;d bib ab it l12 1-11  
 'ABI' IS NOT A VALID FORMAT FOR FILE 'HCAPLUS'  
 ENTER DISPLAY FORMAT (BIB):end  
 => d bib ab it 14 1-3;d bib ab it l12 1-11~~

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2001:868629 HCAPLUS  
 DN 136:15957  
 TI Human nucleic acids and their encoded proteins and antibodies  
 IN Birse, Charles E.; Rosen, Craig A.  
 PA Human Genome Sciences, Inc., USA  
 SO PCT Int. Appl., 2081 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 91

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090304	A2	20011129	WO 2001-US16450	20010518
	WO 2001090304	A3	20020510		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001041411 A5 20010820 AU 2001-41411 20010208  
AU 2001074888 A5 20011203 AU 2001-74888 20010518

PRAI US 2000-205515P P 20000519  
US 2000-241221P P 20001020  
US 2000-241786P P 20001020  
WO 2001-US16450 W 20010518

AB The present invention relates to 1405 novel human polynucleotides and the polypeptides encoded by these polynucleotides and the use of the polypeptides for detecting disorders. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compns. for inhibiting the prodn. and function of the polypeptides of the present invention.

IT Genetic mapping  
(chromosomal; human nucleic acids and their encoded proteins and antibodies)

IT Animal tissue  
(expression patterns in; human nucleic acids and their encoded proteins and antibodies)

IT Genetic methods  
(gene discovery; human nucleic acids and their encoded proteins and antibodies)

IT Disease, animal  
Drug screening  
Drugs  
Epitopes  
Gene therapy  
Molecular cloning  
Protein sequences  
Susceptibility (genetic)  
cDNA sequences

(human nucleic acids and their encoded proteins and antibodies)

IT Proteins  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(human nucleic acids and their encoded proteins and antibodies)

IT Antibodies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(human nucleic acids and their encoded proteins and antibodies)

IT Diagnosis  
(mol.; human nucleic acids and their encoded proteins and antibodies)

IT 160405-33-4P 161477-24-3P 161736-58-9P, Protein (human 233-amino acid)  
169445-07-2P 183682-27-1P, Cellubrevin 2 (human clone 122826)  
185229-04-3P 207353-75-1P 208668-41-1P 208668-48-8P 208668-49-9P  
208668-57-9P 210165-58-5P 210167-80-9P 210478-13-0P, Receptor (human clone HTPEF86) 211304-23-3P, Membrane protein (human gene NHMP1)  
212704-82-0P 212705-37-8P 212705-78-7P 212774-49-7P 212836-76-5P  
212837-30-4P 212837-90-6P 212838-06-7P 212838-42-1P 212838-47-6P  
212838-55-6P 213468-10-1P 213471-68-2P, Protein BBP (human heart Bak binding) 213826-65-4P 220104-93-8P, Protein DC3 (human dendritic



cells) 220239-21-4P 220483-85-2P 220705-63-5P 221369-70-6P  
 221369-74-0P 221877-49-2P 222536-56-3P 222614-91-7P 223607-53-2P  
 224301-63-7P 224564-82-3P 225372-08-7P 225372-14-5P 226934-74-3P  
 227289-57-8P 227792-85-0P 228249-96-5P 229477-09-2P 229486-90-2P  
 229965-62-2P 229965-63-3P 230288-83-2P 231285-13-5P 233674-74-3P  
 235087-94-2P 235088-03-6P 242462-91-5P 242463-31-6P 242795-93-3P  
 242795-95-5P 243122-35-2P 246034-21-9P 249560-68-7P, Protein  
 SBHUNC50 (human) 249907-53-7P 249909-42-0P 250154-03-1P  
 250154-96-2P 250246-75-4P, Receptor (human Incyte clone 2132179)  
 250367-18-1P 251929-01-8P 251929-16-5P 251929-64-3P 251929-75-6P  
 251929-91-6P 252196-58-0P 252197-14-1P 252298-99-0P 252365-96-1P  
 252366-99-7P 253418-81-4P 253418-82-5P 253418-83-6P 253579-85-0P  
 255700-56-2P 255889-03-3P 255889-10-2P 255889-22-6P 256501-75-4P,  
 Membrane protein (human gene C14orf1) 257259-23-7P 257854-53-8P  
 257854-56-1P 259161-25-6P 259163-54-7P 259163-78-5P 260535-23-7P  
 261345-75-9P 264867-37-0P 271231-71-1P, Mannosyltransferase (human  
 gene Hmat-1) 271753-06-1P 271753-24-3P 280786-68-7P, Protein  
 ss3939 (human) 284690-25-1P 292889-88-4P, Protein (human gene  
 YME1L) 294899-00-6P 296284-70-3P 299466-63-0P, Protein CGI-61  
 (human) 300424-58-2P 300596-32-1P 300601-48-3P 300609-42-1P  
 302873-46-7P 304029-28-5P 309763-61-9P 312542-13-5P 312655-45-1P  
 314016-49-4P 316925-26-5P 320644-28-8P 321453-17-2P 322014-56-2P  
 322485-59-6P 326627-73-0P 326833-56-1P 326837-07-4P, Protein (human  
 clone NT2RM2001319) 326838-97-5P, Protein (human clone PLACE1009020)  
 326930-17-0P, Protein (human clone PLACE1009338) 326936-52-1P, Protein  
 (human clone PLACE1001351) 326943-97-9P, Protein (human clone  
 NT2RP3002033) 327111-80-8P, Protein (human clone NT2RM4001731)  
 330603-88-8P 335365-16-7P 339144-09-1P 339602-87-8P 339615-07-5P  
 340050-74-0P 340324-01-8P, Protein HSPC239 (human clone CBMAMB04)  
 340838-22-4P 341066-14-6P 343901-81-5P 343901-86-0P 343906-62-7P  
 344489-25-4P 344489-55-0P 352375-92-9P 352377-74-3P 352380-47-3P  
 352380-70-2P 352383-45-0P 352396-03-3P 352396-30-6P 352815-91-9P  
 352820-65-6P, Enzyme (human clone HELDW45 fragment) 355027-11-1P,  
 Protein (human clone 787CIP2\_123) 360154-33-2P 362068-78-8P  
 372205-06-6P 372539-77-0P 373393-35-2P, MS4A4A protein (human)  
 377094-08-1P, Protein (human clone HCFNH88) 377094-09-2DP, Protein  
 (human clone HODDW37), qqq 377094-10-5P, Protein (human clone HPMFI38)  
 377094-11-6P, Protein (human clone HLTDP38) 377094-12-7P, Protein (human  
 clone HMHBT30) 377094-13-8P, Protein (human clone HFCBA57)  
 377094-14-9P, Protein (human clone HSRAL33) 377094-15-0P, Protein (human  
 clone HSSMQ84) 377094-16-1P, Protein (human clone HUKAB82)  
 377094-17-2P, Protein (human clone HDPPP46) 377094-18-3P, Protein (human  
 clone HMTME11) 377094-19-4P, Protein (human clone HBMUK46)  
 377094-20-7P, Protein (human clone HETDT70) 377094-21-8P, Protein (human  
 clone HMKAD85) 377094-22-9P, Protein (human clone HE9NE12)  
 377094-23-0P, Protein (human clone HE2AX73) 377094-24-1P, Protein (human  
 clone HHGBV89) 377094-25-2P, Protein (human clone HTTDC06)  
 377094-26-3P, Protein (human clone HFXKR35) 377094-27-4P, Protein (human  
 clone HHSDL85) 377094-28-5P, Protein (human clone HTECA32)  
 377094-29-6P, Protein (human clone HTEHL79) 377094-30-9P, Protein (human  
 clone HPJBL54) 377094-31-0P, Protein (human clone HSDDD20)  
 377094-32-1P, Protein (human clone HCUCG74) 377094-33-2P, Protein (human  
 clone HFIXK94) 377094-34-3P, Protein (human clone HPJAV46)  
 377094-35-4P, Protein (human clone HTTDL61) 377094-36-5P, Protein (human  
 clone HFPBN94) 377094-37-6P, Protein (human clone HYBBG69)  
 377094-38-7P, Protein (human clone HDPOJ05) 377094-39-8P, Protein (human  
 clone HMAGF64) 377094-40-1P, Protein (human clone HACCO38)  
 377094-41-2P, Protein (human clone HRAAM31) 377094-42-3P, Protein (human  
 clone HWDAA03) 377094-43-4P, Protein (human clone HTHCV60)  
 377094-44-5P, Protein (human clone HTLEV17) 377094-45-6P, Protein (human

clone HCFAB91) 377094-46-7P, Protein (human clone HMWEE18)  
 377094-47-8P, Protein (human clone HTLAI85) 377094-48-9P, Protein (human  
 clone HHPGQ38) 377094-49-0P, Protein (human clone HNGER82)  
 377094-50-3P, Protein (human clone HBJLU13) 377094-51-4P, Protein (human  
 clone HCFDC55) 377094-52-5P, Protein (human clone HFKCT25)  
 377094-53-6P, Protein (human clone HAPOW05) 377094-54-7P, Protein (human  
 clone HCUFP05) 377094-55-8P, Protein (human clone HE8CX53)  
 377094-56-9P, Protein (human clone HCENB31) 377094-57-0P, Protein (human  
 clone H7TME55) 377094-58-1P, Protein (human clone HDHMA49)  
 377094-59-2P, Protein (human clone H BXBG68) 377094-60-5P, Protein  
 (human clone H GBFC53) 377094-61-6P, Protein (human clone HPMCK47)  
 377094-62-7P, Protein (human clone HAPNX53) 377094-63-8P, Protein (human  
 clone HOFAE02) 377094-64-9P, Protein (human clone HSLIQ83)  
 377094-65-0P, Protein (human clone HNTMD04) 377094-66-1P, Protein (human  
 clone HRABY48) 377094-67-2P, Protein (human clone HDDAA17)  
 377094-68-3P, Protein (human clone HTRAC41) 377094-69-4P, Protein (human  
 clone HOSCV06) 377094-70-7P, Protein (human clone HMCHS27)  
 377094-71-8P, Protein (human clone HEMFC09) 377094-72-9P, Protein (human  
 clone HNTRJ16) 377094-73-0P, Protein (human clone HKAEJ09)  
 377094-74-1P, Protein (human clone HKMMS65) 377094-75-2P, Protein (human  
 clone HNHGE09) 377094-76-3P, Protein (human clone HTTCT34)  
 377094-77-4P, Protein (human clone HBIAS14) 377094-78-5P, Protein (human  
 clone HLHSC60) 377094-79-6P, Protein (human clone HKMAA36)  
 377094-80-9P, Protein (human clone HLTFA02) 377094-81-0P, Protein (human  
 clone HSBBC07)

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,  
 unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical  
 study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; human nucleic acids and their encoded proteins  
 and antibodies)

IT 377094-82-1P, Protein (human clone HL2AE73) 377094-83-2P, Protein (human  
 clone HE20O57) 377094-84-3P, Protein (human clone HEEAR13)  
 377094-85-4P, Protein (human clone HFTYL13) 377094-86-5P, Protein (human  
 clone HLWBH14) 377094-87-6P, Protein (human clone HATDW51)  
 377094-88-7P, Protein (human clone HDPWQ69) 377094-89-8P, Protein (human  
 clone HNTBM67) 377094-90-1P, Protein (human clone HAIDY03)  
 377094-91-2P, Protein (human clone HDPDO12) 377094-92-3P, Protein (human  
 clone HAGHC45) 377094-93-4P, Protein (human clone HNTNT65)  
 377094-94-5P, Protein (human clone HTTAA50) 377094-95-6P, Protein (human  
 clone HAGBX32) 377094-96-7P, Protein (human clone HHTMM18)  
 377094-97-8P, Protein (human clone HHFGR08) 377094-98-9P, Protein (human  
 clone HHBEU19) 377094-99-0P, Protein (human clone HWBBB21)  
 377095-00-6P, Protein (human clone HMMAV06) 377095-01-7P, Protein (human  
 clone HISAM25) 377095-02-8P, Protein (human clone HRODX93)  
 377095-03-9P, Protein (human clone HCFMJ37) 377095-04-0P, Protein (human  
 clone HMWAP17) 377095-05-1P, Protein (human clone HMCFA76)  
 377095-06-2P, Protein (human clone HTHCM28) 377095-07-3P, Protein (human  
 clone HHEDB45) 377095-08-4P, Protein (human clone HTACX15)  
 377095-09-5P, Protein (human clone HFIZN55) 377095-10-8P, Protein (human  
 clone HCE1U38) 377095-11-9P, Protein (human clone HNFIL36)  
 377095-12-0P, Protein (human clone HSKZB03) 377095-13-1P, Protein (human  
 clone HNTMZ26) 377095-14-2P, Protein (human clone HNENC76)  
 377095-15-3P, Protein (human clone HHSGJ30) 377095-16-4P, Protein (human  
 clone HJKSC77) 377095-17-5P, Protein (human clone HDABD32)  
 377095-18-6P, Protein (human clone HWACC64) 377095-19-7P, Protein (human  
 clone HSDIJ72) 377095-20-0P, Protein (human clone HSLGO34)  
 377095-21-1P, Protein (human clone HTOJF39) 377095-22-2P, Protein (human  
 clone HPDEF35) 377095-23-3P, Protein (human clone HFIAW95)  
 377095-24-4P, Protein (human clone HMEIU36) 377095-25-5P, Protein (human  
 clone HHEDM89) 377095-26-6P, Protein (human clone HKABW60)

377095-27-7P, Protein (human clone HWLFB40)	377095-28-8P, Protein (human clone HDTDW40)
377095-29-9P, Protein (human clone HEAAK34)	377095-30-2P, Protein (human clone HLWAH41)
377095-31-3P, Protein (human clone HHSFI89)	377095-32-4P, Protein (human clone HSAVI33)
377095-33-5P, Protein (human clone HMJAX17)	377095-34-6P, Protein (human clone HLJDZ45)
377095-35-7P, Protein (human clone HAHBC57)	377095-36-8P, Protein (human clone HLYDR60)
377095-37-9P, Protein (human clone HCHMQ09)	377095-38-0P, Protein (human clone HADMD75)
377095-39-1P, Protein (human clone HKADW47)	377095-40-4P, Protein (human clone HFAUL30)
377095-41-5P, Protein (human clone HKADD23)	377095-42-6P, Protein (human clone HE8MO09)
377095-43-7P, Protein (human clone HE8FL67)	377095-44-8P, Protein (human clone HEOOA49)
377095-45-9P, Protein (human clone HMSJH49)	377095-46-0P, Protein (human clone HARAX45)
377095-47-1P, Protein (human clone HDTES50)	377095-48-2P, Protein (human clone HKGBC30)
377095-49-3P, Protein (human clone HKIXO37)	377095-50-6P, Protein (human clone HEQBJ81)
377095-51-7P, Protein (human clone HAGES18)	377095-52-8P, Protein (human clone HHSBV20)
377095-53-9P, Protein (human clone HNECD55)	377095-54-0P, Protein (human clone HRAAO53)
377095-55-1P, Protein (human clone HDPGD34)	377095-56-2P, Protein (human clone HLYBU12)
377095-57-3P, Protein (human clone HEONV59)	377095-58-4P, Protein (human clone HE8DF23)
377095-59-5P, Protein (human clone HOECO53)	377095-60-8P, Protein (human clone HNLER32)
377095-61-9P, Protein (human clone HNFJE71)	377095-62-0P, Protein (human clone HMSHT01)
377095-63-1P, Protein (human clone HSLHL67)	377095-64-2P, Protein (human clone HAPQM57)
377095-65-3P, Protein (human clone HCEMF51)	377095-66-4P, Protein (human clone HSLJK58)
377095-67-5P, Protein (human clone HCHCI12)	377095-68-6P, Protein (human clone HTHCV59)
377095-69-7P, Protein (human clone HCHCI12)	377095-70-0P, Protein (human clone HTHCV59)
377095-71-1P, Protein (human clone HCHCI12)	377095-72-2P, Protein (human clone HCHCI12)
377095-73-3P, Protein (human clone HCHCI12)	377095-74-4P, Protein (human clone HCHCI12)
377095-75-5P, Protein (human clone HCHCI12)	377095-76-6P, Protein (human clone HCHCI12)
377095-77-7P, Protein (human clone HCHCI12)	377095-78-8P, Protein (human clone HCHCI12)
377095-79-9P, Protein (human clone HCHCI12)	377095-80-2P, Protein (human clone HCHCI12)
377095-81-3P, Protein (human clone HCHCI12)	377095-82-4P, Protein (human clone HCHCI12)
377095-83-5P, Protein (human clone HCHCI12)	377095-84-6P, Protein (human clone HCHCI12)
377095-85-7P, Protein (human clone HCHCI12)	377095-86-8P, Protein (human clone HCHCI12)
377095-87-9P, Protein (human clone HCHCI12)	377095-88-0P, Protein (human clone HCHCI12)
377095-89-1P, Protein (human clone HCHCI12)	377095-90-4P, Protein (human clone HCHCI12)
377095-91-5P, Protein (human clone HCHCI12)	377095-92-6P, Protein (human clone HCHCI12)
377095-93-7P, Protein (human clone HCHCI12)	377095-94-8P, Protein (human clone HCHCI12)
377095-95-9P, Protein (human clone HCHCI12)	377095-96-0P, Protein (human clone HCHCI12)
377095-97-1P, Protein (human clone HCHCI12)	377095-98-2P, Protein (human clone HCHCI12)
377095-99-3P, Protein (human clone HCHCI12)	377095-99-3P, Protein (human clone HCHCI12)
377096-00-9P, Protein (human clone HCHCI12)	377096-01-0P, Protein (human clone HCHCI12)
377096-02-1P, Protein (human clone HCHCI12)	377096-03-2P, Protein (human clone HCHCI12)
377096-04-3P, Protein (human clone HCHCI12)	377096-05-4P, Protein (human clone HCHCI12)
377096-06-5P, Protein (human clone HCHCI12)	377096-07-6P, Protein (human clone HCHCI12)
377096-08-7P, Protein (human clone HCHCI12)	377096-09-8P, Protein (human clone HCHCI12)
377096-10-1P, Protein (human clone HCHCI12)	377096-11-2P, Protein (human clone HCHCI12)
377096-12-3P, Protein (human clone HCHCI12)	377096-13-4P, Protein (human clone HCHCI12)
377096-14-5P, Protein (human clone HCHCI12)	377096-15-6P, Protein (human clone HCHCI12)
377096-16-7P, Protein (human clone HCHCI12)	377096-16-7P, Protein (human clone HCHCI12)

377096-17-8P, Protein (human clone HRACE71) 377096-18-9P, Protein (human clone HADGC71) 377096-19-0P, Protein (human clone HSXFL85)  
 377096-20-3P, Protein (human clone HNGDQ71) 377096-21-4P, Protein (human clone HTOJT28) 377096-22-5P, Protein (human clone HSDZF13)  
 377096-23-6P, Protein (human clone HTOBH39) 377096-24-7P, Protein (human clone HE9RP73) 377096-25-8P, Protein (human clone HSXDG07)  
 377096-26-9P, Protein (human clone HDPHG57) 377096-27-0P, Protein (human clone HGBAD15) 377096-28-1P, Protein (human clone HOEEP07)  
 377096-29-2P, Protein (human clone HFIHT50) 377096-30-5P, Protein (human clone HPMGQ75) 377096-31-6P, Protein (human clone HBJJH66)  
 377096-32-7P, Protein (human clone HEGBB78) 377096-33-8P, Protein (human clone HAJBC01) 377096-34-9P, Protein (human clone HHGCP75)  
 377096-35-0P, Protein (human clone HAIDO95) 377096-36-1P, Protein (human clone HE8UD19) 377096-37-2P, Protein (human clone HMAIT58)  
 377096-38-3P, Protein (human clone HDAAE77) 377096-39-4P, Protein (human clone HKAOJ07) 377096-40-7P, Protein (human clone HDTFC73)  
 377096-41-8P, Protein (human clone HDTFI32) 377096-42-9P, Protein (human clone HLQCY70) 377096-43-0P, Protein (human clone HELDG78)  
 377096-44-1P, Protein (human clone HAGEK19) 377096-45-2P, Protein (human clone H2CBA34) 377096-46-3P, Protein (human clone HDPTC79)  
 377096-47-4P, Protein (human clone HTHBY73) 377096-48-5P, Protein (human clone HE8DL19) 377096-49-6P, Protein (human clone HMEGE46)  
 377096-50-9P, Protein (human clone HTEIA85) 377096-51-0P, Protein (human clone HLYCQ80) 377096-52-1P, Protein (human clone HE2OF81)  
 377096-53-2P, Protein (human clone HTEBB88) 377096-54-3P, Protein (human clone HWHGD82) 377096-55-4P, Protein (human clone HWADH67)  
 377096-56-5P, Protein (human clone HKADC82) 377096-57-6P, Protein (human clone HHESK83) 377096-58-7P, Protein (human clone HMJAT16)  
 377096-59-8P, Protein (human clone HSLJK83) 377096-60-1P, Protein (human clone HADFW62) 377096-61-2P, Protein (human clone HDTBV64)  
 377096-62-3P, Protein (human clone HOHBR65) 377096-63-4P, Protein (human clone HRABZ84) 377096-64-5P, Protein (human clone HKABD18)  
 377096-65-6P, Protein (human clone HUFAJ06) 377096-66-7P, Protein (human clone HDQFV46) 377096-67-8P, Protein (human clone HMEKH64)  
 377096-68-9P, Protein (human clone HTLEE85) 377096-69-0P, Protein (human clone HCE4Q82) 377096-70-3P, Protein (human clone HODEC95)  
 377096-71-4P, Protein (human clone HCBBA47) 377096-72-5P, Protein (human clone HSKEQ61) 377096-73-6P, Protein (human clone HWEAC64) 377096-74-7P, Protein (human clone HSDFQ43) 377096-75-8P, Protein (human clone HMHBN86)  
 377096-76-9P, Protein (human clone HLTAZ78) 377096-77-0P, Protein (human clone HLDBM50) 377096-78-1P, Protein (human clone HHEDH33)  
 377096-79-2P, Protein (human clone HAIDL86) 377096-80-5P, Protein (human clone HTEPF14) 377096-81-6P, Protein (human clone HOEDD04)  
 377096-82-7P, Protein (human clone HODBK89) 377096-83-8P, Protein (human clone HMUAZ89) 377096-84-9P, Protein (human clone HSBBS92)  
 377096-85-0P, Protein (human clone HHBGJ75) 377096-86-1P, Protein (human clone HDPRY23) 377096-87-2P, Protein (human clone HBBBC20)  
 377096-88-3P, Protein (human clone HMELW08) 377096-89-4P, Protein (human clone HTPDL90) 377096-90-7P, Protein (human clone HTACZ08)  
 377096-91-8P, Protein (human clone HAGEC91) 377096-92-9P, Protein (human clone HTTCB23) 377096-93-0P, Protein (human clone HYAAL21)  
 377096-94-1P, Protein (human clone HTLHY91) 377096-95-2P, Protein (human clone HUTAD91) 377096-96-3P, Protein (human clone HKGDE58)  
 377096-97-4P, Protein (human clone HBIAW78) 377096-98-5P, Protein (human clone HTOIC11) 377096-99-6P, Protein (human clone HNTRM40)  
 377097-00-2P, Protein (human clone HSKAY30) 377097-01-3P, Protein (human clone HSSJN12) 377097-02-4P, Protein (human clone HTFBG93)  
 377097-03-5P, Protein (human clone HCHO084) 377097-04-6P, Protein (human clone HE8OX93) 377097-05-7P, Protein (human clone HOFMV90)  
 377097-06-8P, Protein (human clone HTEFV95) 377097-07-9P,



Protein (human clone HETJA44) 377097-08-0P, Protein (human clone HE3DR93) 377097-09-1P, Protein (human clone HAJBT15) 377097-10-4P, Protein (human clone HDBAD63) 377097-11-5P, Protein (human clone HE8QH85) 377097-12-6P, Protein (human clone HAICU52) 377097-13-7P, Protein (human clone HE6BJ49)

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; human nucleic acids and their encoded proteins and antibodies)

IT 377097-14-8P, Protein (human clone HE8TJ39) 377097-15-9P, Protein (human clone HFTBG92) 377097-16-0P, Protein (human clone HDPBJ94) 377097-17-1P, Protein (human clone HPIAX11) 377097-18-2P, Protein (human clone HBGMW95) 377097-19-3P, Protein (human clone HUSIJ83) 377097-20-6P, Protein (human clone HBGDP38) 377097-21-7P, Protein (human clone HTXEC55) 377097-22-8P, Protein (human clone HFXGI63) 377097-23-9P, Protein (human clone HAMGW19) 377097-24-0P, Protein (human clone HSLDO85) 377097-25-1P, Protein (human clone HDQDF38) 377097-26-2P, Protein (human clone HULAW69) 377097-27-3P, Protein (human clone HE9QK23) 377097-28-4P, Protein (human clone HNTTB36) 377097-29-5P, Protein (human clone HETJG63) 377097-30-8P, Protein (human clone HFIDZ38) 377097-31-9P, Protein (human clone HLMD095) 377097-32-0P, Protein (human clone HSLGA19) 377097-33-1P, Protein (human clone HGBGM53) 377097-34-2P, Protein (human clone HIBCO73) 377097-35-3P, Protein (human clone HDPOM13) 377097-36-4P, Protein (human clone HMEJR75) 377097-37-5P, Protein (human clone HOECE93) 377097-38-6P, Protein (human clone HLHGA65) 377097-39-7P, Protein (human clone HLKDC74) 377097-40-0P, Protein (human clone HDTAV81) 377097-41-1P, Protein (human clone HETIZ34) 377097-42-2P, Protein (human clone HDTJT12) 377097-43-3P, Protein (human clone HSVCA10) 377097-44-4P, Protein (human clone HDFQA53) 377097-45-5P, Protein (human clone HD9PC92) 377097-46-6P, Protein (human clone HMSOU92) 377097-47-7P, Protein (human clone HE8OX52) 377097-48-8P, Protein (human clone HDAAS81) 377097-49-9P, Protein (human clone HPRBB67) 377097-50-2P, Protein (human clone HPIBM51) 377097-51-3P, Protein (human clone HLYFY81) 377097-52-4P, Protein (human clone HDPL068) 377097-53-5P, Protein (human clone HHEUU25) 377097-54-6P, Protein (human clone HNTBH70) 377097-55-7P, Protein (human clone HMIAN37) 377097-56-8P, Protein (human clone HPFDI25) 377097-57-9P, Protein (human clone HCU DM68) 377097-58-0P, Protein (human clone HCFCU33) 377097-59-1P, Protein (human clone HTGCM10) 377097-60-4P, Protein (human clone H2CBH25) 377097-61-5P, Protein (human clone HWLFQ55) 377097-62-6P, Protein (human clone HWLBK80) 377097-63-7P, Protein (human clone HWHQR45) 377097-64-8P, Protein (human clone HTTDO45) 377097-65-9P, Protein (human clone HRGDD63) 377097-66-0P, Protein (human clone HTNBX62) 377097-67-1P, Protein (human clone HLICA76) 377097-68-2P, Protein (human clone HAPOA59) 377097-69-3P, Protein (human clone HLMMX37) 377097-70-6P, Protein (human clone HWLHW64) 377097-71-7P, Protein (human clone HHERA41) 377097-72-8P, Protein (human clone HFXJT43) 377097-73-9P, Protein (human clone HE8CL14) 377097-74-0P, Protein (human clone HLWFJ59) 377097-75-1P, Protein (human clone HAJCQ05) 377097-76-2P, Protein (human clone HAGHC54) 377097-77-3P, Protein (human clone HULAY53) 377097-78-4P, Protein (human clone HD9DL48) 377097-79-5P, Protein (human clone HFKEH50) 377097-80-8P, Protein (human clone HUSXK49) 377097-81-9P, Protein (human clone HELHM15) 377097-82-0P, Protein (human clone HTEJP13) 377097-83-1P, Protein (human clone HDQHB46) 377097-84-2P, Protein (human clone HCETE50) 377097-85-3P, Protein (human clone HDTBO48) 377097-86-4P, Protein (human clone HODGL01) 377097-87-5P, Protein (human clone HE8TO35) 377097-88-6P, Protein (human clone HOHCB06)

377097-89-7P, Protein (human clone HBJNB08)	377097-90-0P, Protein (human clone HHAMF80)
377097-92-2P, Protein (human clone HBWBX66)	377097-93-3P, Protein (human clone HMMBR95)
377097-95-5P, Protein (human clone HMEAD61)	377097-96-6P, Protein (human clone HDTDF94)
377097-98-8P, Protein (human clone HODGZ47)	377097-99-9P, Protein (human clone HOHCE56)
377098-01-6P, Protein (human clone HAJBR52)	377098-02-7P, Protein (human clone HSLEK65)
377098-04-9P, Protein (human clone HOUEA63)	377098-05-0P, Protein (human clone HLWAW36)
377098-07-2P, Protein (human clone HTEPM45)	377098-08-3P, Protein (human clone HTEBP06)
377098-10-7P, Protein (human clone HBUAD85)	377098-11-8P, Protein (human clone HCEIN85)
377098-13-0P, Protein (human clone HHETF37)	377098-14-1P, Protein (human clone HKAAS52)
377098-16-3P, Protein (human clone HTJMJ95)	377098-17-4P, Protein (human clone HTELT78)
377098-19-6P, Protein (human clone HHBCS13)	377098-20-9P, Protein (human clone HAJAT72)
377098-22-1P, Protein (human clone HAGBQ10)	377098-23-2P, Protein (human clone HCRBB73)
377098-25-4P, Protein (human clone HRAEB76)	377098-26-5P, Protein (human clone HPJAO13)
377098-28-7P, Protein (human clone HLQDC55)	377098-29-8P, Protein (human clone HTTJW49)
377098-31-2P, Protein (human clone HLWAR77)	377098-32-3P, Protein (human clone HCE2W33)
377098-34-5P, Protein (human clone HWGQC67)	377098-35-6P, Protein (human clone HFIJC17)
377098-37-8P, Protein (human clone HBGNJ21)	377098-38-9P, Protein (human clone HBGNW78)
377098-40-3P, Protein (human clone HFPCS09)	377098-41-4P, Protein (human clone HAIBB95)
377098-43-6P, Protein (human clone HE8OM63)	377098-44-7P, Protein (human clone HAJAG88)
377098-46-9P, Protein (human clone HHAMA15)	377098-47-0P, Protein (human clone HPJDE45)
377098-49-2P, Protein (human clone HFIHQ53)	377098-50-5P, Protein (human clone HUVFU38)
377098-52-7P, Protein (human clone HKAPB61)	377098-53-8P, Protein (human clone HMEGF05)
377098-55-0P, Protein (human clone HDLBF57)	377098-56-1P, Protein (human clone HE8QT62)
377098-58-3P, Protein (human clone HOUBJ40)	377098-59-4P, Protein (human clone HHEVC06)
377098-61-8P, Protein (human clone HE2SS47)	377098-62-9P, Protein (human clone HTELD06)
377098-64-1P, Protein (human clone HDTPJH06)	377098-65-2P, Protein (human clone HE6CH89)
377098-67-4P, Protein (human clone HWBBZ12)	377098-68-5P, Protein (human clone HDPBI36)
377098-70-9P, Protein (human clone HTYSK68)	377098-71-0P, Protein (human clone HDAAD50)
377098-73-2P, Protein (human clone HCFNG65)	377098-74-3P, Protein (human clone HLMMI85)
377098-76-5P, Protein (human clone HNTNA78)	377098-77-6P, Protein (human clone HOVAN91)
377098-78-7P, Protein (human clone HROAX39)	
377098-80-5P, Protein (human clone HSHCL04)	
377098-83-8P, Protein (human clone HWGAF42)	
377098-86-1P, Protein (human clone HDPHI63)	
377098-89-4P, Protein (human clone HSKYK23)	
377098-92-9P, Protein (human clone HROAX39)	
377098-95-2P, Protein (human clone HISES36)	
377098-98-5P, Protein (human clone HWHHU11)	
377098-101-6P, Protein (human clone HHENF67)	
377098-104-1P, Protein (human clone HSYAD28)	
377098-107-4P, Protein (human clone HAJAV01)	
377098-110-7P, Protein (human clone HSDZN36)	
377098-113-5P, Protein (human clone HHEFI08)	
377098-116-8P, Protein (human clone HAJCL92)	
377098-119-1P, Protein (human clone HPMJG77)	
377098-122-6P, Protein (human clone HDPSB01)	
377098-125-9P, Protein (human clone HPTVF17)	
377098-128-2P, Protein (human clone HE9FI33)	
377098-131-7P, Protein (human clone HAJJCL92)	
377098-134-0P, Protein (human clone HPMJG77)	
377098-137-5P, Protein (human clone HDPSB01)	
377098-140-8P, Protein (human clone HSDZN36)	
377098-143-1P, Protein (human clone HHEFI08)	
377098-146-6P, Protein (human clone HAJCL92)	
377098-149-9P, Protein (human clone HPMJG77)	
377098-152-2P, Protein (human clone HDPSB01)	
377098-155-7P, Protein (human clone HSDZN36)	
377098-158-0P, Protein (human clone HHEFI08)	
377098-161-5P, Protein (human clone HAJCL92)	
377098-164-8P, Protein (human clone HPMJG77)	
377098-167-1P, Protein (human clone HDPSB01)	
377098-170-6P, Protein (human clone HSDZN36)	
377098-173-9P, Protein (human clone HHEFI08)	
377098-176-2P, Protein (human clone HAJCL92)	
377098-179-7P, Protein (human clone HPMJG77)	
377098-182-0P, Protein (human clone HDPSB01)	
377098-185-5P, Protein (human clone HSDZN36)	
377098-188-8P, Protein (human clone HHEFI08)	
377098-191-1P, Protein (human clone HAJCL92)	
377098-194-6P, Protein (human clone HPMJG77)	
377098-197-9P, Protein (human clone HDPSB01)	
377098-200-2P, Protein (human clone HSDZN36)	
377098-203-7P, Protein (human clone HHEFI08)	
377098-206-0P, Protein (human clone HAJCL92)	
377098-209-5P, Protein (human clone HPMJG77)	
377098-212-8P, Protein (human clone HDPSB01)	
377098-215-1P, Protein (human clone HSDZN36)	
377098-218-6P, Protein (human clone HHEFI08)	
377098-221-9P, Protein (human clone HAJCL92)	
377098-224-2P, Protein (human clone HPMJG77)	
377098-227-7P, Protein (human clone HDPSB01)	
377098-230-0P, Protein (human clone HSDZN36)	
377098-233-5P, Protein (human clone HHEFI08)	
377098-236-8P, Protein (human clone H	

377098-79-8P, Protein (human clone HLYER32) 377098-80-1P, Protein (human clone HFPEL47) 377098-81-2P, Protein (human clone HTPIJ41) 377098-82-3P, Protein (human clone HNTNC49) 377098-83-4P, Protein (human clone HLTCO94) 377098-84-5P, Protein (human clone HBIMT77) 377098-85-6P, Protein (human clone HTLIV70) 377098-86-7P, Protein (human clone HFADF33) 377098-87-8P, Protein (human clone HETJQ73) 377098-88-9P, Protein (human clone HAGGV44) 377098-89-0P, Protein (human clone HTTDM15) 377098-90-3P, Protein (human clone HADCY76) 377098-91-4P, Protein (human clone HDPXWS75) 377098-92-5P, Protein (human clone HMCDC50) 377098-93-6P, Protein (human clone HMADZ55) 377098-94-7P, Protein (human clone HTXNB76) 377098-95-8P, Protein (human clone HLWDD49) 377098-96-9P, Protein (human clone HLQGX48) 377098-97-0P, Protein (human clone HLQEF25) 377098-98-1P, Protein (human clone HTOHA37) 377098-99-2P, Protein (human clone HLHAW26) 377099-00-8P, Protein (human clone HKAAZ46) 377099-01-9P, Protein (human clone HAQAF12) 377099-02-0P, Protein (human clone HTXEX35) 377099-03-1P, Protein (human clone HE8TE64) 377099-04-2P, Protein (human clone HL3AC38) 377099-05-3P, Protein (human clone HMUAO31) 377099-06-4P, Protein (human clone HHAWD33) 377099-07-5P, Protein (human clone HTZMB08) 377099-08-6P, Protein (human clone HJBCE86) 377099-09-7P, Protein (human clone HFPCCK56) 377099-10-0P, Protein (human clone HAPSP72) 377099-11-1P, Protein (human clone HACBM44) 377099-12-2P, Protein (human clone HLTEO24) 377099-13-3P, Protein (human clone HHFJP51) 377099-14-4P, Protein (human clone HHFLL87) 377099-15-5P, Protein (human clone HCUDR30) 377099-16-6P, Protein (human clone HHFHI24) 377099-17-7P, Protein (human clone HSIAI48) 377099-18-8P, Protein (human clone HHGBP47) 377099-19-9P, Protein (human clone HKADE35) 377099-20-2P, Protein (human clone HISCV20) 377099-21-3P, Protein (human clone HHEUE88) 377099-22-4P, Protein (human clone HHESR56) 377099-23-5P, Protein (human clone HHENU62) 377099-24-6P, Protein (human clone HE2RG38) 377099-25-7P, Protein (human clone HCEVS49) 377099-26-8P, Protein (human clone HKGBP90) 377099-27-9P, Protein (human clone HHFMX34) 377099-28-0P, Protein (human clone HOUED48) 377099-29-1P, Protein (human clone HHBBI26) 377099-30-4P, Protein (human clone HHAUZ72) 377099-31-5P, Protein (human clone HWMAM41) 377099-32-6P, Protein (human clone HCEOV70) 377099-33-7P, Protein (human clone HKGDL95) 377099-34-8P, Protein (human clone HCEGR84) 377099-35-9P, Protein (human clone HMIBL51) 377099-36-0P, Protein (human clone HFXJP30) 377099-37-1P, Protein (human clone HCHMP94) 377099-38-2P, Protein (human clone HOHBO69) 377099-39-3P, Protein (human clone HBJHY72) 377099-40-6P, Protein (human clone HWEAD78) 377099-41-7P, Protein (human clone HFIBK06) 377099-42-8P, Protein (human clone HE9RF77) 377099-43-9P, Protein (human clone HCEEU61) 377099-44-0P, Protein (human clone HOHBV41) 377099-45-1P, Protein (human clone HHFKC41)

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; human nucleic acids and their encoded proteins and antibodies)

IT 377099-46-2P, Protein (human clone HOEMM23) 377099-47-3P, Protein (human clone HTXPN78) 377099-48-4P, Protein (human clone HFPGR87) 377099-49-5P, Protein (human clone HE8PR67) 377099-50-8P, Protein (human clone HDTDZ65) 377099-51-9P, Protein (human clone HWAEV63) 377099-52-0P, Protein (human clone HOHAV17) 377099-53-1P, Protein (human clone HNTCT36) 377099-54-2P, Protein (human clone HTPDM61) 377099-55-3P, Protein (human clone HTFOH87) 377099-56-4P, Protein (human clone HWBDQ32) 377099-57-5P, Protein (human clone HNHMC08) 377099-58-6P, Protein (human clone HE9QX59) 377099-59-7P, Protein (human clone HNFBU66) 377099-60-0P, Protein (human clone HLDQW16)



377099-61-1P, Protein (human clone HTLGS48)	377099-62-2P, Protein (human clone HNHDY54)
377099-63-3P, Protein (human clone HNGJG75)	377099-64-4P, Protein (human clone HNGJG75)
377099-65-5P, Protein (human clone HNGJG75)	377099-66-6P, Protein (human clone HNGJG75)
377099-67-7P, Protein (human clone HKADF82)	377099-68-8P, Protein (human clone HKADF82)
377099-69-9P, Protein (human clone HNGEK43)	377099-70-2P, Protein (human clone HTAJS93)
377099-71-3P, Protein (human clone HDPUM54)	377099-72-4P, Protein (human clone HDPUM54)
377099-73-5P, Protein (human clone HAIDK89)	377099-74-6P, Protein (human clone HTOHL88)
377099-75-7P, Protein (human clone HTOHL88)	377099-76-8P, Protein (human clone HOQBR51)
377099-77-9P, Protein (human clone HAMGP34)	377099-78-0P, Protein (human clone HAMGP34)
377099-79-1P, Protein (human clone HTLIC39)	377099-80-4P, Protein (human clone HNECI74)
377099-81-5P, Protein (human clone HNECI74)	377099-82-6P, Protein (human clone HEEAF67)
377099-83-7P, Protein (human clone HEEAF67)	377099-84-8P, Protein (human clone HEEAF67)
377099-85-9P, Protein (human clone HDPCX59)	377099-86-0P, Protein (human clone HPJAV04)
377099-87-1P, Protein (human clone HPJAV04)	377099-88-2P, Protein (human clone HNTAI35)
377099-89-3P, Protein (human clone HCE3X63)	377099-90-6P, Protein (human clone HCE3X63)
377099-91-7P, Protein (human clone HOUFG48)	377099-92-8P, Protein (human clone HOUFG48)
377099-93-9P, Protein (human clone HOUFG48)	377099-94-0P, Protein (human clone HCDEG27)
377099-95-1P, Protein (human clone HOUFG48)	377099-96-2P, Protein (human clone HOUFG48)
377099-97-3P, Protein (human clone HOUFG48)	377099-98-4P, Protein (human clone HOUFG48)
377099-99-5P, Protein (human clone HOUFG48)	377100-00-0P, Protein (human clone HSMBE70)
377100-01-1P, Protein (human clone HSMBE70)	377100-02-2P, Protein (human clone HSMBE70)
377100-03-3P, Protein (human clone HBXGQ49)	377100-04-4P, Protein (human clone HBXGQ49)
377100-05-5P, Protein (human clone HUCOT09)	377100-06-6P, Protein (human clone HUCOT09)
377100-07-7P, Protein (human clone HUCOT09)	377100-08-8P, Protein (human clone HUCOT09)
377100-09-9P, Protein (human clone HUCOT09)	377100-10-2P, Protein (human clone HUCOT09)
377100-11-3P, Protein (human clone HUCOT09)	377100-12-4P, Protein (human clone HUCOT09)
377100-13-5P, Protein (human clone HUCOT09)	377100-14-6P, Protein (human clone HUCOT09)
377100-15-7P, Protein (human clone HUCOT09)	377100-16-8P, Protein (human clone HUCOT09)
377100-17-9P, Protein (human clone HUCOT09)	377100-18-0P, Protein (human clone HUCOT09)
377100-19-1P, Protein (human clone HUCOT09)	377100-20-4P, Protein (human clone HUCOT09)
377100-21-5P, Protein (human clone HUCOT09)	377100-22-6P, Protein (human clone HUCOT09)
377100-23-7P, Protein (human clone HUCOT09)	377100-24-8P, Protein (human clone HUCOT09)
377100-25-9P, Protein (human clone HUCOT09)	377100-26-0P, Protein (human clone HUCOT09)
377100-27-1P, Protein (human clone HUCOT09)	377100-28-2P, Protein (human clone HUCOT09)
377100-29-3P, Protein (human clone HUCOT09)	377100-30-6P, Protein (human clone HUCOT09)
377100-31-7P, Protein (human clone HUCOT09)	377100-32-8P, Protein (human clone HUCOT09)
377100-33-9P, Protein (human clone HUCOT09)	377100-34-0P, Protein (human clone HUCOT09)
377100-35-1P, Protein (human clone HUCOT09)	377100-36-2P, Protein (human clone HUCOT09)
377100-37-3P, Protein (human clone HUCOT09)	377100-38-4P, Protein (human clone HUCOT09)
377100-39-5P, Protein (human clone HUCOT09)	377100-40-8P, Protein (human clone HUCOT09)
377100-41-9P, Protein (human clone HUCOT09)	377100-42-0P, Protein (human clone HUCOT09)
377100-43-1P, Protein (human clone HUCOT09)	377100-44-2P, Protein (human clone HUCOT09)
377100-45-3P, Protein (human clone HUCOT09)	377100-46-4P, Protein (human clone HUCOT09)
377100-47-5P, Protein (human clone HUCOT09)	377100-48-6P, Protein (human clone HUCOT09)
377100-49-7P, Protein (human clone HUCOT09)	377100-50-0P, Protein (human clone HUCOT09)

377100-51-1P, Protein (human clone HAJBZ74) 377100-52-2P, Protein (human clone HPMJN59)  
 377100-53-3P, Protein (human clone HPMJN59) 377100-54-4P, Protein (human clone HKAED76)  
 377100-55-5P, Protein (human clone HSPAD49) 377100-56-6P, Protein (human clone HARMV22)  
 377100-57-7P, Protein (human clone HSKIY76) 377100-58-8P, Protein (human clone HPJEV26)  
 377100-59-9P, Protein (human clone HPJEV91) 377100-60-2P, Protein (human clone HAMGK18)  
 377100-61-3P, Protein (human clone HCHOH94) 377100-62-4P, Protein (human clone HPJDA25)  
 377100-63-5P, Protein (human clone HJACF33) 377100-64-6P, Protein (human clone HHFMP57)  
 377100-65-7P, Protein (human clone HMKCV39) 377100-66-8P, Protein (human clone HNTOE45)  
 377100-67-9P, Protein (human clone HCUFV69) 377100-68-0P, Protein (human clone HMCVZ54)  
 377100-69-1P, Protein (human clone HMSHI94) 377100-70-4P, Protein (human clone HAPTE80)  
 377100-71-5P, Protein (human clone HSLJC72) 377100-72-6P, Protein (human clone HWBCR21)  
 377100-73-7P, Protein (human clone HKAU27) 377100-74-8P, Protein (human clone HOSJC09)  
 377100-75-9P, Protein (human clone HWBAE15) 377100-76-0P, Protein (human clone HWAET91)  
 377100-77-1P, Protein (human clone HELHM41) 377100-78-2P, Protein (human clone HEQCA95)  
 377100-79-3P, Protein (human clone HAGEG94) 377100-80-6P, Protein (human clone HHFGM33)  
 377100-81-7P, Protein (human clone HTEQK83) 377100-82-8P, Protein (human clone HSBBS15)  
 377100-83-9P, Protein (human clone HS2IL80) 377100-84-0P, Protein (human clone HUSZB06)  
 377100-85-1P, Protein (human clone HUCNM83) 377100-86-2P, Protein (human clone HUCNW47)  
 377100-87-3P, Protein (human clone HEMGJ42) 377100-88-4P, Protein (human clone HUSYN11)  
 377100-89-5P, Protein (human clone HTADJ34) 377100-90-8P, Protein (human clone HUSYN11)  
 377100-91-9P, Protein (human clone HTXPR30) 377100-92-0P, Protein (human clone HTXPR30)  
 377100-93-1P, Protein (human clone HAHPD69) 377100-94-2P, Protein (human clone HTXBF16)  
 377100-95-3P, Protein (human clone HTXBF16) 377100-96-4P, Protein (human clone HTXHA69)  
 377100-97-5P, Protein (human clone HFTCV95) 377100-98-6P, Protein (human clone HTEHC92)  
 377100-99-7P, Protein (human clone HTFOL05) 377101-00-3P, Protein (human clone HTPDV70)  
 377101-01-4P, Protein (human clone HLYGH73) 377101-02-5P, Protein (human clone HCE3E13)  
 377101-03-6P, Protein (human clone HRAAH37) 377101-04-7P, Protein (human clone HTOFB26)  
 377101-05-8P, Protein (human clone HMELR15) 377101-06-9P, Protein (human clone HTLEI29)  
 377101-07-0P, Protein (human clone HTLGX79) 377101-08-1P, Protein (human clone HHFOV07)  
 377101-09-2P, Protein (human clone HTLDO59) 377101-10-5P, Protein (human clone HE8TM62)  
 377101-11-6P, Protein (human clone HJBCS70) 377101-12-7P, Protein (human clone HTFMP59)  
 377101-13-8P, Protein (human clone HTEKC55) 377101-14-9P, Protein (human clone HTEPK69)  
 377101-15-0P, Protein (human clone HTENV57) 377101-16-1P, Protein (human clone HTEJF45)  
 377101-17-2P, Protein (human clone HTEGF16) 377101-18-3P, Protein (human clone HLTGU35)  
 377101-19-4P, Protein (human clone HTEDK07) 377101-20-7P, Protein (human clone HADGO63)  
 377101-21-8P, Protein (human clone HDPDO84) 377101-22-9P, Protein (human clone HNTAN11)  
 377101-23-0P, Protein (human clone HTTBJ31) 377101-24-1P, Protein (human clone HAMGO24)  
 377101-25-2P, Protein (human clone HODFK55) 377101-26-3P, Protein (human clone HBJMW49)  
 377101-27-4P, Protein (human clone HSXDF62) 377101-28-5P, Protein (human clone HSVCE22)  
 377101-29-6P, Protein (human clone HFKLC74) 377101-30-9P, Protein (human clone HTLEV30)  
 377101-31-0P, Protein (human clone HSRV54) 377101-32-1P, Protein (human clone HTLID05)  
 377101-33-2P, Protein (human clone HWAGU62) 377101-34-3P, Protein (human clone HOEBN65)  
 377101-35-4P, Protein (human clone HOEEY60) 377101-36-5P, Protein (human clone HHECK12)  
 377101-37-6P, Protein (human clone HTLEM32) 377101-38-7P, Protein (human clone HPMUT61)  
 377101-39-8P, Protein (human clone HHEOI72) 377101-40-1P, Protein (human clone HHEOI72)  
 377101-41-2P, Protein (human clone HHEOI72)

Protein (human clone HAPRN77) 377101-42-3P, Protein (human clone HLJDL43) 377101-43-4P, Protein (human clone HLJDU57) 377101-44-5P, Protein (human clone HHFKL03) 377101-45-6P, Protein (human clone HNTTB69) 377101-46-7P, Protein (human clone HKAAA37) 377101-47-8P, Protein (human clone HACCB78) 377101-48-9P, Protein (human clone HTLEO76) 377101-49-0P, Protein (human clone HTPBR76) 377101-50-3P, Protein (human clone HNTNH42) 377101-51-4P, Protein (human clone HFRCB84) 377101-52-5P, Protein (human clone HLWDZ48) 377101-53-6P, Protein (human clone HKAOC61) 377101-54-7P, Protein (human clone HHEMJ13) 377101-55-8P, Protein (human clone HTFOA36) 377101-56-9P, Protein (human clone HULEW22) 377101-57-0P, Protein (human clone HWADE54) 377101-58-1P, Protein (human clone HEMHH46) 377101-59-2P, Protein (human clone HFPIX46) 377101-60-5P, Protein (human clone HHPDK44) 377101-61-6P, Protein (human clone HE2FK85) 377101-62-7P, Protein (human clone HPQSL36) 377101-63-8P, Protein (human clone HEQBF64) 377101-64-9P, Protein (human clone HAMGB22) 377101-65-0P, Protein (human clone HDABD89) 377101-66-1P, Protein (human clone HPMFU11) 377101-67-2P, Protein (human clone HHEFL55) 377101-68-3P, Protein (human clone HHFJG66) 377101-69-4P, Protein (human clone HBMWZ85) 377101-70-7P, Protein (human clone HTTEL61) 377101-71-8P, Protein (human clone HHEKA25) 377101-72-9P, Protein (human clone HTLEH76) 377101-73-0P, Protein (human clone HHEVQ56) 377101-74-1P, Protein (human clone HTPHY39) 377101-75-2P, Protein (human clone HPCRR53) 377101-76-3P, Protein (human clone HLQEW26) 377101-77-4P, Protein (human clone HSLJR04)

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; human nucleic acids and their encoded proteins and antibodies)

IT 377101-78-5P, Protein (human clone HCYBG26) 377101-79-6P, Protein (human clone HNGEZ52) 377101-80-9P, Protein (human clone H2LAY37) 377101-81-0P, Protein (human clone HCRND05) 377101-82-1P, Protein (human clone HCRNP66) 377101-83-2P, Protein (human clone HNTMD17) 377101-84-3P, Protein (human clone HMCZG52) 377101-85-4P, Protein (human clone HOSOL09) 377101-86-5P, Protein (human clone HLQHJ48) 377101-87-6P, Protein (human clone HTTDU01) 377101-88-7P, Protein (human clone HOSMQ26) 377101-89-8P, Protein (human clone HMTME42) 377101-90-1P, Protein (human clone HRADL60) 377101-91-2P, Protein (human clone HWLMB55) 377101-92-3P, Protein (human clone HUSGZ51) 377101-93-4P, Protein (human clone HWDAN86) 377101-94-5P, Protein (human clone HFATS83) 377101-95-6P, Protein (human clone HBION06) 377101-96-7P, Protein (human clone HAPOO57) 377101-97-8P, Protein (human clone HCROG59) 377101-98-9P, Protein (human clone HDTBL01) 377101-99-0P, Protein (human clone HHFJY07) 377102-00-6P, Protein (human clone HOFMV44) 377102-01-7P, Protein (human clone HSLJN60) 377102-02-8P, Protein (human clone HWHGQ44) 377102-03-9P, Protein (human clone HCQDA63) 377102-04-0P, Protein (human clone HCFCS58) 377102-05-1P, Protein (human clone HWLMC49) 377102-06-2P, Protein (human clone HFCDF47) 377102-07-3P, Protein (human clone HCRNJ24) 377102-08-4P, Protein (human clone HCRNT27) 377102-09-5P, Protein (human clone HCQCC37) 377102-10-8P, Protein (human clone HFXKZ44) 377102-11-9P, Protein (human clone HWAAD15) 377102-12-0P, Protein (human clone HDABX38) 377102-13-1P, Protein (human clone HETJZ14) 377102-14-2P, Protein (human clone H2LAJ32) 377102-15-3P, Protein (human clone HTPIQ89) 377102-16-4P, Protein (human clone HTDAI12) 377102-17-5P, Protein (human clone HWLGV14) 377102-18-6P, Protein (human clone HCQBI31) 377102-19-7P, Protein (human clone HE9RM22) 377102-20-0P, Protein (human clone HBIUG54) 377102-21-1P, Protein (human clone HOBAE30) 377102-22-2P, Protein (human clone HEMHA04)

377102-23-3P, Protein (human clone HHEOX44) 377102-24-4P, Protein (human clone HWBBS84) 377102-25-5P, Protein (human clone HWLIP86)  
 377102-26-6P, Protein (human clone HSBZ37) 377102-27-7P, Protein (human clone HOSXA83) 377102-28-8P, Protein (human clone HDQHQ51)  
 377102-29-9P, Protein (human clone HWAAB46) 377102-30-2P, Protein (human clone HOGDT09) 377102-31-3P, Protein (human clone HTEGT79)  
 377102-32-4P, Protein (human clone HOEJS41) 377102-33-5P, Protein (human clone HBXDI92) 377102-34-6P, Protein (human clone HHFMH12)  
 377102-35-7P, Protein (human clone HDPFP36) 377102-36-8P, Protein (human clone HDPWZ46) 377102-37-9P, Protein (human clone HFPBS73)  
 377102-38-0P, Protein (human clone HBBBE08) 377102-39-1P, Protein (human clone HNFIB64) 377102-40-4P, Protein (human clone HBJMN78)  
 377102-41-5P, Protein (human clone HHAUW81) 377102-42-6P, Protein (human clone HAUBB12) 377102-43-7P, Protein (human clone HFPHS77)  
 377102-44-8P, Protein (human clone HBGQN46) 377102-45-9P, Protein (human clone HTAFG29) 377102-46-0P, Protein (human clone HDPCT51)  
 377102-47-1P, Protein (human clone HMAZ08) 377102-48-2P, Protein (human clone HOHCA01) 377102-49-3P, Protein (human clone HTPEF72)  
 377102-50-6P, Protein (human clone HPHAB61) 377102-51-7P, Protein (human clone HTJNI73) 377102-52-8P, Protein (human clone HEOMO40)  
 377102-53-9P, Protein (human clone HBGQR89) 377102-54-0P, Protein (human clone HDPFT14) 377102-55-1P, Protein (human clone HNHFY67)  
 377102-56-2P, Protein (human clone HWLLR80) 377102-57-3P, Protein (human clone HLYAG35) 377102-58-4P, Protein (human clone HDPLU91)  
 377102-59-5P, Protein (human clone HDABG90) 377102-60-8P, Protein (human clone HDPQO40) 377102-61-9P, Protein (human clone HKAHL37)  
 377102-62-0P, Protein (human clone HBXAX11) 377102-63-1P, Protein (human clone HEEAG84) 377102-64-2P, Protein (human clone HE8PT01)  
 377102-65-3P, Protein (human clone HMVCG79) 377102-66-4P, Protein (human clone HSLJF33) 377102-67-5P, Protein (human clone HFKJI43)  
 377102-68-6P, Protein (human clone HFVHV40) 377102-69-7P, Protein (human clone HTXLR12) 377102-70-0P, Protein (human clone HDQEX68)  
 377102-71-1P, Protein (human clone HTPHG81) 377102-72-2P, Protein (human clone HETFJ66) 377102-73-3P, Protein (human clone HUVCM58)  
 377102-74-4P, Protein (human clone HDPGJ03) 377102-75-5P, Protein (human clone HWHHN55) 377102-76-6P, Protein (human clone HTTJH57)  
 377102-77-7P, Protein (human clone HMSNQ62) 377102-78-8P, Protein (human clone HGBHG78) 377102-79-9P, Protein (human clone HTLHJ08)  
 377102-80-2P, Protein (human clone HSIDI48) 377102-81-3P, Protein (human clone HRDDU37) 377102-82-4P, Protein (human clone HFLUI19)  
 377102-83-5P, Protein (human clone HTWAG66) 377102-84-6P, Protein (human clone HLCLE14) 377102-85-7P, Protein (human clone HOFMH52)  
 377102-86-8P, Protein (human clone HWAHE17) 377102-87-9P, Protein (human clone HWAEG32) 377102-88-0P, Protein (human clone HSLHB42)  
 377102-89-1P, Protein (human clone HDSAC28) 377102-90-4P, Protein (human clone HFIHT27) 377102-91-5P, Protein (human clone HBIMS61)  
 377102-92-6P, Protein (human clone HCDAH28) 377102-93-7P, Protein (human clone HSDFD90) 377102-94-8P, Protein (human clone HTLJK34)  
 377102-95-9P, Protein (human clone HNGKC65) 377102-96-0P, Protein (human clone HDPBD83) 377102-97-1P, Protein (human clone HHEVU86) 377102-98-2P, Protein (human clone HNFIB27) 377102-99-3P, Protein (human clone HAPSG46)  
 377103-00-9P, Protein (human clone HCWFW07) 377103-01-0P, Protein (human clone HUFCR29) 377103-02-1P, Protein (human clone HNTCN90) 377103-03-2P, Protein (human clone HCMSE07) 377103-04-3P, Protein (human clone HWMEV61) 377103-05-4P, Protein (human clone HDPWT82) 377103-06-5P, Protein (human clone HBGOU17) 377103-07-6P, Protein (human clone HETBT53) 377103-08-7P, Protein (human clone HRAEC49) 377103-09-8P, Protein (human clone HNHBD03) 377103-10-1P, Protein (human clone HTTCB17) 377103-11-2P, Protein (human clone HE9QG38) 377103-12-3P, Protein (human clone HTTJY18) 377103-13-4P,



Protein (human clone HPSND10) 377103-14-5P, Protein (human clone  
 HDABX58) 377103-15-6P, Protein (human clone HDABX58) 377103-16-7P,  
 Protein (human clone HELGM94) 377103-17-8P, Protein (human clone  
 HJBBC09) 377103-18-9P, Protein (human clone HTXJF02) 377103-19-0P,  
 Protein (human clone HKAEN78) 377103-20-3P, Protein (human clone  
 HKADD76) 377103-21-4P, Protein (human clone HKIYF62) 377103-22-5P,  
 Protein (human clone HDQDF85) 377103-23-6P, Protein (human clone  
 HRAAA79) 377103-24-7P, Protein (human clone HFPAD41) 377103-25-8P,  
 Protein (human clone HTAIV82) 377103-26-9P, Protein (human clone  
 HACBW10) 377103-27-0P, Protein (human clone HUFBN79) 377103-28-1P,  
 Protein (human clone HCFCN07) 377103-29-2P, Protein (human clone  
 HLWDZ66) 377103-30-5P, Protein (human clone HEONP58) 377103-31-6P,  
 Protein (human clone HMAGN19) 377103-32-7P, Protein (human clone  
 HFCAP42) 377103-33-8P, Protein (human clone HWBBT49) 377103-34-9P,  
 Protein (human clone HDPBT62) 377103-35-0P, Protein (human clone  
 HWHHS59) 377103-36-1P, Protein (human clone HJPCP29) 377103-37-2P,  
 Protein (human clone HHEBM09) 377103-38-3P, Protein (human clone  
 HDPIV17) 377103-39-4P, Protein (human clone HBGNO49) 377103-40-7P,  
 Protein (human clone HWAFQ40) 377103-41-8P, Protein (human clone  
 HTLGZ03) 377103-42-9P, Protein (human clone HLYCX18) 377103-43-0P,  
 Protein (human clone HSDEK82) 377103-44-1P, Protein (human clone  
 HCEMU86) 377103-45-2P, Protein (human clone HEORN16) 377103-46-3P,  
 Protein (human clone HKGBJ74) 377103-47-4P, Protein (human clone  
 HOSPA48) 377103-48-5P, Protein (human clone HWHQN16) 377103-49-6P,  
 Protein (human clone HFVIK60) 377103-50-9P, Protein (human clone  
 HMAIH15) 377103-51-0P, Protein (human clone HTTDZ74) 377103-52-1P,  
 Protein (human clone HUSGC38) 377103-53-2P, Protein (human clone  
 HLHAN77) 377103-54-3P, Protein (human clone HFPKI70) 377103-55-4P,  
 Protein (human clone HDRMD17) 377103-56-5P, Protein (human clone  
 HEMDM16) 377103-57-6P, Protein (human clone HSLGA24) 377103-58-7P,  
 Protein (human clone HMHBT84) 377103-59-8P, Protein (human clone  
 HHEDW60) 377103-60-1P, Protein (human clone HNGNU93) 377103-61-2P,  
 Protein (human clone HARMS29) 377103-62-3P, Protein (human clone  
 HAMHH25) 377103-63-4P, Protein (human clone HLCLA47) 377103-64-5P,  
 Protein (human clone HDPSO06) 377103-65-6P, Protein (human clone  
 HFXKG51) 377103-66-7P, Protein (human clone HELEL31) 377103-67-8P,  
 Protein (human clone HTLGQ83) 377103-68-9P, Protein (human clone  
 HETJU23) 377103-69-0P, Protein (human clone HNGKB25) 377103-70-3P,  
 Protein (human clone HADAM67) 377103-71-4P, Protein (human clone  
 HDQPJ92) 377103-72-5P, Protein (human clone HHFFX31) 377103-73-6P,  
 Protein (human clone HHESF39) 377103-74-7P, Protein (human clone  
 HTLHB93) 377103-75-8P, Protein (human clone HDTJA78) 377103-76-9P,  
 Protein (human clone HNGPL75) 377103-77-0P, Protein (human clone  
 HNTDV93) 377103-78-1P, Protein (human clone HNSMB73) 377103-79-2P,  
 Protein (human clone HTLGL03) 377103-80-5P, Protein (human clone  
 HGBCN41) 377103-81-6P, Protein (human clone HWMBU89) 377103-82-7P,  
 Protein (human clone HSEBA38) 377103-83-8P, Protein (human clone  
 HEEAX26) 377103-84-9P, Protein (human clone HTLAG19) 377103-85-0P,  
 Protein (human clone HISBV17) 377103-86-1P, Protein (human clone  
 HFKLN07) 377103-87-2P, Protein (human clone HTLID36) 377103-88-3P,  
 Protein (human clone HSLHV27) 377103-89-4P, Protein (human clone  
 HSLJG70) 377103-90-7P, Protein (human clone HSFAC30) 377103-91-8P,  
 Protein (human clone HTTBM62) 377103-92-9P, Protein (human clone  
 HFCDT23) 377103-93-0P, Protein (human clone HDPGU86) 377103-94-1P,  
 Protein (human clone H2CBE07) 377103-95-2P, Protein (human clone  
 HTXLP33) 377103-96-3P, Protein (human clone HMEKG76) 377103-97-4P,  
 Protein (human clone HTENG02) 377103-98-5P, Protein (human clone  
 HTOAW80) 377103-99-6P, Protein (human clone HAJAW57) 377104-00-2P,  
 Protein (human clone HTEHF89) 377104-01-3P, Protein (human clone  
 HSYBB84) 377104-02-4P, Protein (human clone HTJMD30) 377104-03-5P,

Protein (human clone HELFG05) 377104-04-6P, Protein (human clone HHEHG38) 377104-05-7P, Protein (human clone HSLDT25) 377104-06-8P, Protein (human clone HSDGH19) 377104-07-9P, Protein (human clone HCEOU19) 377104-08-0P, Protein (human clone HBIMF04) 377104-09-1P, Protein (human clone HSKZE56)  
 RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (amino acid sequence; human nucleic acids and their encoded proteins and antibodies)

IT 377104-10-4P, Protein (human clone HLJBD90) 377104-11-5P, Protein (human clone HAUAX28) 377104-12-6P, Protein (human clone HUCPU88) 377104-13-7P, Protein (human clone HFXKJ22) 377104-14-8P, Protein (human clone HWHPD05) 377104-15-9P, Protein (human clone HFRAN15) 377104-16-0P, Protein (human clone HHGCV39) 377104-17-1P, Protein (human clone HMAFM80) 377104-18-2P, Protein (human clone HAPOW71) 377104-19-3P, Protein (human clone HBCBW64) 377104-20-6P, Protein (human clone HBING74) 377104-21-7P, Protein (human clone HBIMJ94) 377104-22-8P, Protein (human clone HNHCI36) 377104-23-9P, Protein (human clone HAFAH26) 377104-24-0P, Protein (human clone HE8MV45) 377104-25-1P, Protein (human clone HUKAQ96) 377104-26-2P, Protein (human clone HKADF73) 377104-27-3P, Protein (human clone HSLEN72) 377104-28-4P, Protein (human clone HTPHK88) 377104-29-5P, Protein (human clone HDPFA53) 377104-30-8P, Protein (human clone HMSDQ93) 377104-31-9P, Protein (human clone HSXAD12) 377104-32-0P, Protein (human clone HWBAL42) 377104-33-1P, Protein (human clone HUJBO10) 377104-34-2P, Protein (human clone HMUAP06) 377104-35-3P, Protein (human clone HLYCA31) 377104-36-4P, Protein (human clone HETTY94) 377104-37-5P, Protein (human clone HMTAU01) 377104-38-6P, Protein (human clone HDPVO38) 377104-39-7P, Protein (human clone HSDKL35) 377104-40-0P, Protein (human clone HTLJA77) 377104-41-1P, Protein (human clone HCFLJ17) 377104-42-2P, Protein (human clone HNGKM74) 377104-43-3P, Protein (human clone HTTJQ27) 377104-44-4P, Protein (human clone HBCBF11) 377104-45-5P, Protein (human clone HFOYG86) 377104-46-6P, Protein (human clone HKGCJ92) 377104-47-7P, Protein (human clone HFPAB23) 377104-48-8P, Protein (human clone HWAGL92) 377104-49-9P, Protein (human clone HADME31) 377104-50-2P, Protein (human clone HEGBA84) 377104-51-3P, Protein (human clone HKLSC61) 377104-52-4P, Protein (human clone HEOMP62) 377104-53-5P, Protein (human clone HAMFN18) 377104-54-6P, Protein (human clone HWAEU20) 377104-55-7P, Protein (human clone HDPBG11) 377104-56-8P, Protein (human clone HWLEQ41) 377104-57-9P, Protein (human clone HTOIB37) 377104-58-0P, Protein (human clone HTGBM16) 377104-59-1P, Protein (human clone HOUGB95) 377104-60-4P, Protein (human clone HTELC21) 377104-61-5P, Protein (human clone HTPGV36) 377104-62-6P, Protein (human clone HFTDC58) 377104-63-7P, Protein (human clone HMUAG30) 377104-64-8P, Protein (human clone HCBME31) 377104-65-9P, Protein (human clone HDQDC13) 377104-66-0P, Protein (human clone HLHFX80) 377104-67-1P, Protein (human clone HOGBN93) 377104-68-2P, Protein (human clone HTPHE46) 377104-69-3P, Protein (human clone HTXQU08) 377104-70-6P, Protein (human clone HE8MU78) 377104-71-7P, Protein (human clone HTNBJ17) 377104-72-8P, Protein (human clone HTTJZ84) 377104-73-9P, Protein (human clone HLYBD96) 377104-74-0P, Protein (human clone HTTJT40) 377104-75-1P, Protein (human clone HETDR50) 377104-76-2P, Protein (human clone HDPRH64) 377104-77-3P, Protein (human clone HPIAN49) 377104-78-4P, Protein (human clone HDPVB49) 377104-79-5P, Protein (human clone HPJCP79) 377104-80-8P, Protein (human clone HHEVK59) 377104-81-9P, Protein (human clone HMKAK61) 377104-82-0P, Protein (human clone HWADM65) 377104-83-1P, Protein (human clone HLQFF81) 377104-84-2P, Protein (human clone HDPIG80)

377104-85-3P, Protein (human clone HUSID53)	377104-86-4P, Protein (human clone HE8CW35)
377104-87-5P, Protein (human clone HDPFZ30)	377104-88-6P, Protein (human clone HBHMH72)
377104-89-7P, Protein (human clone HLWAH05)	377104-90-0P, Protein (human clone HDPFI84)
377104-91-1P, Protein (human clone HCRPU72)	377104-92-2P, Protein (human clone HFTCG52)
377104-93-3P, Protein (human clone HBINP48)	377104-94-4P, Protein (human clone HCQDE22)
377104-95-5P, Protein (human clone HLWBY26)	377104-96-6P, Protein (human clone HKAHR43)
377104-97-7P, Protein (human clone HLDCE43)	377104-98-8P, Protein (human clone HFXKW18)
377104-99-9P, Protein (human clone HBGOJ26)	377105-00-5P, Protein (human clone HVEDS40)
377105-01-6P, Protein (human clone HBMBF28)	377105-02-7P, Protein (human clone HSCV39)
377105-03-8P, Protein (human clone HJPAZ12)	377105-04-9P, Protein (human clone HPTVU91)
377105-05-0P, Protein (human clone HSLJD02)	377105-06-1P, Protein (human clone HNHOF94)
377105-07-2P, Protein (human clone H2CBM85)	377105-08-3P, Protein (human clone HCYAC03)
377105-09-4P, Protein (human clone HOGBM94)	377105-10-7P, Protein (human clone HTTBH18)
377105-11-8P, Protein (human clone HSLAS08)	377105-12-9P, Protein (human clone HTLJA52)
377105-13-0P, Protein (human clone HSCG60)	377105-14-1P, Protein (human clone HKAEK20)
377105-15-2P, Protein (human clone HCFBF02)	377105-16-3P, Protein (human clone HDPVZ07)
377105-17-4P, Protein (human clone HE8TB14)	377105-18-5P, Protein (human clone HHEFI15)
377105-19-6P, Protein (human clone HHEQF50)	377105-20-9P, Protein (human clone HOSAY56)
377105-21-0P, Protein (human clone HHEJV91)	377105-22-1P, Protein (human clone HOGEA82)
377105-23-2P, Protein (human clone HAD39)	377105-24-3P, Protein (human clone HKAKC86)
377105-25-4P, Protein (human clone HUKP18)	377105-26-5P, Protein (human clone HL2AE66)
377105-27-6P, Protein (human clone HHGJS83)	377105-28-7P, Protein (human clone HHGQ67)
377105-29-8P, Protein (human clone HHFNI70)	377105-30-1P, Protein (human clone HNTAP78)
377105-31-2P, Protein (human clone HOGEN56)	377105-32-3P, Protein (human clone HWLOU33)
377105-33-4P, Protein (human clone HDPKJ19)	377105-34-5P, Protein (human clone HPMKP09)
377105-35-6P, Protein (human clone HUEJZ65)	377105-36-7P, Protein (human clone HHASY37)
377105-37-8P, Protein (human clone HUEJZ65)	377105-38-9P, Protein (human clone HKIXQ06)
377105-39-0P, Protein (human clone HUEJZ65)	377105-40-3P, Protein (human clone HUEJZ65)
377105-41-4P, Protein (human clone HUEJZ65)	377105-42-5P, Protein (human clone HUEJZ65)
377105-43-6P, Protein (human clone HUEJZ65)	377105-44-7P, Protein (human clone HUEJZ65)
377105-45-8P, Protein (human clone HUEJZ65)	377105-46-9P, Protein (human clone HUEJZ65)
377105-47-0P, Protein (human clone HUEJZ65)	377105-48-1P, Protein (human clone HUEJZ65)
377105-49-2P, Protein (human clone HUEJZ65)	377105-50-5P, Protein (human clone HUEJZ65)
377105-51-6P, Protein (human clone HUEJZ65)	377105-52-7P, Protein (human clone HUEJZ65)
377105-53-8P, Protein (human clone HUEJZ65)	377105-54-9P, Protein (human clone HUEJZ65)
377105-55-0P, Protein (human clone HUEJZ65)	377105-56-1P, Protein (human clone HUEJZ65)
377105-57-2P, Protein (human clone HUEJZ65)	377105-58-3P, Protein (human clone HUEJZ65)
377105-59-4P, Protein (human clone HUEJZ65)	377105-60-7P, Protein (human clone HUEJZ65)
377105-61-8P, Protein (human clone HUEJZ65)	377105-62-9P, Protein (human clone HUEJZ65)
377105-63-0P, Protein (human clone HUEJZ65)	377105-64-1P, Protein (human clone HUEJZ65)
377105-65-2P, Protein (human clone HUEJZ65)	377105-66-3P, Protein (human clone HUEJZ65)
377105-67-4P, Protein (human clone HUEJZ65)	377105-68-5P, Protein (human clone HUEJZ65)
377105-69-6P, Protein (human clone HUEJZ65)	377105-70-9P, Protein (human clone HUEJZ65)
377105-71-0P, Protein (human clone HUEJZ65)	377105-72-1P, Protein (human clone HUEJZ65)
377105-73-2P, Protein (human clone HUEJZ65)	377105-74-3P, Protein (human clone HUEJZ65)



377105-75-4P, Protein (human clone HLICA89) 377105-76-5P, Protein (human clone HTTDZ50) 377105-77-6P, Protein (human clone HTLHL43) 377105-78-7P, Protein (human clone HDQPN32) 377105-79-8P, Protein (human clone HOHBT28) 377105-80-1P, Protein (human clone HTPCP50) 377105-81-2P, Protein (human clone HWLCJ12) 377105-82-3P, Protein (human clone HTHCK88) 377105-83-4P, Protein (human clone HCE3M15) 377105-84-5P, Protein (human clone HSKGT01) 377105-85-6P, Protein (human clone HTAIJ50) 377105-86-7P, Protein (human clone HPJAS61) 377105-87-8P, Protein (human clone HTEKL48) 377105-88-9P, Protein (human clone HUVFI01) 377105-89-0P, Protein (human clone HHAOD94) 377105-90-3P, Protein (human clone HAGGF22) 377105-91-4P, Protein (human clone HTJMG26) 377105-92-5P, Protein (human clone HNTND88) 377105-93-6P, Protein (human clone HJABT11) 377105-94-7P, Protein (human clone HOUCY70) 377105-95-8P, Protein (human clone HNHCM07) 377105-96-9P, Protein (human clone HTAFC46) 377105-97-0P, Protein (human clone HRADL67) 377105-98-1P, Protein (human clone HCFCS40) 377105-99-2P, Protein (human clone HBINS69) 377106-00-8P, Protein (human clone HKGAO47) 377106-01-9P, Protein (human clone HMTBI19) 377106-02-0P, Protein (human clone HPMGN27) 377106-03-1P, Protein (human clone HWLEP57) 377106-04-2P, Protein (human clone HADGF57) 377106-05-3P, Protein (human clone HHEXO20) 377106-06-4P, Protein (human clone HWLGN53) 377106-07-5P, Protein (human clone HMIAH65) 377106-08-6P, Protein (human clone HWAAX38) 377106-09-7P, Protein (human clone HTJNG15) 377106-10-0P, Protein (human clone HSDJA72) 377106-11-1P, Protein (human clone HMCHF75) 377106-12-2P, Protein (human clone HDTAZ43) 377106-13-3P, Protein (human clone HAAAN55) 377106-14-4P, Protein (human clone HBODI05) 377106-15-5P, Protein (human clone HAJAH16) 377106-16-6P, Protein (human clone HOUDS09) 377106-17-7P, Protein (human clone HLWAF59) 377106-18-8P, Protein (human clone HCFNN18) 377106-19-9P, Protein (human clone HMSCR89) 377106-20-2P, Protein (human clone HDPCW53) 377106-21-3P, Protein (human clone HTOGI77) 377106-22-4P, Protein (human clone HAPBL13) 377106-23-5P, Protein (human clone HHEEN22) 377106-24-6P, Protein (human clone H2CBH75) 377106-25-7P, Protein (human clone HTLHU05) 377106-26-8P, Protein (human clone HDPPG85) 377106-27-9P, Protein (human clone HWMIB81) 377106-28-0P, Protein (human clone HHFJU87) 377106-29-1P, Protein (human clone HDHIB39) 377106-30-4P, Protein (human clone HTXSR92) 377106-31-5P, Protein (human clone HWEAD65) 377106-32-6P, Protein (human clone HUUAR12) 377106-33-7P, Protein (human clone HEMBT61) 377106-34-8P, Protein (human clone HNTCE17) 377106-35-9P, Protein (human clone HFFAV24) 377106-36-0P, Protein (human clone HEOPL36) 377106-37-1P, Protein (human clone HFKJM30) 377106-38-2P, Protein (human clone HTEPE35) 377106-39-3P, Protein (human clone HIBEG14) 377106-40-6P, Protein (human clone HIBCH43) 377106-41-7P, Protein (human clone HELDY60)

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; human nucleic acids and their encoded proteins and antibodies)

IT 377106-42-8P, Protein (human clone HDPRX11) 377106-43-9P, Protein (human clone HDPBN81) 377106-44-0P, Protein (human clone HSLJF08) 377106-45-1P, Protein (human clone HAGAE60) 377106-46-2P, Protein (human clone HTJNI49) 377106-47-3P, Protein (human clone HUFBA64) 377106-48-4P, Protein (human clone HSSAL39) 377106-49-5P, Protein (human clone HE8QR01) 377106-50-8P, Protein (human clone HLDQK77) 377106-51-9P, Protein (human clone HMSHP51) 377106-52-0P, Protein (human clone HJPBB56) 377106-53-1P, Protein (human clone HPWAS05) 377106-54-2P, Protein (human clone HUSIC81)

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,

unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(amino acid sequence; human nucleic acids and their encoded proteins and antibodies)

IT	165475-99-0P	191434-95-4P	212773-87-0P	212836-28-7P	213252-94-9P
	213254-36-5P	213254-40-1P	213822-24-3P	213822-74-3P	217304-49-9P
	223910-90-5P	252351-38-5P	252364-49-1P	257853-72-8P	261343-79-7P
	284689-61-8P	291580-59-1P	291786-20-4P	291788-87-9P	291789-02-1P
	291789-07-6P	291791-80-5P	291794-25-7P	292090-67-6P	292096-92-5P
	292097-04-2P	292097-81-5P	292098-02-3P	292187-90-7P	292188-28-4P
	292188-81-9P	292645-10-4P	292645-45-5P	292645-48-8P	292645-67-1P
	292647-08-6P	292647-44-0P	292647-75-7P	292647-83-7P	292648-16-9P
	292648-52-3P	292650-40-9P	292876-72-3P	293332-27-1P	294683-87-7P
	294906-25-5P	295373-34-1P	295376-89-5P	296965-17-8P	300426-87-3P
	300619-52-7P	300871-69-6P	312651-54-0P	312778-91-9P	328596-42-5P
	331880-86-5P	332086-67-6P	332087-00-0P	332430-48-5P	333460-94-9P
	333461-94-2P	333462-51-4P	333462-59-2P	333462-86-5P	333463-43-7P
	333463-72-2P	333464-31-6P	333464-50-9P	333464-95-2P	333464-96-3P
	334026-84-5P	334027-12-2P	334027-17-7P	334027-73-5P	334028-65-8P
	334030-55-6P	334031-10-6P	334031-58-2P	334031-59-3P	334031-75-3P
	334032-33-6P	334032-39-2P	334032-77-8P	334032-89-2P	334032-95-0P
	334033-50-0P	334034-37-6P	334034-58-1P	334034-63-8P	334034-68-3P
	334035-08-4P	334035-30-2P	334035-58-4P	334041-59-7P	334042-30-7P
	334042-35-2P	334043-98-0P	334045-32-8P	334045-35-1P	334045-65-7P
	334045-71-5P	334045-77-1P	334045-87-3P	334045-91-9P	334046-03-6P
	334046-08-1P	334046-25-2P	334046-75-2P	334046-96-7P	334047-00-6P
	334047-03-9P	334047-13-1P	334047-18-6P	334047-19-7P	334047-25-5P
	334047-28-8P	337542-30-0P	337986-67-1P	339139-75-2P	339140-39-5P
	339143-36-1P	339215-91-7P	339216-04-5P	339605-51-5P	339605-64-0P
	339608-97-8P	339611-10-8P	339613-56-8P	339613-59-1P	339613-69-3P
	340050-17-1P	340837-91-4P	341065-71-2P	352395-48-3P	352589-80-1P
	352730-25-7P	352730-85-9P	352737-03-2P	352802-14-3P	352804-39-8P
	352812-01-2P	353530-04-8P	353530-98-0P	353545-06-9P	355466-91-0P
	355469-32-8P	357226-22-3P	368491-91-2P	376398-19-5P	376398-20-8DP,
qqq	376398-21-9P	376398-22-0P	376398-23-1P	376398-24-2P	
	376398-25-3P	376398-26-4P	376398-27-5P	376398-28-6P	376398-29-7P
	376398-30-0P	376398-31-1P	376398-32-2P	376398-33-3P	376398-34-4P
	376398-35-5P	376398-36-6P	376398-37-7P	376398-38-8P	376398-39-9P
	376398-40-2P	376398-41-3P	376398-42-4P	376398-43-5P	376398-44-6P
	376398-45-7P	376398-46-8P	376398-47-9P	376398-48-0P	376398-49-1P
	376398-50-4P	376398-51-5P	376398-52-6P	376398-53-7P	376398-54-8P
	376398-55-9P	376398-56-0P	376398-57-1P	376398-58-2P	376398-59-3P
	376398-60-6P	376398-61-7P	376398-62-8P	376398-63-9P	376398-64-0P
	376398-65-1P	376398-66-2P	376398-67-3P	376398-68-4P	376398-69-5P
	376398-70-8P	376398-71-9P	376398-72-0P	376398-73-1P	376398-74-2P
	376398-75-3P	376398-76-4P	376398-77-5P	376398-78-6P	376398-79-7P
	376398-80-0P	376398-81-1P	376398-82-2P	376398-83-3P	376398-84-4P
	376398-85-5P	376398-86-6P	376398-87-7P	376398-88-8P	376398-89-9P
	376398-90-2P	376398-91-3P	376398-92-4P	376398-93-5P	376398-94-6P
	376398-95-7P	376398-96-8P	376398-97-9P	376398-98-0P	376398-99-1P
	376399-00-7P	376399-01-8P	376399-02-9P		

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT	376399-03-0P	376399-04-1P	376399-05-2P	376399-06-3P	376399-07-4P
	376399-08-5P	376399-09-6P	376399-10-9P	376399-11-0P	376399-12-1P
	376399-13-2P	376399-14-3P	376399-15-4P	376399-16-5P	376399-17-6P
	376399-18-7P	376399-19-8P	376399-20-1P	376399-21-2P	376399-22-3P

376399-23-4P	376399-24-5P	376399-25-6P	376399-26-7P	376399-27-8P
376399-28-9P	376399-29-0P	376399-30-3P	376399-31-4P	376399-32-5P
376399-33-6P	376399-34-7P	376399-35-8P	376399-36-9P	376399-37-0P
376399-38-1P	376399-39-2P	376399-40-5P	376399-41-6P	376399-42-7P
376399-43-8P	376399-44-9P	376399-45-0P	376399-46-1P	376399-47-2P
376399-48-3P	376399-49-4P	376399-50-7P	376399-51-8P	376399-52-9P
376399-53-0P	376399-54-1P	376399-55-2P	376399-56-3P	376399-57-4P
376399-58-5P	376399-59-6P	376399-60-9P	376399-61-0P	376399-62-1P
376399-63-2P	376399-64-3P	376399-65-4P	376399-66-5P	376399-67-6P
376399-68-7P	376399-69-8P	376399-70-1P	376399-71-2P	376399-72-3P
376399-73-4P	376399-74-5P	376399-75-6P	376399-76-7P	376399-77-8P
376399-78-9P	376399-79-0P	376399-80-3P	376399-81-4P	376399-82-5P
376399-83-6P	376399-84-7P	376399-85-8P	376399-86-9P	376399-87-0P
376399-88-1P	376399-89-2P	376399-90-5P	376399-91-6P	376399-92-7P
376399-93-8P	376399-94-9P	376399-95-0P	376399-96-1P	376399-97-2P
376399-98-3P	376399-99-4P	376400-00-9P	376400-01-0P	376400-02-1P
376400-03-2P	376400-04-3P	376400-05-4P	376400-06-5P	376400-07-6P
376400-08-7P	376400-09-8P	376400-10-1P	376400-11-2P	376400-12-3P
376400-13-4P	376400-14-5P	376400-15-6P	376400-16-7P	376400-17-8P
376400-18-9P	376400-19-0P	376400-20-3P	376400-21-4P	376400-22-5P
376400-23-6P	376400-24-7P	376400-25-8P	376400-26-9P	376400-27-0P
376400-28-1P	376400-29-2P	376400-30-5P	376400-31-6P	376400-32-7P
376400-33-8P	376400-34-9P	376400-35-0P	376400-36-1P	376400-37-2P
376400-38-3P	376400-39-4P	376400-40-7P	376400-41-8P	376400-42-9P
376400-43-0P	376400-44-1P	376400-45-2P	376400-46-3P	376400-47-4P
376400-48-5P	376400-49-6P	376400-50-9P	376400-51-0P	376400-52-1P
376400-53-2P	376400-54-3P	376400-55-4P	376400-56-5P	376400-57-6P
376400-58-7P	376400-59-8P	376400-60-1P	376400-61-2P	376400-62-3P
376400-63-4P	376400-64-5P	376400-65-6P	376400-66-7P	376400-67-8P
376400-68-9P	376400-69-0P	376400-70-3P	376400-71-4P	376400-72-5P
376400-73-6P	376400-74-7P	376400-75-8P	376400-76-9P	376400-77-0P
376400-78-1P	376400-79-2P	376400-80-5P	376400-81-6P	376400-82-7P
376400-83-8P	376400-84-9P	376400-85-0P	376400-86-1P	376400-87-2P
376400-88-3P	376400-89-4P	376400-90-7P	376400-91-8P	376400-92-9P
376400-93-0P	376400-94-1P	376400-95-2P	376400-96-3P	376400-97-4P
376400-98-5P	376400-99-6P	376401-00-2P	376401-01-3P	376401-02-4P
376401-03-5P	376401-04-6P	376401-05-7P	376401-06-8P	376401-07-9P
376401-08-0P	376401-09-1P	376401-10-4P	376401-11-5P	376401-12-6P
376401-13-7P	376401-14-8P	376401-15-9P	376401-16-0P	376401-17-1P
376401-18-2P	376401-19-3P	376401-20-6P	376401-21-7P	376401-22-8P
376401-23-9P	376401-24-0P	376401-25-1P	376401-26-2P	376401-27-3P
376401-28-4P	376401-29-5P	376401-30-8P	376401-31-9P	376401-32-0P
376401-33-1P	376401-34-2P			

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT	376401-35-3P	376401-36-4P	376401-37-5P	376401-38-6P	376401-39-7P
	376401-40-0P	376401-41-1P	376401-42-2P	376401-43-3P	376401-44-4P
	376401-45-5P	376401-46-6P	376401-47-7P	376401-48-8P	376401-49-9P
	376401-50-2P	376401-51-3P	376401-52-4P	376401-53-5P	376401-54-6P
	376401-55-7P	376401-56-8P	376401-57-9P	376401-58-0P	376401-59-1P
	376401-60-4P	376401-61-5P	376401-62-6P	376401-63-7P	376401-64-8P
	376401-65-9P	376401-66-0P	376401-67-1P	376401-68-2P	376401-69-3P
	376401-70-6P	376401-71-7P	376401-72-8P	376401-73-9P	376401-74-0P
	376401-75-1P	376401-76-2P	376401-77-3P	376401-78-4P	376401-79-5P
	376401-80-8P	376401-81-9P	376401-82-0P	376401-83-1P	376401-84-2P
	376401-85-3P	376401-86-4P	376401-87-5P	376401-88-6P	376401-89-7P
	376401-90-0P	376401-91-1P	376401-92-2P	376401-93-3P	376401-94-4P

376401-95-5P	376401-96-6P	376401-97-7P	376401-98-8P	376401-99-9P
376402-00-5P	376402-01-6P	376402-02-7P	376402-03-8P	376402-04-9P
376402-05-0P	376402-06-1P	376402-07-2P	376402-08-3P	376402-09-4P
376402-10-7P	376402-11-8P	376402-12-9P	376402-13-0P	376402-14-1P
376402-15-2P	376402-16-3P	376402-17-4P	376402-18-5P	376402-19-6P
376402-20-9P	376402-21-0P	376402-22-1P	376402-23-2P	376402-24-3P
376402-25-4P	376402-26-5P	376402-27-6P	376402-28-7P	376402-29-8P
376402-30-1P	376402-31-2P	376402-32-3P	376402-33-4P	376402-34-5P
376402-35-6P	376402-36-7P	376402-37-8P	376402-38-9P	376402-39-0P
376402-40-3P	376402-41-4P	376402-42-5P	376402-43-6P	376402-44-7P
376402-45-8P	376402-46-9P	376402-47-0P	376402-48-1P	376402-49-2P
376402-50-5P	376402-51-6P	376402-52-7P	376402-53-8P	376402-54-9P
376402-55-0P	376402-56-1P	376402-57-2P	376402-58-3P	376402-59-4P
376402-60-7P	376402-61-8P	376402-62-9P	376402-63-0P	376402-64-1P
376402-65-2P	376402-66-3P	376402-67-4P	376402-68-5P	376402-69-6P
376402-70-9P	376402-71-0P	376402-72-1P	376402-73-2P	376402-74-3P
376402-75-4P	376402-76-5P	376402-77-6P	376402-78-7P	376402-79-8P
376402-80-1P	376402-81-2P	376402-82-3P	376402-83-4P	376402-84-5P
376402-85-6P	376402-86-7P	376402-87-8P	376402-88-9P	376402-89-0P
376402-90-3P	376402-91-4P	376402-92-5P	376402-93-6P	376402-94-7P
376402-95-8P	376402-96-9P	376402-97-0P	376402-98-1P	376402-99-2P
376403-00-8P	376403-01-9P	376403-02-0P	376403-03-1P	376403-04-2P
376403-05-3P	376403-06-4P	376403-07-5P	376403-08-6P	376403-09-7P
376403-10-0P	376403-11-1P	376403-12-2P	376403-13-3P	376403-14-4P
376403-15-5P	376403-16-6P	376403-17-7P	376403-18-8P	376403-19-9P
376403-20-2P	376403-21-3P	376403-22-4P	376403-23-5P	376403-24-6P
376403-25-7P	376403-26-8P	376403-27-9P	376403-28-0P	376403-29-1P
376403-30-4P	376403-31-5P	376403-32-6P	376403-33-7P	376403-34-8P
376403-35-9P	376403-36-0P	376403-37-1P	376403-38-2P	376403-39-3P
376403-40-6P	376403-41-7P	376403-42-8P	376403-43-9P	376403-44-0P
376403-45-1P	376403-46-2P	376403-47-3P	376403-48-4P	376403-49-5P
376403-50-8P	376403-51-9P	376403-52-0P	376403-53-1P	376403-54-2P
376403-55-3P	376403-56-4P	376403-57-5P	376403-58-6P	376403-59-7P
376403-60-0P	376403-61-1P	376403-62-2P	376403-63-3P	376403-64-4P
376403-65-5P	376403-66-6P			

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT	376403-67-7P	376403-68-8P	376403-69-9P	376403-70-2P	376403-71-3P
	376403-72-4P	376403-73-5P	376403-74-6P	376403-75-7P	376403-76-8P
	376403-77-9P	376403-78-0P	376403-79-1P	376403-80-4P	376403-81-5P
	376403-82-6P	376403-83-7P	376403-84-8P	376403-85-9P	376403-86-0P
	376403-87-1P	376403-88-2P	376403-89-3P	376403-90-6P	376403-91-7P
	376403-92-8P	376403-93-9P	376403-94-0P	376403-95-1P	376403-96-2P
	376403-97-3P	376403-98-4P	376403-99-5P	376404-00-1P	376404-01-2P
	376404-02-3P	376404-03-4P	376404-04-5P	376404-05-6P	376404-06-7P
	376404-07-8P	376404-08-9P	376404-09-0P	376404-10-3P	376404-11-4P
	376404-12-5P	376404-13-6P	376404-14-7P	376404-15-8P	376404-16-9P
	376404-17-0P	376404-18-1P	376404-19-2P	376404-20-5P	376404-21-6P
	376404-22-7P	376404-23-8P	376404-24-9P	376404-25-0P	376404-26-1P
	376404-27-2P	376404-28-3P	376404-29-4P	376404-30-7P	376404-31-8P
	376404-32-9P	376404-33-0P	376404-34-1P	376404-35-2P	376404-36-3P
	376404-37-4P	376404-38-5P	376404-39-6P	376404-40-9P	376404-41-0P
	376404-42-1P	376404-43-2P	376404-44-3P	376404-45-4P	376404-46-5P
	376404-47-6P	376404-48-7P	376404-49-8P	376404-50-1P	376404-51-2P
	376404-52-3P	376404-53-4P	376404-54-5P	376404-55-6P	376404-56-7P
	376404-57-8P	376404-58-9P	376404-59-0P	376404-60-3P	376404-61-4P
	376404-62-5P	376404-63-6P	376404-64-7P	376404-65-8P	376404-66-9P



376404-67-0P	376404-68-1P	376404-69-2P	376404-70-5P	376404-71-6P
376404-72-7P	376404-73-8P	376404-74-9P	376404-75-0P	376404-76-1P
376404-77-2P	376404-78-3P	376404-79-4P	376404-80-7P	376404-81-8P
376404-82-9P	376404-83-0P	376404-84-1P	376404-85-2P	376404-86-3P
376404-87-4P	376404-88-5P	376404-89-6P	376404-90-9P	376404-91-0P
376404-92-1P	376404-93-2P	376404-94-3P	376404-95-4P	376404-96-5P
376404-97-6P	376404-98-7P	376404-99-8P	376405-00-4P	376405-01-5P
376405-02-6P	376405-03-7P	376405-04-8P	376405-05-9P	376405-06-0P
376405-07-1P	376405-08-2P	376405-09-3P	376405-10-6P	376405-11-7P
376405-12-8P	376405-13-9P	376405-14-0P	376405-15-1P	376405-16-2P
376405-17-3P	376405-18-4P	376405-19-5P	376405-20-8P	376405-21-9P
376405-22-0P	376405-23-1P	376405-24-2P	376405-25-3P	376405-26-4P
376405-27-5P	376405-28-6P	376405-29-7P	376405-30-0P	376405-31-1P
376405-32-2P	376405-33-3P	376405-34-4P	376405-35-5P	376405-36-6P
376405-37-7P	376405-38-8P	376405-39-9P	376405-40-2P	376405-41-3P
376405-42-4P	376405-43-5P	376405-44-6P	376405-45-7P	376405-46-8P
376405-47-9P	376405-48-0P	376405-49-1P	376405-50-4P	376405-51-5P
376405-52-6P	376405-53-7P	376405-54-8P	376405-55-9P	376405-56-0P
376405-57-1P	376405-58-2P	376405-59-3P	376405-60-6P	376405-61-7P
376405-62-8P	376405-63-9P	376405-64-0P	376405-65-1P	376405-66-2P
376405-67-3P	376405-68-4P	376405-69-5P	376405-70-8P	376405-71-9P
376405-72-0P	376405-73-1P	376405-74-2P	376405-75-3P	376405-76-4P
376405-77-5P	376405-78-6P	376405-79-7P	376405-80-0P	376405-81-1P
376405-82-2P	376405-83-3P	376405-84-4P	376405-85-5P	376405-86-6P
376405-87-7P	376405-88-8P	376405-89-9P	376405-90-2P	376405-91-3P
376405-92-4P	376405-93-5P	376405-94-6P	376405-95-7P	376405-96-8P
376405-97-9P	376405-98-0P			

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT	376405-99-1P	376406-00-7P	376406-01-8P	376406-02-9P	376406-03-0P
	376406-04-1P	376406-05-2P	376406-06-3P	376406-07-4P	376406-08-5P
	376406-09-6P	376406-10-9P	376406-11-0P	376406-12-1P	376406-13-2P
	376406-14-3P	376406-15-4P	376406-16-5P	376406-17-6P	376406-18-7P
	376406-19-8P	376406-20-1P	376406-21-2P	376406-22-3P	376406-23-4P
	376406-24-5P	376406-25-6P	376406-26-7P	376406-27-8P	376406-28-9P
	376406-29-0P	376406-30-3P	376406-31-4P	376406-32-5P	376406-33-6P
	376406-34-7P	376406-35-8P	376406-36-9P	376406-37-0P	376406-38-1P
	376406-39-2P	376406-40-5P	376406-41-6P	376406-42-7P	376406-43-8P
	376406-44-9P	376406-45-0P	376406-46-1P	376406-47-2P	376406-48-3P
	376406-49-4P	376406-50-7P	376406-51-8P	376406-52-9P	376406-53-0P
	376406-54-1P	376406-55-2P	376406-56-3P	376406-57-4P	376406-58-5P
	376406-59-6P	376406-60-9P	376406-61-0P	376406-62-1P	376406-63-2P
	376406-64-3P	376406-65-4P	376406-66-5P	376406-67-6P	376406-68-7P
	376406-69-8P	376406-70-1P	376406-71-2P	376406-72-3P	376406-73-4P
	376406-74-5P	376406-75-6P	376406-76-7P	376406-77-8P	376406-78-9P
	376406-79-0P	376406-80-3P	376406-81-4P	376406-82-5P	376406-83-6P
	376406-84-7P	376406-85-8P	376406-86-9P	376406-87-0P	376406-88-1P
	376406-89-2P	376406-90-5P	376406-91-6P	376406-92-7P	376406-93-8P
	376406-94-9P	376406-95-0P	376406-96-1P	376406-97-2P	376406-98-3P
	376406-99-4P	376407-00-0P	376407-01-1P	376407-02-2P	376407-03-3P
	376407-04-4P	376407-05-5P	376407-06-6P	376407-07-7P	376407-08-8P
	376407-09-9P	376407-10-2P	376407-11-3P	376407-12-4P	376407-13-5P
	376407-14-6P	376407-15-7P	376407-16-8P	376407-17-9P	376407-18-0P
	376407-19-1P	376407-20-4P	376407-21-5P	376407-22-6P	376407-23-7P
	376407-24-8P	376407-25-9P	376407-26-0P	376407-27-1P	376407-28-2P
	376407-29-3P	376407-30-6P	376407-31-7P	376407-32-8P	376407-33-9P
	376407-34-0P	376407-35-1P	376407-36-2P	376407-37-3P	376407-38-4P

376407-39-5P	376407-40-8P	376407-41-9P	376407-42-0P	376407-43-1P
376407-44-2P	376407-45-3P	376407-46-4P	376407-47-5P	376407-48-6P
376407-49-7P	376407-50-0P	376407-51-1P	376407-52-2P	376407-53-3P
376407-54-4P	376407-55-5P	376407-56-6P	376407-57-7P	376407-58-8P
376407-59-9P	376407-60-2P	376407-61-3P	376407-62-4P	376407-63-5P
376407-64-6P	376407-65-7P	376407-66-8P	376407-67-9P	376407-68-0P
376407-69-1P	376407-70-4P	376407-71-5P	376407-72-6P	376407-73-7P
376407-74-8P	376407-75-9P	376407-76-0P	376407-77-1P	376407-78-2P
376407-79-3P	376407-80-6P	376407-81-7P	376407-82-8P	376407-83-9P
376407-84-0P	376407-85-1P	376407-86-2P	376407-87-3P	376407-88-4P
376407-89-5P	376407-90-8P	376407-91-9P	376407-92-0P	376407-93-1P
376407-94-2P	376407-95-3P	376407-96-4P	376407-97-5P	376407-98-6P
376407-99-7P	376408-00-3P	376408-01-4P	376408-02-5P	376408-03-6P
376408-04-7P	376408-05-8P	376408-06-9P	376408-07-0P	376408-08-1P
376408-09-2P	376408-10-5P	376408-11-6P	376408-12-7P	376408-13-8P
376408-14-9P	376408-15-0P	376408-16-1P	376408-17-2P	376408-18-3P
376408-19-4P	376408-20-7P	376408-21-8P	376408-22-9P	376408-23-0P
376408-24-1P	376408-25-2P	376408-26-3P	376408-27-4P	376408-28-5P
376408-29-6P	376408-30-9P			

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT	376408-31-0P	376408-32-1P	376408-33-2P	376408-34-3P	376408-35-4P
	376408-36-5P	376408-37-6P	376408-38-7P	376408-39-8P	376408-40-1P
	376408-41-2P	376408-42-3P	376408-43-4P	376408-44-5P	376408-45-6P
	376408-46-7P	376408-47-8P	376408-48-9P	376408-49-0P	376408-50-3P
	376408-51-4P	376408-52-5P	376408-53-6P	376408-54-7P	376408-55-8P
	376408-56-9P	376408-57-0P	376408-58-1P	376408-59-2P	376408-60-5P
	376408-61-6P	376408-62-7P	376408-63-8P	376408-64-9P	376408-65-0P
	376408-66-1P	376408-67-2P	376408-68-3P	376408-69-4P	376408-70-7P
	376408-71-8P	376408-72-9P	376408-73-0P	376408-74-1P	376408-75-2P
	376408-76-3P	376408-77-4P	376408-78-5P	376408-79-6P	376408-80-9P
	376408-81-0P	376408-82-1P	376408-83-2P	376408-84-3P	376408-85-4P
	376408-86-5P	376408-87-6P	376408-88-7P	376408-89-8P	376408-90-1P
	376408-91-2P	376408-92-3P	376408-93-4P	376408-94-5P	376408-95-6P
	376408-96-7P	376408-97-8P	376408-98-9P	376408-99-0P	376409-00-6P
	376409-01-7P	376409-02-8P	376409-03-9P	376409-04-0P	376409-05-1P
	376409-06-2P	376409-07-3P	376409-08-4P	376409-09-5P	376409-10-8P
	376409-11-9P	376409-12-0P	376409-13-1P	376409-14-2P	376409-15-3P
	376409-16-4P	376409-17-5P	376409-18-6P	376409-19-7P	376409-20-0P
	376409-21-1P	376409-22-2P	376409-23-3P	376409-24-4P	376409-25-5P
	376409-26-6P	376409-27-7P	376409-28-8P	376409-29-9P	376409-30-2P
	376409-31-3P	376409-32-4P	376409-33-5P	376409-34-6P	376409-35-7P
	376409-36-8P	376409-37-9P	376409-38-0P	376409-39-1P	376409-40-4P
	376409-41-5P	376409-42-6P	376409-43-7P	376409-44-8P	376409-45-9P
	376409-46-0P	376409-47-1P	376409-48-2P	376409-49-3P	376409-50-6P
	376409-51-7P	376409-52-8P	376409-53-9P	376409-54-0P	376409-55-1P
	376409-56-2P	376409-57-3P	376409-58-4P	376409-59-5P	376409-60-8P
	376409-61-9P	376409-62-0P	376409-63-1P	376409-64-2P	376409-65-3P
	376409-66-4P	376409-67-5P	376409-68-6P	376409-69-7P	376409-70-0P
	376409-71-1P	376409-72-2P	376409-73-3P	376409-74-4P	376409-75-5P
	376409-76-6P	376409-77-7P	376409-78-8P	376409-79-9P	376409-80-2P
	376409-81-3P	376409-82-4P	376409-83-5P	376409-84-6P	376409-85-7P
	376409-86-8P	376409-87-9P	376409-88-0P	376409-89-1P	376409-90-4P
	376409-91-5P	376409-92-6P	376409-93-7P	376409-94-8P	376409-95-9P
	376409-96-0P	376409-97-1P	376409-98-2P	376409-99-3P	376410-00-3P
	376410-01-4P	376410-02-5P	376410-03-6P	376410-04-7P	376410-05-8P
	376410-06-9P	376410-07-0P	376410-08-1P	376410-09-2P	376410-10-5P

376410-11-6P 376410-12-7P 376410-13-8P 376410-14-9P 376410-15-0P  
 376410-16-1P 376410-17-2P 376410-18-3P 376410-19-4P 376410-20-7P  
 376410-21-8P 376410-22-9P 376410-23-0P 376410-24-1P 376410-25-2P  
 376410-26-3P 376410-27-4P 376410-28-5P 376410-29-6P 376410-30-9P  
 376410-31-0P 376410-32-1P 376410-33-2P 376410-34-3P 376410-35-4P  
 376410-36-5P 376410-37-6P 376410-38-7P 376410-39-8P 376410-40-1P  
 376410-41-2P 376410-42-3P 376410-43-4P 376410-44-5P 376410-45-6P  
 376410-46-7P 376410-47-8P 376410-48-9P 376410-49-0P 376410-50-3P  
 376410-51-4P 376410-52-5P 376410-53-6P 376410-54-7P 376410-55-8P  
 376410-56-9P 376410-57-0P 376410-58-1P 376410-59-2P 376410-60-5P  
 376410-61-6P 376410-62-7P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT 376410-63-8P 376410-64-9P 376410-65-0P 376410-66-1P 376410-67-2P  
 376410-68-3P 376410-69-4P 376410-70-7P 376410-71-8P 376410-72-9P  
 376410-73-0P 376410-74-1P 376410-75-2P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT 229477-44-5 244008-03-5, PN: WO9947540 SEQID: 3 unclaimed DNA  
 244008-06-8, PN: WO9947540 SEQID: 4 unclaimed DNA 244008-07-9, PN:  
 WO9947540 SEQID: 5 unclaimed DNA 244008-08-0, PN: WO9947540 SEQID: 6  
 unclaimed DNA 244008-09-1, PN: WO9947540 SEQID: 7 unclaimed DNA  
 244008-12-6, 8: PN: WO0183510 SEQID: 8 unclaimed DNA 244008-13-7, PN:  
 WO9947540 SEQID: 9 unclaimed DNA 244008-14-8, PN: WO9947540 SEQID: 10  
 unclaimed DNA

RL: PRP (Properties)  
 (unclaimed nucleotide sequence; human nucleic acids and their encoded proteins and antibodies)

IT 377754-45-5  
 RL: PRP (Properties)  
 (unclaimed sequence; human nucleic acids and their encoded proteins and antibodies)

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:435111 HCAPLUS

DN 135:29911

TI DNA encoding twenty-one human extracellular matrix and cell adhesion molecules

IN Yue, Henry; Tang, Y. Tom; Lal, Preeti; Burford, Neil; Azimzai, Yalda; Patterson, Chandra; Baughn, Mariah R.; Lu, Dyung Aina M.; Shah, Purvi; Au-young, Janice

PA Incyte Genomics, Inc., USA; et al.

SO PCT Int. Appl., 135 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042285	A2	20010614	WO 2000-US32990	20001205
	WO 2001042285	A3	20020307		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,			



LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
EP 1244695 A2 20021002 EP 2000-989218 20001205  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
US 2003044913 A1 20030306 US 2002-149819 20020610  
PRAI US 1999-172852P P 19991210  
US 1999-172354P P 19991216  
WO 2000-US32990 W 20001205  
AB The invention provides human extracellular matrix and cell adhesion mols.  
(XMAD) and polynucleotides which identify and encode XMAD. The invention  
also provides expression vectors, host cells, antibodies, agonists, and  
antagonists. The invention also provides methods for diagnosing,  
treating, or preventing disorders assocd. with expression of XMAD.  
IT Bladder  
Brain  
Drugs  
Kidney, neoplasm  
Lung, neoplasm  
Mammary gland  
Nucleic acid hybridization  
PCR (polymerase chain reaction)  
Protein sequences  
Stomach, neoplasm  
Synovial membrane  
Testis, neoplasm  
cDNA library  
cDNA sequences  
(DNA encoding twenty-one human extracellular matrix and cell adhesion  
mols.)  
IT Cell adhesion molecules  
RL: ANT (Analyte); ANST (Analytical study)  
(DNA encoding twenty-one human extracellular matrix and cell adhesion  
mols.)  
IT Antibodies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
(Uses)  
(DNA encoding twenty-one human extracellular matrix and cell adhesion  
mols.)  
IT Proteins, specific or class  
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,  
unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical  
study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)  
(XMAD (extracellular matrix and cell adhesion mol.); DNA encoding  
twenty-one human extracellular matrix and cell adhesion mols.)  
IT Molecular cloning  
(XMAD; DNA encoding twenty-one human extracellular matrix and cell  
adhesion mols.)  
IT Penis  
(acuminate wart; DNA encoding twenty-one human extracellular matrix and  
cell adhesion mols.)  
IT Uterus  
(cervix; DNA encoding twenty-one human extracellular matrix and cell  
adhesion mols.)  
IT Artery  
(coronary; DNA encoding twenty-one human extracellular matrix and cell

adhesion mols.)

IT Uterus  
(endometrium; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Bronchi  
(epithelium; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Animal tissue  
(expression patterns in; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Proteins, specific or class  
RL: ANT (Analyte); ANST (Analytical study)  
(extracellular matrix-assocd.; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Immunoglobulins  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(fragments; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Animal cell line  
(hNT2; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Chromosome  
(human; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Prostate gland  
(neoplasm; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Intestine  
(small; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT Salivary gland  
(submandibular; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT 149408-35-5, Mucin MG 2 (human clone MG2-6-1 gene MUC7 precursor reduced)  
252049-91-5 280786-68-7, Protein **ss3939** (human) 319020-53-6,  
Protein (human clone HP03377) 327142-80-3 343895-34-1 343895-35-2  
343895-36-3 343895-37-4 343895-38-5 343895-39-6 343895-40-9  
343895-41-0 343895-42-1 343895-43-2 343895-44-3 343895-45-4  
343895-46-5 343895-47-6 343895-48-7 343895-49-8  
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)  
(amino acid sequence; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

IT 343895-33-0 343895-50-1 343895-51-2 343895-52-3 343895-53-4  
343895-54-5 343895-55-6 343895-56-7 343895-57-8 343895-58-9  
343895-59-0 343895-60-3 343895-61-4 343895-62-5 343895-63-6  
343895-64-7 343895-65-8 343895-66-9 343895-67-0 343895-68-1  
343895-69-2  
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)  
(nucleotide sequence; DNA encoding twenty-one human extracellular matrix and cell adhesion mols.)

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1  
AN 2000:457208 HCAPLUS  
DN 133:85160  
TI Protein and cDNA sequences of human protein **ss3939**, which has

homology to C-type lectins  
 IN Anderson, Dirk A.  
 PA Immunex Corporation, USA  
 SO PCT Int. Appl., 73 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039296	A1	20000706	WO 1999-US30523	19991222
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002058310	A1	20020516	US 2001-887855	20010622
PRAI	US 1998-113820P	P	19981223		
	WO 1999-US30523	A1	19991222		
AB	The invention provides protein and cDNA sequences of a novel protein, designated <b>ss3939</b> , which has an extracellular domain that has homol. to C-type lectin domains. The invention also provides chimeric proteins created by fusing <b>ss3939</b> , or fragments thereof, with an <u>Fc protein</u> . The invention further provides processes for prodn. of recombinant forms of <b>ss3939</b> , antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.				
IT	Fusion proteins (chimeric proteins) RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation) (Fc/ <b>ss3939</b> ; protein and cDNA sequences of human protein <b>ss3939</b> , which has homol. to C-type lectins)				
IT	Immunoglobulins RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation) (fragments, Fc/ <b>ss3939</b> ; protein and cDNA sequences of human protein <b>ss3939</b> , which has homol. to C-type lectins)				
IT	Animal cell Bacteria (Eubacteria) Plant cell Yeast (host; protein and cDNA sequences of human protein <b>ss3939</b> , which has homol. to C-type lectins)				
IT	Chromosome (human 11, mapping of <b>ss3939</b> gene to 11q22; protein and cDNA sequences of human protein <b>ss3939</b> , which has homol. to C-type lectins)				
IT	Animal cell (mammalian, host; protein and cDNA sequences of human protein <b>ss3939</b> , which has homol. to C-type lectins)				
IT	Antibodies RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) (monoclonal; protein and cDNA sequences of human protein <b>ss3939</b> , which has homol. to C-type lectins)				
IT	Genetic mapping (of <b>ss3939</b> gene to h11q22; protein and cDNA sequences of				

human protein **ss3939**, which has homol. to C-type lectins)

IT Proteins, specific or class  
 RL: BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)  
 (oligomeric, **ss3939**; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)

IT Genetic engineering  
 Protein sequences  
 cDNA sequences  
 (protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)

IT Antibodies  
 Primers (nucleic acid)  
 Probes (nucleic acid)  
 RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)  
 (protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)

IT Mouse  
 (**ss3939** homolog from; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)

IT Proteins, specific or class  
 RL: BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)  
 (**ss3939**; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)

IT 280786-68-7DP, Protein **ss3939** (human), subfragments are claimed  
 280786-69-8DP, 22-227-Protein **ss3939** (human), subfragments are claimed  
 280786-71-2P, 249-374-Protein **ss3939** (human)  
 RL: BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)  
 (amino acid sequence; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)

IT 280786-67-6  
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)  
 (nucleotide sequence; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)

IT 280788-08-1, 3: PN: WO0039296 SEQID: 3 unclaimed DNA 280788-09-2, 4: PN: WO0039296 SEQID: 4 unclaimed DNA  
 RL: PRP (Properties)  
 (unclaimed nucleotide sequence; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)

IT 157214-04-5  
 RL: PRP (Properties)  
 (unclaimed protein sequence; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)

IT 98849-88-8 203244-38-6  
 RL: PRP (Properties)  
 (unclaimed sequence; protein and cDNA sequences of human protein **ss3939**, which has homol. to C-type lectins)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 2003:491063 HCAPLUS  
 DN 139:57897  
 TI Novel pharmaceutical composition of interferon gamma or pirfenidone  
 combined with molecular diagnostics for the improved treatment of  
 interstitial lung diseases  
 IN Bevec, Dorian; Ziesche, Rolf  
 PA Mondobiotech SA, Switz.  
 SO PCT Int. Appl., 80 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051388	A2	20030626	WO 2002-CH691	20021212
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI EP 2001-130011 A 20011218

AB The present invention relates to a novel pharmaceutical compn. of compds.  
 having the biol. activity of interferon gamma (IFN-.gamma.) or pirfenidone  
 in combination with a diagnostic array of candidate polynucleotides for  
 the improved treatment of all forms of interstitial lung diseases, in  
 particular of idiopathic pulmonary fibrosis (IPF). This invention  
 describes the combination of mol. diagnosis and clin. therapy as a novel  
 medication principle for redn. of mortality and improvement of disease  
 management in interstitial lung diseases.

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
 unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
 ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (14-3-3.sigma.; pharmaceutical compn. of interferon gamma or  
 pirfenidone combined with mol. diagnostics for improved treatment of  
 interstitial lung diseases (ILD))

IT Keratins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
 unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
 ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (15, BC002641; pharmaceutical compn. of interferon gamma or pirfenidone  
 combined with mol. diagnostics for improved treatment of interstitial  
 lung diseases (ILD))

IT Keratins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
 unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
 ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (15; pharmaceutical compn. of interferon gamma or pirfenidone combined  
 with mol. diagnostics for improved treatment of interstitial lung  
 diseases (ILD))

IT Keratins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
 unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
 ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (17, Z19574; pharmaceutical compn. of interferon gamma or pirfenidone

- combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Keratins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (17; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Fibrillins  
 Thrombospondins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Thrombospondins  
 Uncoupling protein  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Keratins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (4, X07695; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Keratins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (5, M21389; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Cadherins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (5, U84722; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT G protein-coupled receptors  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (51, AF056085; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Calcium-binding proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (A2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))



- IT Annexins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(A8; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(ADAN28, disintegrin and metalloproteinase domain 28, transcript variant 3: AF137335; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Hemoglobins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(AF349571, BC005931, NM\_000519; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(AL133067; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(Apo-2 ligand tumor necrosis factor (ligand) superfamily, member 10, U37518; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(B7; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(BCG induced integral membrane protein BIGMo-103; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(BG538564, DKFZp564A132, AL049963; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,



unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(BLu protein: U70824; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(BLu protein; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Apolipoproteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(C-I; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(CD209 antigen-like: AB015629; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(CD24 signal transducer; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT CD antigens

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(CD52; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(CGI-83 protein: BC000878; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(CGI-92 protein; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(CLONE=IMAGE:1032795=Hs.83623 nuclear receptor subfamily1; pharmaceutical compn. of interferon gamma or pirfenidone combined with

mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(CLONE=IMAGE:1982571 ATPase, H<sup>+</sup> transporting; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Disease, animal

(Churg-Strauss syndrome; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Receptors

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(DDR1 (discoidin domain receptor 1), isoform b; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(DEADH (Asp-Glu-Ala-AspHis) box polypeptide; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(DKFZP586G011; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(DKFZp434A119; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(DKFZp434A119; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(DKFZp564A132; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(DKFZp564D066, AL050025; pharmaceutical compn. of interferon gamma or

pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(DKFZp564D193; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(DKFZp586E1124; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(DKFZp586M1120; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(DKFZp761N09121: BF435376; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(Duffy blood group: U01839; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Cadherins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(E-, type 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transcription factors

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(E74-like factor 3 (ets domain transcription factor, epithelial-specific) : U73844; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(E74-like factor 3 (ets domain transcription factor; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Escherichia coli

(EPEC, ETEC, EIEC, EHEC; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(FLJ10430: NM 018092.1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(FLJ10921; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(FLJ10970; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(FLJ11767; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(FLJ12983; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(FLJ13110; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(FLJ13310; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(FLJ13945 fis, clone Y79AA1000969; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins



RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(FLJ14054; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(FLJ21616; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(FLJ23049; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(FLJ23571; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(FYN oncogene: N20923; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT GABA receptors

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(GABAA, .alpha.5; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT DNA microarray technology

(GENECHIP; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(GTP-binding, similar to RAYRAB1C:BC000566; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Kidney, disease

(Goodpasture's syndrome; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Apolipoproteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(H; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(HLA (human leukocyte-assocd. antigen), B51, DR beta 5,35 M11867; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(HLA (human leukocyte-assocd. antigen), B51; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(HLA (human leukocyte-assocd. antigen), DQ alpha 1, M33906; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(HLA (human leukocyte-assocd. antigen), DR beta 1, M33600; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(HLA (human leukocyte-assocd. antigen), HLA-B39; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transcription factors

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(HNF-3.alpha. (hepatocyte nuclear factor 3.alpha.); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Heat-shock proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(HSP 104, 105kD, D86956; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(HSPC156; pharmaceutical compn. of interferon gamma or pirfenidone

- combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Fibronectins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (I; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Insulin-like growth factor-binding proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (IGFBP-2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Insulin-like growth factor-binding proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (IGFBP-6; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Gene, animal  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (ILD differentially expressed; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Transcription factors  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (ISGF-3: M97935; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (Jagged2 (JAG2); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein re-tention receptor 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (KIAA0362 gene, MCF.2 cell line derived transforming se-15 quence-like: AB002360; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(KIAA0372; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(KIAA0433; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(KIAA1199; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(KIAA1598; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Ribosomal proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(L37A; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(LIM domain protein: BC003096; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(LUNX protein; PLUNC (palate lung and nasal epithelium clone); :AB024937; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT CD2 (antigen)  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(M16445; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Thrombomodulin  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);



- ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(M16552; pharmaceutical compn. of interferon gamma or pirfenidone  
combined with mol. diagnostics for improved treatment of interstitial  
lung diseases (ILD))
- IT Perforin  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(M28393; pharmaceutical compn. of interferon gamma or pirfenidone  
combined with mol. diagnostics for improved treatment of interstitial  
lung diseases (ILD))
- IT Interleukin 7 receptors  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(M29696; pharmaceutical compn. of interferon gamma or pirfenidone  
combined with mol. diagnostics for improved treatment of interstitial  
lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(MAD (mothers against decapentaplegic, Drosophila) homolog;  
pharmaceutical compn. of interferon gamma or pirfenidone combined with  
mol. diagnostics for improved treatment of interstitial lung diseases  
(ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(MGC:2854; pharmaceutical compn. of interferon gamma or pirfenidone  
combined with mol. diagnostics for improved treatment of interstitial  
lung diseases (ILD))
- IT Histocompatibility antigens  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(MHC (major histocompatibility complex), class II, DQ beta 1, AW276186;  
pharmaceutical compn. of interferon gamma or pirfenidone combined with  
mol. diagnostics for improved treatment of interstitial lung diseases  
(ILD))
- IT Histocompatibility antigens  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(MHC (major histocompatibility complex), class II, .alpha.;  
pharmaceutical compn. of interferon gamma or pirfenidone combined with  
mol. diagnostics for improved treatment of interstitial lung diseases  
(ILD))
- IT Mucins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(MUC4, sv7-MUC4 apomucin, tracheobronchial; pharmaceutical compn. of  
interferon gamma or pirfenidone combined with mol. diagnostics for  
improved treatment of interstitial lung diseases (ILD))
- IT Mucins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)

(MUC4; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Mucins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(MUC5; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(MUF1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(NG22; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(NTT5; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(P311 protein: U36189; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(PRO2834: AF119903; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(PTH-responsive osteosarcoma B1 protein; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT G proteins (guanine nucleotide-binding proteins)

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(RAB, member of RAS oncogene family-like 2A: AF095350; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(RAS guanyl releasing protein 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(Ras-related assocd. with diabetes: L24564; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(Ras-related assocd. with diabetes; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Calcium-binding proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(S100; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Calcium-binding proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(S100A4; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Ribosomal proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(S4; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(SAM domain; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Histocompatibility antigens

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(SB classII, alpha-chain, A1128225; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(SH3-contg. protein SH3GLB2; pharmaceutical compn. of interferon gamma

or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(SMC (mouse) homolog; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transcription factors

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(STAT1 (signal transducer and activator of transcription 1); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transcription factors

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(T-cell specific, HMG-box; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transforming growth factor receptors

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(TGF-.beta. receptor, type I; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Granulomatous disease

(Wegener's granulomatosis; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(Wilms tumor 1, (WT1), variant D; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Transport proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(X transporter protein 3: NM\_020208.1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(adaptor-related protein complex 1, mu 2 subuni; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)



(adipose differentiation-related protein, BC005127; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Filamin

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(alpha (actin-binding protein-280); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Glycoproteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(alpha-2-HS-glycoprotein, BG538564; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(anterior gradient 2 (Xenopus laevis) homolog; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(aquaporine 3 (water channel), AQP3 gene, AB001325; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(ataxia-telangiectasia group D-assocd. protein; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Dyneins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(axonemal, intermediate polypeptide: AF091619; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(bone marrow stromal cell antigen 1, D21878; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(brain specific protein (LOC51673): AF132972; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(calcitonin receptor-like: L76380; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Calcium-binding proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(calgranulin A; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(carboxypeptidase B-like protein: AB011969; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Drug delivery systems

(carriers; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(cerebellar degeneration-related protein (34kD), M16965; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(chitinase 3-like 1 (cartilage glycoprotein-39): M80927; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(chitinase 3-like 2: U58515; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(chloride intracellular channel 2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(chondroitin sulfate proteoglycan 2 (versican); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (chromosome 11 open reading frame 16;  
 pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (claudin-3; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (claudins, 15; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (clone MGC:12387: M16942; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (clone=IMAGE-2406340: AI830563; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Complement

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (component 6; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (cysteine-rich, 1, BC002738; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (deleted in lung and esophageal cancer 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Mycobacterium

(diagnosis; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

- IT Bacteria (Eubacteria)  
 Fungi  
 Mycoplasma  
 Virus  
 Yeast  
 (diagnostics; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (disintegrin and metalloproteinase domain 28 (ADAM28), isoform 2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (disintegrin and metalloproteinase domain 9 (meltrigamma) (ADAM9): U41766; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (disks, large (Drosophila) homolog 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (diubiquitin; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Initiation factors (protein formation)  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (eIF-1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (endothelial PAS domain protein 1, U51626; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Cytokines  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (eosinophil chemotactic, TSA1902; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Receptors



RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(ephrin, EPHA3, AF213459; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Receptors

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(ephrin; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(expressed in osteoblast: AB000115; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(eyes absent (Drosophila) homolog 2: U71207; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(fatty acid binding protein 4, adipocyte, BC003672; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(fatty acid binding protein 6, U19869; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(fenestrated-endothelial linked structure protein (FELS), PVL protein (PLVAP): AF326591; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(fibronectin leucine rich transmembrane protein 2, AB007865.; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Lung, disease

(fibrosis; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial

- lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (fibulin, 2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT cDNA library  
 (for ILD differentially expressed genes; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Genomic library  
 (for infection agents genes; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (forkhead box J1 (FOXJ1); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (forkhead box J1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Agglutinins and Lectins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (galectin-7; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (guanylate binding protein 1, interferon-inducible, 67kD:BC002666; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (haptoglobin-related protein; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (hematopoietic PBX-interacting protein; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(hepatic leukemia factor: M95585; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(hydroxyacid oxidase homolog; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Lung, disease

(hypersensitivity pneumonitis; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Drug delivery systems

(inhalants; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT CD antigens

Integrins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(integrin .alpha.7; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(interferon, alpha-inducible protein (clone IFI-6-16); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(interferon, alpha-inducible protein 27: NM\_005532; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(interferon, gamma-inducible protein 30, AF097362; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(interferon-stimulated protein, 15 kDa (ISG15): M13755; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);

ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(interleukin 1 receptor-like 1 (IL1RL1): NM 003856.1; pharmaceutical  
compn. of interferon gamma or pirfenidone combined with mol.  
diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(interleukin 1 receptor-like 1; pharmaceutical compn. of interferon  
gamma or pirfenidone combined with mol. diagnostics for improved  
treatment of interstitial lung diseases (ILD))

IT Interleukin receptors  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(interleukin 13; pharmaceutical compn. of interferon gamma or  
pirfenidone combined with mol. diagnostics for improved treatment of  
interstitial lung diseases (ILD))

IT Dyneins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(intermediate chain 2; pharmaceutical compn. of interferon gamma or  
pirfenidone combined with mol. diagnostics for improved treatment of  
interstitial lung diseases (ILD))

IT Lung, disease  
(interstitial; pharmaceutical compn. of interferon gamma or pirfenidone  
combined with mol. diagnostics for improved treatment of interstitial  
lung diseases (ILD))

IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(klotho; pharmaceutical compn. of interferon gamma or pirfenidone  
combined with mol. diagnostics for improved treatment of interstitial  
lung diseases (ILD))

IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(latent transforming growth factor beta binding protein 4;  
pharmaceutical compn. of interferon gamma or pirfenidone combined with  
mol. diagnostics for improved treatment of interstitial lung diseases  
(ILD))

IT G protein-coupled receptors  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(latrophilin; pharmaceutical compn. of interferon gamma or pirfenidone  
combined with mol. diagnostics for improved treatment of interstitial  
lung diseases (ILD))

IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(leiomodulin 1; pharmaceutical compn. of interferon gamma or pirfenidone  
combined with mol. diagnostics for improved treatment of interstitial  
lung diseases (ILD))

IT Polynucleotides  
RL: ARG (Analytical reagent use); DEV (Device component use); DGN



(Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(library of, pharmaceutical compn. comprising; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(lipocalin, 2 (oncogene 24p3); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(lung type-I cell membrane-assocd. glycoprotein, AU154455; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(lysosomal-assocd. membrane protein 2: J04183; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(macrophage receptor with collagenous structure, MARCO, AF035819; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(matrilin 3; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(matrix assocd., actin dependent regulator of chromatin, subfamily f, member 1, AF231056; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Glycoproteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(membrane, LIG-1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Polyamide fibers, uses

RL: DEV (Device component use); USES (Uses)

(membrane, diagnostic array on; pharmaceutical compn. of interferon

gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(membrane, golgi, GP73; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(mesoderm specific transcript (mouse) homolog: BC002413; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(microtubule-assocd. protein, RPEB family; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Diagnosis

(mol., combination with therapy; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(monokine induced by gamma interferon; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(myosin regulatory light chain 2, smooth muscle isoform; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(nasopharyngeal epithelium specific protein 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(natural killer cell group 7; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(nectin-like protein 2 (NECL2): AF132811; pharmaceutical compn. of

- interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteoglycans, biological studies  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (neuroglycan C; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (neuroligin; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Transcription factors  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (neuronal specific, DAT1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (nidogen (enactin): M30269; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Antigens  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (non-specific cross reacting antigen; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Receptors  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (nuclear receptor subfamily 4, group A, member 2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (nuclear receptor subfamily 4, group A; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Membranes, nonbiological  
 (nylon, or nitrocellulose, diagnostic array on; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (ound in inflammatory zone 3 (FIZZ3), AF323081; pharmaceutical compn.

of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (peroxisome biogenesis factor 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Glucocorticoids  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical compn. comprising; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Acinetobacter baumannii  
 Acinetobacter calcoaceticus  
 Aeromonas  
 Bartonella bacilliformis  
 Bartonella henselae  
 Borrelia  
 Brucella  
 Burkholderia cepacia  
 Calymmatobacterium granulomatis  
 Campylobacter fetus  
 Campylobacter jejuni  
 Cardiobacterium hominis  
 Chlamydia  
 Citrobacter  
 Eikenella corrodens  
 Enterobacter  
 Fungi  
 Fusobacterium  
 Gardnerella vaginalis  
 Hepadnaviridae  
 Human adenovirus  
 Human herpesvirus  
 Influenza virus  
 Klebsiella  
 Lab-on-a-chip  
 Leptospira interrogans  
 Moraxella catarrhalis  
 Morganella (bacterium)  
 Mycoplasma  
 Nucleic acid hybridization  
 Paramyxovirus  
 Porphyromonas  
 Prevotella  
 Prognosis  
 Proteus (bacterium)  
 Providencia  
 Pseudomonas aeruginosa  
 Retroviridae  
 Rheumatoid arthritis  
 Rickettsia prowazeki  
 Salmonella enterica  
 Serratia  
 Shigella  
 Staphylococcus aureus  
 Stenotrophomonas maltophilia  
 Streptococcus



Susceptibility (genetic)

Toxoplasma

Treponema pallidum

Vibrio cholerae

Yeast

Yersinia enterocolitica

(pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Biglycans

CD14 (antigen)

CD36 (antigen)

Calretinin

Elastins

Ezrin

Ferritins

Insulin-like growth factor I receptors

Integrins

Interleukin 7 receptors

Leukosialin

Myelin basic protein

RANTES (chemokine)

Transferrin receptors

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Antibodies

Oligonucleotides

Probes (nucleic acid)

RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(plectins, intermediate filament binding protein, 500kD; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Receptors

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(plexin, B1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(prosaposins; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Receptors

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,

unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(protein C, endothelial (EPCR), L35545; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Cadherins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(protocadherin, 12, AF231025; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Cadherins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(protocadherin, 17, AF029343; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Cadherins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(protocadherin, .alpha.12; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(pulmonary surfactant protein (SP5), J03553; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(ranslocase of inner mitochondrial membrane 8 (yeast) ho-molog A: BC005236; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(regulator of G protein signaling-Z (RGSZ1): AF060877; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(retinol-binding protein 4, interstitial, AF119868; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

IT Proteins

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(rocollagen C-endopeptidase enhancer 2, AF098269; pharmaceutical compn.

- of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Connective tissue, disease  
(scleroderma; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(semaphorin, sem2: AB029496; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(serine threonine kinase 11 (STK11); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(similar to swine acylneuraminatylase; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Drug delivery systems  
(single dose; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Glass, uses  
Glass beads  
RL: DEV (Device component use); USES (Uses)  
(slide, diagnostic array on; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(small inducible cytokine subfamily A (Cys-Cys), member 18, AB000221; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(small inducible cytokine subfamily A (Cys-Cys); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Chemokines  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(small inducible cytokine subfamily B (Cys-X-Cys), member 11: AF002985; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(small inducible cytokine subfamily C, member 2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Transport proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(solute carrier family 14 (urea transporter), member 1 (Kidd blood group): U35735; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Transport proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(solute carrier family 14 (urea transporter), member 1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Transport proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(solute carrier family 6; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(sorting nexin 10, (SNX10), AF121860; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Antigens  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(sperm assocd. antigen 6: AF079363; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Antigens  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(sperm assocd. antigen 6; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(surfactant, pulmonary-assocd. protein A2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);



- ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (surfactant, pulmonary-assocd. protein C, BC005913; pharmaceutical  
 compn. of interferon gamma or pirfenidone combined with mol.  
 diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Lupus erythematosus  
 (systemic; pharmaceutical compn. of interferon gamma or pirfenidone  
 combined with mol. diagnostics for improved treatment of interstitial  
 lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
 unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
 ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (tetraspan, transmembrane 4 superfamily member; pharmaceutical compn.  
 of interferon gamma or pirfenidone combined with mol. diagnostics for  
 improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
 unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
 ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (tetraspanin, TM4-C; pharmaceutical compn. of interferon gamma or  
 pirfenidone combined with mol. diagnostics for improved treatment of  
 interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
 unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
 ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (transmembrane 4 superfamily member 1, M90657; pharmaceutical compn. of  
 interferon gamma or pirfenidone combined with mol. diagnostics for  
 improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
 unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
 ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (tumor necrosis factor .alpha.-induced protein 6; pharmaceutical compn.  
 of interferon gamma or pirfenidone combined with mol. diagnostics for  
 improved treatment of interstitial lung diseases (ILD))
- IT Fibroblast growth factor receptors  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
 unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
 ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (type 2, M80634; pharmaceutical compn. of interferon gamma or  
 pirfenidone combined with mol. diagnostics for improved treatment of  
 interstitial lung diseases (ILD))
- IT Collagens, biological studies  
 Scavenger receptors  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
 unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
 ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (type I; pharmaceutical compn. of interferon gamma or pirfenidone  
 combined with mol. diagnostics for improved treatment of interstitial  
 lung diseases (ILD))
- IT Collagens, biological studies  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
 unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
 ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (type IV, .alpha.3; pharmaceutical compn. of interferon gamma or  
 pirfenidone combined with mol. diagnostics for improved treatment of  
 interstitial lung diseases (ILD))
- IT Collagens, biological studies  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,

- unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(type V, .alpha.2; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Collagens, biological studies  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(type VII, 1, L02870; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Collagens, biological studies  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(type XIV, CLONE=IMAGE:3579023; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Gene expression profiles, animal  
(use in diagnostics; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(vascular cell adhesion mol. 1: M60335; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(wingless-type MMTV integration site family, member 5A; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(zinc finger-contg., 331: AF272148; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Proteins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(zinc finger-contg., Cip1-interacting; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Integrins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(.alpha.1; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Integrins  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,

- unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (.alpha.4; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Transforming growth factors  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (.beta.1-; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Tubulins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (.beta.2-, BC002783; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Microglobulins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (.beta.2-; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Integrins  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (.beta.4; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Interferons  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (.gamma., X87308; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Interferons  
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (.gamma., pegylated, (PRG-IFN-.gamma.); pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT Fibrinogens  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (.gamma.; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9048-63-9, Epoxide hydrolase  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (2, cytoplasmic: AF233334; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))

- IT 109136-49-4, Ubiquitin specific protease  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (9; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9031-94-1, Aminopeptidase  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (AF191545; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9031-98-5, Carboxypeptidase  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (B1, (tissue), M81057; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 172521-74-3, Relaxin 1  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (BC005956; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9026-43-1, Serine/threonine kinase  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (Fas-interacting, 3; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 321976-25-4, Sialyltransferase  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (U14550; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9035-51-2, Cytochrome P 450, biological studies  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (XXVIIA, M62401; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9025-82-5, Phosphodiesterase  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (cAMP-specific, NM\_000923; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 7440-21-3, Silicon, uses  
 RL: DEV (Device component use); USES (Uses)  
 (chip; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial



- lung diseases (ILD))
- IT 139691-92-2, Serine proteinase inhibitor  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (clade B (ovalbumin), member 5 (SERPINB5): U04313; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9001-62-1, Lipase  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (endothelial: AF118767; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9023-09-0, Sulfotransferase  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (family, cytosolic, 1C, member 1:AF186254; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9028-86-8, Aldehyde dehydrogenase  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (family, member A1: BC004370; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9033-07-2, UDP-Glycosyltransferase  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (family, **polypeptide** A1:M57899; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 117849-44-2, Gastrotropin  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (fatty acid binding protein 6, ileal; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9001-84-7, Phospholipase A2  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (group IIA; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9029-17-8, Proline oxidase  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (homolog; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9014-51-1, Indoleamine 2,3-dioxygenase  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);

- ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(interferon-gamma-inducible; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9013-18-7  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(long-chain 4; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 372092-80-3, Protein kinase  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(male germ cell-assocd.; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9004-70-0, Nitrocellulose  
RL: DEV (Device component use); USES (Uses)  
(membrane, diagnostic array on; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9001-59-6, Pyruvate kinase  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(muscle; pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9001-06-3, Chitotriosidase) 9001-61-0, Leucine aminopeptidase  
9014-42-0, Proteoglycan 4 9025-62-1, Steroid sulfatase 9027-95-6, ATP citrate lyase 9047-22-7, Cathepsin B 9082-73-9, Steroid dehydrogenase 37270-94-3, Platelet factor 4 50812-37-8, Glutathione S-transferase 60202-07-5, Cholesterol 25-hydroxylase 71965-46-3, Cathepsin S 80295-33-6, Complement C1q 80295-41-6, Complement C3 82249-77-2, Arachidonate 15-lipoxygenase 87397-91-9, Thymosin .beta.10 109489-77-2, Tetranectin 120038-28-0, Carboxypeptidase M 140610-48-6, Matrix metalloproteinase 10 141256-52-2, Matrix metalloproteinase 7 143180-74-9, Granzyme B 149371-18-6, Legumain 151185-16-9, Fibroblast growth factor 9 151662-20-3, Myotonic dystrophy kinase 160477-63-4, Tissue factor pathway inhibitor 2 171715-12-1, Cathepsin Z 189460-40-0, Connective tissue growth factor 194739-73-6, MAP kinase kinase 6 196414-33-2, Disintegrin 198154-07-3, Cystatin F 227018-38-4, Neuropilin 2 334677-51-9, Cytochrome P450-IIB 377734-62-8, Granulysin  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 53179-13-8, Pirfenidone  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pharmaceutical compn. of interferon gamma or pirfenidone combined with mol. diagnostics for improved treatment of interstitial lung diseases (ILD))
- IT 9001-77-8, Acid phosphatase  
RL: ADV (Adverse effect, including toxicity); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);

ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (phosphatidic, type 2C: BC002806; pharmaceutical compn. of interferon  
 gamma or pirfenidone combined with mol. diagnostics for improved  
 treatment of interstitial lung diseases (ILD))

IT 97501-93-4, Tryptase  
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,  
 unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use);  
 ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (.beta.III, mast cell; pharmaceutical compn. of interferon gamma or  
 pirfenidone combined with mol. diagnostics for improved treatment of  
 interstitial lung diseases (ILD))

L12 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2002:645997 HCAPLUS  
 DN 137:228345  
 TI Molecular cloning and characterization of a novel mouse macrophage C-type  
 lectin, mMGL2, which has a distinct carbohydrate specificity from  
 mMGL1  
 AU Tsuiji, Makoto; Fujimori, Mayuko; Ohashi, Yoshimi; Higashi, Nobuaki;  
 Onami, Thandi M.; Hedrick, Stephen M.; Irimura, Tatsuro  
 CS Laboratory of Cancer Biology and Molecular Immunology, Graduate School of  
 Pharmaceutical Sciences, The University of Tokyo, Tokyo, 113-0033, Japan  
 SO Journal of Biological Chemistry (2002), 277(32), 28892-28901  
 CODEN: JBCHA3; ISSN: 0021-9258  
 PB American Society for Biochemistry and Molecular Biology  
 DT Journal  
 LA English  
 AB A novel mouse macrophage galactose-type C-type lectin 2 (mMGL2) was  
 identified by BLAST anal. of expressed sequence tags. The sequence of  
 mMGL2 is highly homologous to the mMGL, which should now be called mMGL1.  
 The open reading frame of mMGL2 contains a sequence corresponding to a  
 type II transmembrane protein with 332 amino acids having a single  
 extracellular C-type lectin domain. The 3'-untranslated region included  
 long terminal repeats of mouse early transposon. The Mgl2 gene was cloned  
 from a 129/SvJ mouse genomic library and sequenced. The gene spans 7,136  
 base pairs and consists of 10 exons, which is similar to the genomic  
 organization of mMGL1. The reverse transcriptase-PCR anal. indicates that  
 mMGL2 is expressed in cell lines and normal mouse tissues in a  
 macrophage-restricted manner, also very similar to that of mMGL1. The  
 mMGL2 mRNA was also detected in mMGL1-pos. cells, which were sorted from  
 thioglycollate-induced peritoneal cells with a mMGL1-specific monoclonal  
 antibody, LOM-8.7. The sol. recombinant proteins of mMGL2 exhibited  
 carbohydrate specificity for .alpha.- and .beta.-GalNAc-conjugated sol.  
 polyacrylamides, whereas mMGL1 preferentially bound Lewis X-conjugated  
 sol. polyacrylamides in solid phase assays. These two lectins may  
 function cooperatively as recognition and endocytic mols. on macrophages  
 and related cells.

IT Agglutinins and Lectins  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
 (Biological study)  
 (C-type (calcium-dependent type), mMGL2; mol. cloning and  
 characterization of a novel mouse macrophage C-type lectin  
 mMGL2)

IT Protein motifs  
 (C-type lectin domain; mol. cloning and characterization of a  
 novel mouse macrophage C-type lectin mMGL2)

IT Gene, animal  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
 (Biological study)  
 (Mgl2; mol. cloning and characterization of a novel mouse macrophage

C-type lectin mMGL2)

IT Gene, animal  
RL: PRP (Properties)  
(Mgl2; mol. cloning and characterization of a novel mouse macrophage C-type lectin mMGL2)

IT **Protein sequences**  
(amino acid sequence of mMGL2)

IT **DNA sequences**  
(for C-type lectin of mouse macrophage)

IT Animal tissue  
Genetic mapping  
Macrophage  
Mouse  
(mol. cloning and characterization of a novel mouse macrophage C-type lectin mMGL2)

IT Promoter (genetic element)  
RL: PRP (Properties)  
(mol. cloning and characterization of a novel mouse macrophage C-type lectin mMGL2)

IT **Chromosome**  
(mouse 11; mol. cloning and characterization of a novel mouse macrophage C-type lectin mMGL2)

IT **cDNA sequences**  
(nucleotide sequence for mMGL2)

IT 457115-93-4 457683-60-2  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(amino acid sequence; mol. cloning and characterization of a novel mouse macrophage C-type lectin mMGL2)

IT 14131-60-3, .beta.-N-Acetyl-galactosamine 14215-68-0, .alpha.-N-Acetyl-galactosamine  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(mol. cloning and characterization of a novel mouse macrophage C-type lectin mMGL2)

IT 432487-87-1, GenBank AY103461 432487-88-2, GenBank AY103462  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(nucleotide sequence; mol. cloning and characterization of a novel mouse macrophage C-type lectin mMGL2)

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:636093 HCAPLUS

DN 135:209361

TI Novel human Breast cancer associated membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses

IN Boyd, Robert Simon; Stamps, Alasdair Craig; Terrett, Jonathan Alexander

PA Oxford Glycosciences (UK) Ltd., UK

SO PCT Int. Appl., 136 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001062784	A2	20010830	WO 2001-GB748	20010221
	WO 2001062784	A3	20020131		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,



HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 2001008659 A 20021105 BR 2001-8659 20010221

EP 1257285 A2 20021120 EP 2001-905965 20010221

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2003524017 T2 20030812 JP 2001-562565 20010221

US 2003130214 A1 20030710 US 2001-791392 20010223

US 2003099662 A1 20030529 US 2002-227616 20020823

PRAI GB 2000-4576 A 20000225

GB 2000-31341 A 20001221

WO 2001-GB748 W 20010221

AB The present invention provides novel human proteins (BCMP 11, 81 and 84) isolated from breast cancer cell line membrane prepsns., compns. comprising the protein, including vaccines and antibodies which are immunospecific for the protein. The gene encoding BCMP 11 is mapped on human chromosome 7p21. BCMP 84 gene is mapped on human chromosome 1q21. The use of the protein in the diagnosis, screening, treatment and prophylaxis of breast cancer is also provided.

IT Genetic mapping  
 (BCMP 11 mapped on human chromosome 7p21; BCMP 84 gene mapped on human chromosome 1q21; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Agglutinins and **Lectins**  
 Carbohydrates, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (as capture agents for BCMP; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Diagnosis  
 (cancer; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Drugs  
 (comprising BCMP; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Antibodies  
 RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (conjugates; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Mammary gland  
 (detecting BCMP expression from; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT Polyacrylamide gel electrophoresis  
 (for detecting BCMP; **protein** and **cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

- IT Test kits  
(for diagnosis of cancer; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Antisense DNA  
Ribozymes  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(for modulating BCMP expression or activities; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Chromosome  
(human 1, q21, BCMP 84 gene mapped on; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Chromosome  
(human 7, p21, BCMP 11 gene mapped on; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Diagnosis  
(immunodiagnosis; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Antitumor agents  
(mammary gland, metastasis; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Antitumor agents  
(mammary gland; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Proteins, specific or class  
RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(membrane, BCMP 11; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Proteins, specific or class  
RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(membrane, BCMP 81; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Proteins, specific or class  
RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(membrane, BCMP 84; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Mammary gland  
(metastasis, inhibitors; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Diagnosis  
(mol.; **protein and cDNA sequences** of

- novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Antibodies  
RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(monoclonal; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Mammary gland  
(neoplasm, inhibitors; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Mammary gland  
(neoplasm; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Drug screening  
Molecular cloning  
(**protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Antibodies  
RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(**protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Immobilization, biochemical  
(protein, of BCMP; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Antigens  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tumor-assocd., BCMP; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Vaccines  
(tumor; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Immunization  
(vaccination, against breast cancer; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT Antitumor agents  
(vaccines; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT 21820-51-9, phosphotyrosine  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(as capture agents for BCMP; **protein and cDNA sequences** of novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)
- IT 357142-80-4    357142-91-7    357142-92-8    357466-26-3    357466-27-4  
357466-28-5    357466-29-6    357466-30-9    357466-31-0    357676-37-0  
357676-39-2    357676-40-5    357676-44-9, 7: PN: WO0162784 PAGE: 107

unclaimed DNA 357676-45-0, 8: PN: WO0162784 PAGE: 107  
 unclaimed DNA 357692-25-2 357692-26-3 357693-30-2  
 357693-31-3 357693-32-4 357693-33-5 357693-34-6 357693-35-7  
 357693-36-8

RL: PRP (Properties)

(unclaimed nucleotide sequence; novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT 204081-34-5, Growth factor XAG-1 (human precursor) 204081-38-9, Growth factor XAG-3 (human precursor) 222614-91-7 357464-92-7, Protein BCMP 84 (human)

RL: PRP (Properties)

(unclaimed protein sequence; novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

IT 216157-12-9 357609-73-5 357609-74-6 357609-89-3 357609-90-6  
 357627-10-2 357627-11-3 357656-18-9 357656-19-0 357656-20-3  
 357656-21-4 357656-22-5 357656-23-6 357656-24-7 357656-25-8  
 357656-26-9 357656-27-0 357656-28-1 357656-29-2 357656-30-5  
 357656-31-6 357656-32-7 357656-33-8 357656-35-0 357656-37-2  
 357656-38-3 357656-39-4 357656-41-8 357656-42-9 357656-43-0  
 357656-44-1 357656-45-2 357656-46-3 357656-47-4 357656-48-5  
 357656-49-6 357656-50-9 357656-51-0 357656-52-1 357656-53-2  
 357656-54-3 357656-55-4 357656-56-5 357656-57-6 357656-58-7  
 357656-59-8 357656-60-1 357656-61-2 357656-62-3 357656-63-4  
 357656-64-5 357656-65-6 357656-66-7 357656-67-8 357656-68-9  
 357656-69-0 357656-70-3 357656-71-4 357656-72-5 357656-73-6  
 357656-74-7 357656-75-8 357656-76-9 357656-77-0 357656-78-1  
 357656-79-2 357656-80-5 357656-81-6 357656-82-7 357656-83-8  
 357656-84-9 357656-85-0 357656-86-1 357656-87-2 357656-88-3  
 357656-89-4 357656-90-7 357656-91-8 357656-92-9 357656-93-0  
 357656-94-1 357656-95-2 357656-96-3 357656-97-4

RL: PRP (Properties)

(unclaimed sequence; novel human Breast cancer assocd. membrane proteins BCMP 11, 81 and 84, and therapeutic and diagnostic uses)

L12 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:448136 HCAPLUS

DN 136:162023

TI The human gene for mannan-binding lectin-associated serine protease-2 (MASP-2), the effector component of the lectin route of complement activation, is part of a tightly linked gene cluster on chromosome 1p36.2-3

AU Stover, C.; Endo, Y.; Takahashi, M.; Lynch, N. J.; Constantinescu, C.; Vorup-Jensen, T.; Thiel, S.; Friedl, H.; Hankeln, T.; Hall, R.; Gregory, S.; Fujita, T.; Schwaebler, W.

CS Department of Microbiology and Immunology, University of Leicester, Leicester, LE1 9HN, UK

SO Genes and Immunity (2001), 2(3), 119-127

CODEN: GEIMA2; ISSN: 1466-4879

PB Nature Publishing Group

DT Journal

LA English

AB The proteases of the lectin pathway of complement activation, MASP-1 and MASP-2, are encoded by two sep. genes. The MASP1 gene is located on chromosome 3q27, the MASP2 gene on chromosome 1p36.23-31. The genes for the classical complement activation pathway proteases, C1r and C1s, are linked on chromosome 12p13. We have shown that the MASP2 gene encodes two gene products, the 76 kDa MASP-2 serine protease and a plasma protein of 19 kDa, termed MAP19 or sMAP. Both gene products are components of the



lectin pathway activation complex. We present the complete primary structure of the human MASP2 gene and the tight cluster that this locus forms with non-complement genes. A comparison of the MASP2 gene with the previously characterized C1s gene revealed identical positions of introns sepg. orthologous coding sequences, underlining the hypothesis that the C1s and MASP2 genes arose by exon shuffling from one ancestral gene.

IT Proteins

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(CDT6 (cornea-derived transcript 6); of cornea-derived transcript 6 (CDT6) protein, gene located on chromosome 1p36.2-3 near the MASP-2 gene)

IT DNA sequences

(DNA sequence and chromosomal organization of genes on human chromosome 1p36.2-3, including MASP-2, PM-scl, FRAP kinase and CDT6 genes)

IT Promoter (genetic element)

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(DNA sequence and initial promoter characterization of human gene MASP2, including transcription start site, and putative binding sites for transcription factors)

IT Genetic polymorphism

Human  
(DNA sequence, genomic organization, genetic polymorphism, initial promoter characterization, and chromosomal organization of human gene MASP2, encodes MASP-2 serine protease, and sMAP (MAP19))

IT Gene, animal

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(MASP-2; DNA sequence and chromosomal organization of genes on human chromosome 1p36.2-3, including MASP-2, PM-scl, FRAP kinase and CDT6 genes)

IT Gene, animal

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(PM-scl; DNA sequence and chromosomal organization of genes on human chromosome 1p36.2-3, including MASP-2, PM-scl, FRAP kinase and CDT6 genes)

IT RNA splicing

(alternative; human gene MASP2 encodes sMAP (MAP19) protein due to alternative splicing and polyadenylation)

IT Antigens

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(autoantigens, PM-scl (polymyositis-scleroderma); of human polymyositis-scleroderma autoantigen (PM-scl), gene located on chromosome 1p36.2-3 near the MASP-2 gene)

IT Chromosome

(human 1, 1p36.23-31; DNA sequence, genomic organization, genetic polymorphism, initial promoter characterization, and chromosomal organization of human gene MASP2, encodes MASP-2 serine protease, and sMAP (MAP19))

IT Complement

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(lectin pathway; chromosomal organization of human gene MASP2, encodes mannan-binding lectin-assocd. serine protease-2, and sMAP (MAP19), two components of lectin pathway activation complex)

IT Evolution

(mol.; DNA sequence and characterization of human mannan-binding lectin-assocd. serine protease-2 (MASP-2) gene, including hypothesis that C1s and MASP2 genes arose by exon shuffling from one ancestral gene)

- IT **Protein sequences**  
(of proteins encoded by genes on human chromosome 1p36.2-3, including MASP-2, sMAP (MAP19), PM-scl, FRAP kinase and CDT6)
- IT **Proteins**  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(sMAP (small MBL-assocd. protein), also known as MAP19; sequence and protein motifs of human mannan-binding lectin-assocd. serine protease-2, and sMAP (MAP19))
- IT **Protein motifs**  
(sequence and protein motifs of human mannan-binding lectin-assocd. serine protease-2, and sMAP (MAP19))
- IT **Genetic element**  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(tsp (transcription start point); DNA sequence and initial promoter characterization of human gene MASP2, including transcription start site, and putative binding sites for transcription factors)
- IT 395688-05-8  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(amino acid sequence; of cornea-derived transcript 6 (CDT6) protein, gene located on chromosome 1p36.2-3 near the MASP-2 gene)
- IT 395688-04-7  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(amino acid sequence; of human phosphatidylinositol kinase FRAP, gene located on chromosome 1p36.2-3 near the MASP-2 gene)
- IT 395688-03-6  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(amino acid sequence; of human polymyositis-scleroderma autoantigen (PM-scl), gene located on chromosome 1p36.2-3 near the MASP-2 gene)
- IT 395687-99-7 395688-00-3 395688-01-4 395688-02-5  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(amino acid sequence; sequence and protein motifs of human mannan-binding lectin-assocd. serine protease-2, and sMAP (MAP19))
- IT 302876-75-1  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(nucleotide sequence; DNA sequence and chromosomal organization of genes on human chromosome 1p36.2-3, including MASP-2, PM-scl, FRAP kinase and CDT6 genes)
- IT 233581-98-1, GenBank AL109811  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(nucleotide sequence; DNA sequence of genes found on human chromosome 1p36.11-1p36.31)
- IT 245103-40-6, GenBank AB033742 290791-85-4, GenBank AJ299718  
304836-23-5, GenBank AJ297949  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(nucleotide sequence; DNA sequence, genomic organization, genetic polymorphism, initial promoter characterization, and chromosomal organization of human gene MASP2, encodes MASP-2 serine

protease, and sMAP (MAP19))  
 IT 171715-28-9, Protein kinase FRAP  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
 (Biological study)  
 (of human phosphatidylinositol kinase FRAP, gene located on chromosome  
 1p36.2-3 near the MASP-2 gene)  
 IT 214915-16-9, Mannan-binding lectin-associated serine protease-2  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
 (Biological study)  
 (sequence and protein motifs of human mannan-binding lectin  
 -assocd. serine protease-2, and sMAP (MAP19))  
 RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2000:756719 HCAPLUS  
 DN 133:330541  
 TI Cloning and cDNA sequence encoding human galectin 11  
 IN Ni, Jian; Rosen, Craig A.; Gentz, Reiner L.; Lui, Fu-Tong  
 PA Human Genome Sciences, Inc., USA; Lajolla Institute for Allergy and  
 Immunology  
 SO PCT Int. Appl., 314 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 36

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063221	A2	20001026	WO 2000-US10714	20000421
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1192168	A1	20020403	EP 2000-923556	20000421
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541832	T2	20021210	JP 2000-612311	20000421
US 1999-130390P	P	19990421		
US 1999-169932P	P	19991210		
WO 2000-US10714	W	20000421		
AB The present invention relates to novel galectin 11 proteins which are members of the galectin superfamily. In particular, isolated nucleic acid mols. are provided encoding the human galectin 11 proteins, including isoform .alpha. and .beta. resulted from alternative RNA splicing. The human galectin 11 gene is located on chromosome 11, contains 5 exons, and the cDNA has an open reading frame encoding a protein of 133 amino acid residues. The galectin 11 protein shares homol. with rat galectin 5, chicken galectin 3, and human galectin 8. Transfection of Jurkat cells with a galectin 11 expression construct induces apoptosis of transfected T-cells. Also provided are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of galectin 11 activity. Also provided are diagnostic and therapeutic methods.				
IT Animal cell line (CHO, recombinant expression host; cloning and cDNA sequence				

- encoding human galectin 11)
- IT Animal cell line
  - (COS, recombinant expression host; cloning and cDNA sequence encoding human galectin 11)
- IT Animal cell line
  - (SF9, recombinant expression host; cloning and cDNA sequence encoding human galectin 11)
- IT T cell (lymphocyte)
  - (apoptosis induction; cloning and cDNA sequence encoding human galectin 11)
- IT Diagnosis
  - (cancer; cloning and cDNA sequence encoding human galectin 11)
- IT Drug delivery systems
  - (carriers; cloning and cDNA sequence encoding human galectin 11)
- IT Allergy inhibitors
  - Anti-inflammatory agents
  - Antiasthmatics
  - Antitumor agents
  - Molecular cloning
    - (cloning and cDNA sequence encoding human galectin 11)
- IT Antibodies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)
  - (cloning and cDNA sequence encoding human galectin 11)
- IT Immunoassay
  - (detection by; cloning and cDNA sequence encoding human galectin 11)
- IT Autoimmune disease
  - (diagnosis and treatment of; cloning and cDNA sequence encoding human galectin 11)
- IT Cell differentiation
  - Cell proliferation
    - (diagnosis of disorders of; cloning and cDNA sequence encoding human galectin 11)
- IT cDNA sequences
  - (for human galectin 11; cloning and cDNA sequence encoding human galectin 11)
- IT Gene, animal
  - RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)
  - (for human galectin 11; cloning and cDNA sequence encoding human galectin 11)
- IT Agglutinins and Lectins
  - RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
  - (galectin-11; cloning and cDNA sequence encoding human galectin 11)
- IT Genetic mapping
  - (gene mapping and organization on human chromosome 11; cloning and cDNA sequence encoding human galectin 11)
- IT Chromosome
  - (human 11, gene mapping and organization on human chromosome 11; cloning and cDNA sequence encoding human galectin 11)
- IT Apoptosis
  - (induced in T-cells; cloning and cDNA sequence encoding human galectin 11)



IT Animal cell  
(mammalian, recombinant expression host; cloning and cDNA  
sequence encoding human galectin 11)

IT Diagnosis  
(mol.; cloning and cDNA sequence encoding human galectin 11)

IT **Protein sequences**  
(of human galectin 11; cloning and cDNA sequence encoding  
human galectin 11)

IT Escherichia coli  
(recombinant expression host; cloning and cDNA sequence  
encoding human galectin 11)

IT 303071-83-2DP, Galectin 11 (human isoform .alpha.), subfragments claimed  
303071-84-3DP, Galectin 11 (human isoform .beta.), subfragments claimed  
RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU  
(Biological study, unclassified); PRP (Properties); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
(amino acid sequence; cloning and cDNA sequence encoding  
human galectin 11)

IT 210478-30-1DP, Receptor (human clone HJACE54), subfragments claimed  
RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU  
(Biological study, unclassified); PRP (Properties); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
(cloning and cDNA sequence encoding human galectin 11)

IT 210478-29-8, DNA (human clone HJACE54 receptor cDNA  
plus flanks) 303071-85-4 303071-86-5  
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological  
study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL  
(Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)  
(nucleotide sequence; cloning and cDNA sequence encoding  
human galectin 11)

IT 229477-44-5 244008-03-5, PN: WO9947540 SEQID: 3 unclaimed DNA  
244008-06-8, PN: WO9947540 SEQID: 4 unclaimed DNA 244008-07-9,  
PN: WO9947540 SEQID: 5 unclaimed DNA 244008-08-0, PN:  
WO9947540 SEQID: 6 unclaimed DNA 244008-09-1, PN: WO9947540  
SEQID: 7 unclaimed DNA 244008-12-6, 19: PN: WO9962934 PAGE: 65  
unclaimed DNA 244008-13-7, PN: WO9947540 SEQID: 9 unclaimed  
DNA 244008-14-8, PN: WO9947540 SEQID: 10 unclaimed DNA  
254855-13-5, 5: PN: WO0001728 SEQID: 7 unclaimed DNA  
254855-14-6, 6: PN: WO0001728 SEQID: 8 unclaimed DNA  
254855-16-8, 8: PN: WO0001728 SEQID: 10 unclaimed DNA  
254855-17-9, 9: PN: WO0001728 SEQID: 11 unclaimed DNA  
303072-63-1, 4: PN: WO0063221 SEQID: 6 unclaimed DNA  
303072-64-2, 7: PN: WO0063221 SEQID: 9 unclaimed DNA  
303072-66-4  
RL: PRP (Properties)  
(unclaimed nucleotide sequence; cloning and cDNA sequence  
encoding human galectin 11)

IT 165945-20-0 254855-10-2 303113-31-7  
RL: PRP (Properties)  
(unclaimed protein sequence; cloning and  
cDNA sequence encoding human galectin 11)

IT 210478-30-1, Receptor (human clone HJACE54) 303044-52-2 303072-67-5  
303113-07-7  
RL: PRP (Properties)  
(unclaimed sequence; cloning and cDNA sequence encoding human  
galectin 11)

L12 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN  
AN 2000:34903 HCAPLUS  
DN 132:89793

TI Cloning and cDNA sequence encoding human galectin 11  
 IN Rosen, Craig A.; Ni, Jian; Gentz, Reiner L.  
 PA Human Genome Sciences, Inc., USA  
 SO PCT Int. Appl., 99 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English  
 FAN.CNT 36

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000001728	A1	20000113	WO 1999-US15169	19990702
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2336406	AA	20000113	CA 1999-2336406	19990702
	AU 9949695	A1	20000124	AU 1999-49695	19990702
	EP 1095060	A1	20010502	EP 1999-933694	19990702
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2003512291	T2	20030402	JP 2000-558129	19990702
PRAI	US 1998-109864	A	19980706		
	WO 1999-US15169	W	19990702		
AB	The present invention relates to novel galectin 11 proteins which are members of the galectin superfamily. In particular, isolated nucleic acid mols. are provided encoding the human galectin 11 proteins. The human galectin 11 gene is located on chromosome 11, contains 5 exons, and the cDNA has an open reading frame encoding a protein of 133 amino acid residues. The galectin 11 protein shares homol. with rat galectin 5, chicken galectin 3, and human galectin 8. Transfection of Jurkat cells with a galectin 11 expression construct induces apoptosis of transfected T-cells. Also provided are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of galectin 11 activity. Also provided are diagnostic and therapeutic methods.				
IT	Animal cell line (CHO, recombinant expression host; cloning and cDNA sequence encoding human galectin 11)				
IT	Animal cell line (COS, recombinant expression host; cloning and cDNA sequence encoding human galectin 11)				
IT	Animal cell line (SF9, recombinant expression host; cloning and cDNA sequence encoding human galectin 11)				
IT	T cell (lymphocyte) (apoptosis induction; cloning and cDNA sequence encoding human galectin 11)				
IT	Diagnosis (cancer; cloning and cDNA sequence encoding human galectin 11)				
IT	Allergy inhibitors Anti-inflammatory agents Antiasthmatics Antitumor agents Drugs				

- Molecular cloning  
(cloning and cDNA sequence encoding human galectin 11)
- IT Antibodies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(cloning and cDNA sequence encoding human galectin 11)
- IT Immunoassay  
(detection by; cloning and cDNA sequence encoding human  
galectin 11)
- IT Autoimmune disease  
(diagnosis and treatment of; cloning and cDNA sequence  
encoding human galectin 11)
- IT Cell differentiation  
Cell proliferation  
(diagnosis of disorders of; cloning and cDNA sequence  
encoding human galectin 11)
- IT Neoplasm  
(diagnosis; cloning and cDNA sequence encoding human galectin  
11)
- IT cDNA sequences  
(for human galectin 11)
- IT Agglutinins and Lectins  
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse);  
BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP  
(Properties); THU (Therapeutic use); ANST (Analytical study); BIOL  
(Biological study); PREP (Preparation); USES (Uses)  
(galectin-11; cloning and cDNA sequence encoding human  
galectin 11)
- IT Genetic mapping  
(gene mapping and organization on human **chromosome 11**  
; cloning and cDNA sequence encoding human galectin 11)
- IT Gene, animal  
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP  
(Properties); BIOL (Biological study); OCCU (Occurrence)  
(gene mapping and organization on human **chromosome 11**  
; cloning and cDNA sequence encoding human galectin 11)
- IT **Chromosome**  
(human 11, gene mapping and organization on human  
**chromosome 11**; cloning and cDNA sequence  
encoding human galectin 11)
- IT Apoptosis  
(induced in T-cells; cloning and cDNA sequence encoding human  
galectin 11)
- IT Animal cell  
(mammalian, recombinant expression host; cloning and cDNA  
sequence encoding human galectin 11)
- IT Diagnosis  
(mol.; cloning and cDNA sequence encoding human galectin 11)
- IT **Protein sequences**  
(of human galectin 11)
- IT Escherichia coli  
(recombinant expression host; cloning and cDNA sequence  
encoding human galectin 11)
- IT 210478-30-1DP, Receptor (human clone HJACE54), subfragments are claimed  
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse);  
BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP  
(Properties); THU (Therapeutic use); ANST (Analytical study); BIOL  
(Biological study); PREP (Preparation); USES (Uses)  
(nucleotide sequence; cloning and cDNA sequence encoding  
human galectin 11)
- IT 210478-29-8DP, subfragments are claimed

RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(nucleotide sequence; cloning and cDNA sequence encoding human galectin 11)

IT 254855-11-3, 3: PN: WO0001728 SEQID: 5 unclaimed DNA  
254855-12-4, 4: PN: WO0001728 SEQID: 6 unclaimed DNA  
254855-13-5, 5: PN: WO0001728 SEQID: 7 unclaimed DNA  
254855-14-6, 6: PN: WO0001728 SEQID: 8 unclaimed DNA  
254855-15-7, 7: PN: WO0001728 SEQID: 9 unclaimed DNA  
254855-16-8, 8: PN: WO0001728 SEQID: 10 unclaimed DNA  
254855-17-9, 9: PN: WO0001728 SEQID: 11 unclaimed DNA

RL: PRP (Properties)  
(unclaimed nucleotide sequence; cloning and cDNA sequence encoding human galectin 11)

IT 165945-20-0 254855-10-2

RL: PRP (Properties)  
(unclaimed protein sequence; cloning and cDNA sequence encoding human galectin 11)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:629148 HCAPLUS

DN 132:261213

TI Genomic structure and chromosomal location of the mouse macrophage C-type lectin gene

AU Tsuiji, Makoto; Fujimori, Mayuko; Seldin, Michael F.; Taketo, Makoto M.; Irimura, T.

CS Laboratory of Cancer Biology and Molecular Immunology, The University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan

SO Immunogenetics (1999), 50(1-2), 67-70

CODEN: IMNGBK; ISSN: 0093-7711

PB Springer-Verlag

DT Journal

LA English

AB The mouse macrophage c-type lectin (MGL) is a Gal/GalNAc-specific C-type lectin. The Mgl gene was cloned and sequenced. It consists of 10 exons. The Mgl gene was linked to transformation-related protein 53 (Trp53) and located on mouse chromosome 11.

IT Agglutinins and Lectins

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(C-type (calcium-dependent type), galactose/N-acetylgalactosamine-specific; genomic structure and chromosomal location of mouse macrophage C-type lectin gene)

IT Molecular recognition

(carbohydrate; genomic structure and chromosomal location of mouse macrophage C-type lectin gene)

IT Genetic element

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(exon-intron junction; genomic structure and chromosomal location of mouse macrophage C-type lectin gene)

IT DNA sequences

Genetic mapping

Macrophage

Mouse

Protein sequences

RNA splicing

(genomic structure and chromosomal location of mouse macrophage C-type



lectin gene)

IT Chromosome  
(mouse 11; genomic structure and chromosomal location of mouse macrophage C-type lectin gene)

IT 263233-84-7  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(amino acid sequence; genomic structure and chromosomal location of mouse macrophage C-type lectin gene)

IT 225706-76-3, GenBank AF132744  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(nucleotide sequence; genomic structure and chromosomal location of mouse macrophage C-type lectin gene)

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:189359 HCAPLUS

DN 126:195991

TI Structural organization and expression of the gene for the mouse GM2 activator protein

AU Bertoni, C.; Appolloni, M.G.; Stirling, J.L.; Li, S-C.; Li, Y-T.; Orlacchio, A.; Beccari, T.

CS Dipartimento di Biologia Cellulare e Molecolare, Sezione di Biochimica e Biologia Molecolare, Universita di Perugia, Perugia, 06126, Italy

SO Mammalian Genome (1997), 8(2), 90-93  
CODEN: MAMGEC; ISSN: 0938-8990

PB Springer

DT Journal

LA English

AB The GM2 activator protein is an essential component for the degrdn. of GM2 ganglioside by hexosaminidase A in vivo. Mutations in the human gene coding for the GM2 activator protein cause the AB variant of GM2-gangliosidosis, a condition that is clin. indistinguishable from Tay-Sachs disease. To understand better factors affecting the expression of the GM2 activator protein gene (Gm2a) in mouse tissues, we have detd. its exon-intron organization and analyzed its promoter region. Gm2a is about 14 kb, has four exons, and the 5' flanking region contains a CAAT box, Sp1 binding sites, AP-1, AP-2 sites, and a pair of IRE sites. A 1.2-kb fragment upstream from the initiation codon was shown to have promoter activity in NIH 3T3 cells. Similarities between the elements present in Gm2a and Hexa promoters might in part explain their similar expression patterns in mouse tissues. The different levels of GM2 activator protein mRNA in liver, kidney, brain, and testis are not owing to the use of different transcription start sites, because a single start site was found 50 bp upstream from the initiation codon in each these tissues. Northern blot anal. demonstrated variation in the GM2 activator protein mRNA expression during mouse development. Gm2a was mapped to Chromosome (Chr) 11, where it co-segregated with Csfgm.

IT Gene, animal  
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)  
(Gm2a; structural organization, mapping, and expression of the gene for the mouse GM2 activator protein)

IT Proteins, specific or class  
RL: PRP (Properties)  
(ganglioside GM2a hydrolysis-activating; structural organization, mapping, and expression of the gene for the mouse GM2 activator

protein)

IT **Chromosome**  
(mouse 11; mapping of mouse GM2 activator protein gene to  
**chromosome 11**)

IT **Protein sequences**  
(of mouse GM2 activator protein)

IT Genetic mapping  
(of mouse GM2 activator protein gene to **chromosome 11**  
)

IT **DNA sequences**  
(of the gene for the mouse GM2 activator protein)

IT Mouse  
(structural organization, mapping, and expression of the gene for the  
mouse GM2 activator protein)

IT 128004-04-6, **Lectin** (Aleuria aurantia clone .lambda.AAL-3  
subunit precursor reduced)  
RL: PRP (Properties)  
(amino acid sequence; structural organization, mapping, and expression  
of the gene for the mouse GM2 activator protein)

IT 168580-79-8, Genbank U34356 168580-80-1, Genbank U34357 168580-81-2,  
Genbank U34358 168580-82-3, Genbank U34359  
RL: PRP (Properties)  
(nucleotide sequence; structural organization, mapping, and expression  
of the gene for the mouse GM2 activator protein)

IT 19600-01-2, Ganglioside GM2  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
(Biological study); PROC (Process)  
(structural organization, mapping, and expression of the gene for the  
mouse GM2 activator protein)

L12 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 1995:440637 HCAPLUS

DN 123:162447

TI Sequence and mapping of galectin-5, a .beta.-galactoside-binding  
**lectin**, found in rat erythrocytes

AU Gitt, Michael A.; Wiser, Mark F.; Leffler, Hakon; Herrmann, Joerg; Xia,  
Yurong; Massa, Stephen M.; Copper, Douglas N. W.; Lusic, Aldons J.;  
Barondes, Samuel H.

CS Center Neurobiology Psychiatry, Univ. California, San Francisco, CA,  
94143-0984, USA

SO Journal of Biological Chemistry (1995), 270(10), 5032-8  
CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

AB A monomeric rat .beta.-galactoside-binding lectin previously purified from  
exts. of rat lung was localized to erythrocytes, and the cDNA encoding it  
was isolated from a rat reticulocyte cDNA library. The deduced amino acid  
sequence of the cDNA predicts a protein with a Mr of 16,199, with no  
evidence of a signal peptide. The deduced sequence is identical to the  
sequences of 7 proteolytic peptides derived from the purified lectin.  
Peptide anal. by mass spectrometry indicates that the N-terminal  
methionine is cleaved and that serine-2 is acetylated. The lectin shares  
all the strictly conserved amino acid residues of other members of the  
mammalian galectin family and is designated galectin-5 (GenBank accession  
no. L36862). Galectin-5 is a weak agglutinin of rat erythrocytes, despite  
its monomeric structure. The gene encoding galectin-5 (LGALS5) was mapped  
in mouse to chromosome 11, .apprx.50 centimorgans from the centromere and  
1.8 centimorgans from the polymorphic marker D11Mit34n, a region syntenic  
with human chromosome 17q11.

IT Gene, animal  
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)  
 (LGALS5; sequence and mapping of galectin-5, a .beta.-galactoside-binding lectin, found in rat erythrocytes)

IT Agglutinins and Lectins  
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)  
 (galectin-5; sequence and mapping of galectin-5, a .beta.-galactoside-binding lectin, found in rat erythrocytes)

IT Protein sequences  
 (of galectin-5 lectin from rat)

IT Genetic mapping  
 Mouse  
 Rat  
 (sequence and mapping of galectin-5, a .beta.-galactoside-binding lectin, found in rat erythrocytes)

IT Deoxyribonucleic acid sequences  
 (complementary, for galectin-5 lectin from rat)

IT Chromosome  
 (mouse 11, sequence and mapping of galectin-5, a .beta.-galactoside-binding lectin, found in rat erythrocytes)

IT 164782-89-2, Galectin 5 (rat clone Le1h/Le2b) 165945-20-0  
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)  
 (amino acid sequence; sequence and mapping of galectin-5, a .beta.-galactoside-binding lectin, found in rat erythrocytes)

IT 164956-62-1  
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)  
 (nucleotide sequence; sequence and mapping of galectin-5, a .beta.-galactoside-binding lectin, found in rat erythrocytes)

L12 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1993:140975 HCAPLUS  
 DN 118:140975  
 TI Rat gene mapping using PCR-analyzed microsatellites  
 AU Serikawa, Tadao; Kuramoto, Takashi; Hilbert, Pascale; Mori, Masayuki; Yamada, Junzo; Dubay, Christopher J.; Lindpainter, Klaus; Ganten, Detlev; Guenet, Jean Louis; et al.  
 CS Fac. Med., Kyoto Univ., Kyoto, 606, Japan  
 SO Genetics (1992), 131(3), 701-21  
 CODEN: GENTAE; ISSN: 0016-6731  
 DT Journal  
 LA English  
 AB One hundred and seventy-four rat loci which contain short tandem repeat sequences were extd. from the GenBank or EMBL data bases and used to define primers for amplification by the polymerase chain reaction (PCR) of the microsatellite regions, creating PCR-formatted sequence-tagged microsatellite sites (STMSs). One hundred and thirty-four STMSs for 118 loci, including 6 randomly cloned STMSs, were characterized: (1) PCR-analyzed loci were assigned to specific chromosomes using a panel of rat .times. mouse somatic cell hybrid clones. (2) Length variation of the STMSs among 8 inbred rat strains could be visualized at 85 of 107 loci examd. (79.4%). (3) A genetic map, integrating biochem., coat color, mutant, and restriction fragment length polymorphism loci, was constructed based on the segregation of 125 polymorphic markers in 7 rat backcrosses and in two F2 crosses. Twenty-four linkage groups were identified, all of which were assigned to a defined chromosome. As a reflection of the bias for coding sequences in the public data bases, the STMSs described herein

are often assocd. with genes. Hence, the genetic map reported coincides with a gene map. The corresponding map locations of the homologous mouse and human genes are also listed for comparative mapping purposes.

- IT Proteins, specific or class  
RL: BIOL (Biological study)  
(9Ka, gene for, mapping on rat chromosome of)
- IT Rat  
(gene and marker loci of, mapping of, PCR-analyzed microsatellite DNA in)
- IT Hemoglobins  
RL: BIOL (Biological study)  
(gene for .beta.-chain of, linkage mapping of rat)
- IT Albumins, biological studies  
Haptoglobins  
Immunoglobulins  
Prealbumins  
RL: BIOL (Biological study)  
(gene for, mapping on rat chromosome of)
- IT Myosins  
RL: PRP (Properties)  
(genes for light and heavy chains of, mapping on rat chromosome of)
- IT Fibrinogens  
RL: BIOL (Biological study)  
(genes for .alpha. and .gamma. chains of, mapping on rat chromosome of)
- IT Proteins, specific or class  
RL: BIOL (Biological study)  
(leukosianin-related, gene for, mapping on rat chromosome of)
- IT Polymerase chain reaction  
(microsatellite DNA analyzed by, for rat gene mapping)
- IT Proteins, specific or class  
RL: BIOL (Biological study)  
(nerve growth factor-induced, mapping on rat chromosome of)
- IT Receptors  
RL: BIOL (Biological study)  
(neuromedin K, gene for, linkage mapping of rat)
- IT Genetic mapping  
(of rat genes and arbitrary marker loci, PCR-analyzed microsatellite DNA in)
- IT Chromosome  
(rat 11, gene mapping on, PCR-analyzed microsatellite DNA in)
- IT Chromosome  
(rat 12, gene mapping on, PCR-analyzed microsatellite DNA in)
- IT Antigens  
RL: BIOL (Biological study)  
(thymus cell I, gene for, mapping on rat chromosome of)
- IT Proteins, specific or class  
RL: BIOL (Biological study)  
(trypsin inhibitor-like, gene for, mapping on rat chromosome of)
- IT Proteins, specific or class  
RL: BIOL (Biological study)  
(zitter, gene for, linkage mapping of rat)
- IT Gene, animal  
RL: BIOL (Biological study)  
(BSIS, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)
- IT Gene, animal  
RL: BIOL (Biological study)  
(DBPCEP, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(FGA, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(FABP1, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(FST, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(GJA1,, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(GLUTB, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(GCK, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(KCPVD, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(LALBA, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(LSN, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(LSNR, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(TKG, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(TTR, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(TILP, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(TON, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(TPM, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)



IT Gene, animal  
RL: BIOL (Biological study)  
(TRAG, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(ZI, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(MBPA, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(MYL2, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(MYLC1V, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(MYCS, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(MYHSE, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(IGFBBP, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(IGF1, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(IGHE, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(IVD, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(INHA, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(INS1, linkage mapping of, on rat chromosome, PCR-analyzed  
microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(ADRB2, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(ADRA1B, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(AGT, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(A2UG, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(AMPP, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(ACRM, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(AEP, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(CBPI, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(CYPBE, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(CYPE, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(CALM3, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(CEAR, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(CPB, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(CSNA, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(CSPMO2, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(ELAI, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(ES6, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(HA01, linkage mapping of, on rat chromosome, PCR-analyzed  
microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(HEOXG, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(HHITTS, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(NGF1, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(NGFR, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(NKR, linkage mapping of, on rat chromosome, PCR-analyzed  
microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(OLF, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(PBPC2, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(PFKFB, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(PFLG, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(PG1, linkage mapping of, on rat chromosome, PCR-analyzed  
microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(PKL, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(PKATA, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(PKCS, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(PLANH, mapping of, on rat chromosome, PCR-analyzed microsatellite  
DNA in)

- IT Gene, animal  
RL: BIOL (Biological study)  
(PTP, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)
- IT Gene, animal  
RL: BIOL (Biological study)  
(P9KA, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)
- IT Gene, animal  
RL: BIOL (Biological study)  
(PCK, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)
- IT Gene, animal  
RL: BIOL (Biological study)  
(PERF, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)
- IT Gene, animal  
RL: BIOL (Biological study)  
(PRLR, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)
- IT Gene, animal  
RL: BIOL (Biological study)  
(RBP2, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)
- IT Gene, animal  
RL: BIOL (Biological study)  
(SVS2P, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)
- IT Gene, animal  
RL: BIOL (Biological study)  
(SCN2A, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)
- IT Gene, animal  
RL: BIOL (Biological study)  
(SECR, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)
- IT Gene, animal  
RL: BIOL (Biological study)  
(SHDL, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)
- IT Gene, animal  
RL: BIOL (Biological study)  
(SPAT, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)
- IT Gene, animal  
RL: BIOL (Biological study)  
(SPR, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)
- IT Proteins, specific or class  
RL: BIOL (Biological study)  
(2, RBP2 (retinol-binding protein, gene for, mapping on rat chromosome of)
- IT Proteins, specific or class  
RL: BIOL (Biological study)  
(ABP (androgen-binding protein), gene for, mapping on rat chromosome of)
- IT Antigens  
RL: BIOL (Biological study)  
(CEA (carcinoembryonic antigen)-related, gene for, mapping on rat chromosome of)

IT Proteins, specific or class  
RL: BIOL (Biological study)  
(DNA-binding, C/ep, gene for, mapping on rat chromosome of)

IT Proteins, specific or class  
RL: BIOL (Biological study)  
(F1, gene for, mapping on rat chromosome of)

IT Proteins, specific or class  
RL: BIOL (Biological study)  
(FABP (fatty acid-binding protein), gene for, mapping on rat chromosome of)

IT Globulins, biological studies  
RL: BIOL (Biological study)  
(Gc, gene for, linkage mapping of rat)

IT G proteins (guanine nucleotide-binding proteins)  
RL: BIOL (Biological study)  
(Golf (olfactory nerve), gene for, mapping on rat chromosome of)

IT Histones  
RL: BIOL (Biological study)  
(H1t, gene for, mapping on rat chromosome of)

IT Histones  
RL: BIOL (Biological study)  
(H4t, gene for, mapping on rat chromosome of)

IT Genetic element  
RL: BIOL (Biological study)  
(ID element, brain-specific, mapping on rat chromosome of)

IT Glycoproteins, specific or class  
RL: BIOL (Biological study)  
(IGF-BP-3 (insulin-like growth factor-binding protein 3), gene for, mapping on rat chromosome of)

IT Calmodulins  
RL: BIOL (Biological study)  
(III, gene for, mapping on rat chromosome of)

IT Antigens  
RL: BIOL (Biological study)  
(L-CA (leukocyte common antigen), gene for, mapping on rat chromosome of)

IT Phospholipoproteins  
RL: BIOL (Biological study)  
(MBP (myelin basic protein), gene for, linkage mapping of rat)

IT Histocompatibility antigens  
RL: BIOL (Biological study)  
(MHC (major histocompatibility complex), gene for, linkage mapping of rat)

IT Glycoproteins, specific or class  
RL: BIOL (Biological study)  
(SVS II (seminal vesicle secretion II), gene for, mapping on rat chromosome of)

IT Proteins, specific or class  
RL: BIOL (Biological study)  
(Svp-1 (seminal vesicle protein 1), gene for, linkage mapping of rat)

IT Kininogens  
RL: BIOL (Biological study)  
(T-, gene for, mapping on rat chromosome of)

IT Proteins, specific or class  
RL: BIOL (Biological study)  
(TCP-1, gene for, linkage mapping of rat)

IT Proteins, specific or class  
RL: BIOL (Biological study)  
(VAMP-2 (vesicle-assocd. membrane protein 2), gene for, mapping on rat chromosome of)



IT Receptors  
RL: BIOL (Biological study)  
(androgen, gene for, mapping on rat chromosome of)

IT Lipoproteins  
RL: BIOL (Biological study)  
(apo-, C-III, gene for, mapping on rat chromosome of)

IT Genetic element  
RL: BIOL (Biological study)  
(arbitrary DNA segment, mapping of, on rat chromosome,  
PCR-analyzed microsatellite DNA in)

IT Sialoglycoproteins  
RL: BIOL (Biological study)  
(asialo-, receptors, gene for, mapping on rat chromosome of)

IT Receptors  
RL: BIOL (Biological study)  
(asialoglycoprotein, gene for, mapping on rat chromosome of)

IT Ribonucleic acids, transfer  
RL: BIOL (Biological study)  
(aspartic acid-specific, gene for, mapping on rat chromosome of)

IT Glycolipoproteins  
RL: BIOL (Biological study)  
(band 3, gene for, mapping on rat chromosome of)

IT Proteins, specific or class  
RL: BIOL (Biological study)  
(calbindins, intestinal, gene for, mapping on rat chromosome of)

IT Proteins, specific or class  
RL: BIOL (Biological study)  
(cell surface-assocd., gene for, mapping on rat chromosome of)

IT Phosphoproteins  
RL: BIOL (Biological study)  
(connexins 43, gene for, mapping on rat chromosome of)

IT Phosphoproteins  
RL: BIOL (Biological study)  
(filaggrins, pro-, gene for, mapping on rat chromosome of)

IT Proteins, specific or class  
RL: BIOL (Biological study)  
(gene B, gene for, linkage mapping of rat)

IT Proteins, specific or class  
RL: BIOL (Biological study)  
(gene C, gene for, linkage mapping of rat)

IT Proteins, specific or class  
RL: BIOL (Biological study)  
(gene H, gene for, linkage mapping of rat)

IT Phosphoproteins  
RL: BIOL (Biological study)  
(gene c-myc, gene for, mapping on rat chromosome of)

IT Proteins, specific or class  
RL: BIOL (Biological study)  
(gene s-myc, gene for, mapping on rat chromosome of)

IT Corticosteroids  
RL: BIOL (Biological study)  
(gluco-, receptors, gene for, mapping on rat chromosome of)

IT Receptors  
RL: BIOL (Biological study)  
(glucocorticosteroid, gene for, mapping on rat chromosome of)

IT Proteins, specific or class  
RL: BIOL (Biological study)  
(glucose-transporting, gene for, mapping on rat chromosome of)

IT Ribonucleic acids, transfer  
RL: BIOL (Biological study)

(glutamic acid-specific, gene for, mapping on rat chromosome of)  
IT Ribonucleic acids, transfer  
RL: BIOL (Biological study)  
(glycine-specific, gene for, mapping on rat chromosome of)  
IT Lymphokines and Cytokines  
RL: BIOL (Biological study)  
(interleukin 6, gene for, mapping on rat chromosome of)  
IT Ribonucleic acids, transfer  
RL: BIOL (Biological study)  
(leucine-specific, gene for, mapping on rat chromosome of)  
IT Sialoglycoproteins  
RL: BIOL (Biological study)  
(leukosialins, gene for, mapping on rat chromosome of)  
IT Agglutinins and Lectins  
RL: BIOL (Biological study)  
(mannose-binding protein A, gene for, mapping on rat chromosome of)  
IT Deoxyribonucleic acids  
RL: BIOL (Biological study)  
(microsatellite, polymerase chain reaction-analyzed, for rat gene mapping)  
IT Receptors  
RL: BIOL (Biological study)  
(muscarinic M3, gene for, mapping on rat chromosome of)  
IT Receptors  
RL: BIOL (Biological study)  
(nerve growth factor, gene for, mapping on rat chromosome of)  
IT Proteins, specific or class  
RL: BIOL (Biological study)  
(peripherins (eye rod outer segment), gene for, mapping on rat chromosome of)  
IT Proteins, specific or class  
RL: BIOL (Biological study)  
(phosphorylation-uncoupling, gene for, mapping on rat chromosome of)  
IT Proteins, specific or class  
RL: BIOL (Biological study)  
(potassium channel-forming, voltage-regulated, gene for, mapping on rat chromosome of)  
IT Receptors  
RL: BIOL (Biological study)  
(prolactin, gene for, mapping on rat chromosome of)  
IT Glycoproteins, specific or class  
RL: BIOL (Biological study)  
(prostateins, C2, gene for, mapping on rat chromosome of)  
IT Gene, animal  
RL: BIOL (Biological study)  
(pseudo-, mapping of rat, PCR-analyzed microsatellite DNA in)  
IT Chromosome  
(rat 1, gene mapping on, PCR-analyzed microsatellite DNA in)  
IT Chromosome  
(rat 10, gene mapping on, PCR-analyzed microsatellite DNA in)  
IT Chromosome  
(rat 13, gene mapping on, PCR-analyzed microsatellite DNA in)  
IT Chromosome  
(rat 14, gene mapping on, PCR-analyzed microsatellite DNA in)  
IT Chromosome  
(rat 15, gene mapping on, PCR-analyzed microsatellite DNA in)  
IT Chromosome  
(rat 16, gene mapping on, PCR-analyzed microsatellite DNA in)  
IT Chromosome  
(rat 17, gene mapping on, PCR-analyzed microsatellite DNA in)

IT Chromosome  
     (rat 18, gene mapping on, PCR-analyzed microsatellite DNA in)

IT Chromosome  
     (rat 19, gene mapping on, PCR-analyzed microsatellite DNA in)

IT Chromosome  
     (rat 2, gene mapping on, PCR-analyzed microsatellite DNA in)

IT Chromosome  
     (rat 20, gene mapping on, PCR-analyzed microsatellite DNA in)

IT Chromosome  
     (rat 3, gene mapping on, PCR-analyzed microsatellite DNA in)

IT Chromosome  
     (rat 4, gene mapping on, PCR-analyzed microsatellite DNA in)

IT Chromosome  
     (rat 5, gene mapping on, PCR-analyzed microsatellite DNA in)

IT Chromosome  
     (rat 6, gene mapping on, PCR-analyzed microsatellite DNA in)

IT Chromosome  
     (rat 7, gene mapping on, PCR-analyzed microsatellite DNA in)

IT Chromosome  
     (rat 8, gene mapping on, PCR-analyzed microsatellite DNA in)

IT Chromosome  
     (rat 9, gene mapping on, PCR-analyzed microsatellite DNA in)

IT Chromosome  
     (rat X, gene mapping on, PCR-analyzed microsatellite DNA in)

IT Androgens  
     RL: BIOL (Biological study)  
         (receptors, gene for, mapping on rat chromosome of)

IT Receptors  
     RL: BIOL (Biological study)  
         (serotonergic 51A, gene for, mapping on rat chromosome of)

IT Proteins, specific or class  
     RL: BIOL (Biological study)  
         (sodium channel-forming, II, gene for, mapping on rat chromosome of)

IT Receptors  
     RL: BIOL (Biological study)  
         (tachykinin NK1, gene for, mapping on rat chromosome of)

IT Kinins (animal hormones)  
     RL: BIOL (Biological study)  
         (tachykinin NK1 receptors, gene for, mapping on rat chromosome of)

IT Lymphokines and Cytokines  
     RL: BIOL (Biological study)  
         (tumor necrosis factor, gene for, mapping on rat chromosome of)

IT Gene, animal  
     RL: BIOL (Biological study)  
         (B, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
     RL: BIOL (Biological study)  
         (FGG, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
     RL: BIOL (Biological study)  
         (FH, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
     RL: BIOL (Biological study)  
         (GDC-1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
     RL: BIOL (Biological study)

(GC, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(GH, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(GRL, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(KAL, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(Lap-1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(TGFA, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(TAT, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(TCP1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(TNF, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(TRY1, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(Thy-1, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(Ucp, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(MBP, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(MDH2, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)  
(IGF2, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
RL: BIOL (Biological study)

(IL-6, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Caseins, biological studies  
 Fetoproteins  
 Lactalbumins  
 Tropomyosins  
 RL: BIOL (Biological study)  
 (.alpha.-, gene for, mapping on rat chromosome of)

IT Animal growth regulators  
 RL: BIOL (Biological study)  
 (.alpha.-transforming growth factors, gene for, mapping on rat chromosome of)

IT Receptors  
 RL: BIOL (Biological study)  
 (.alpha.1B-adrenergic, gene for, mapping on rat chromosome of)

IT Macroglobulins  
 RL: BIOL (Biological study)  
 (.alpha.2-, gene for, mapping on rat chromosome of)

IT Globulins, biological studies  
 RL: BIOL (Biological study)  
 (.alpha.2u-, gene for, mapping on rat chromosome of)

IT Receptors  
 RL: BIOL (Biological study)  
 (.beta.2-adrenergic, gene for, mapping on rat chromosome of)

IT Crystallins  
 RL: BIOL (Biological study)  
 (.gamma.-, gene for, mapping on rat chromosome of)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (ALB, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (A2M, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (ACO1, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (APOC3, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Abp, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Ace, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Acph, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Afp, mapping of, on rat chromosome, PCR-analyzed microsatellite DNA in)

IT Gene, animal



RL: BIOL (Biological study)  
 (Ahd-2, linkage mapping of, on rat chromosome, PCR-analyzed  
 microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Amy-1, linkage mapping of, on rat chromosome, PCR-analyzed  
 microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Ar, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Asgr, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (C, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (CTRB, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (CPA, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (CRYG, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Cat, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (ENO2, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Es-2, linkage mapping of, on rat chromosome, PCR-analyzed  
 microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Es-3, linkage mapping of, on rat chromosome, PCR-analyzed  
 microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (H, linkage mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (HBB, linkage mapping of, on rat chromosome, PCR-analyzed  
 microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Hp, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal

RL: BIOL (Biological study)  
 (Htr-1a, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (NPY, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (PKC, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (PND, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (PPY, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (PRPS2, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Pep-3, linkage mapping of, on rat chromosome, PCR-analyzed  
 microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Pgd, linkage mapping of, on rat chromosome, PCR-analyzed  
 microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Pthlh, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (RT1, linkage mapping of, on rat chromosome, PCR-analyzed  
 microsatellite DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (REN, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (SYB2, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (Smst, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (c-myc, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (ckb, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal

RL: BIOL (Biological study)  
 (lca, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (prl, mapping of, on rat chromosome, PCR-analyzed microsatellite  
 DNA in)

IT Gene, animal  
 RL: BIOL (Biological study)  
 (svp-1, linkage mapping of, on rat chromosome, PCR-analyzed  
 microsatellite DNA in)

IT 9000-92-4, Amylase 9001-10-9, Pepsinogen A 9028-71-1 9075-65-4,  
 .alpha.-Glycerophosphate dehydrogenase  
 RL: PRP (Properties)  
 (1, gene for, linkage mapping of rat)

IT 9004-06-2, Elastase  
 RL: PRP (Properties)  
 (1, gene for, mapping on rat chromosome of)

IT 9013-79-0, Esterase  
 RL: PRP (Properties)  
 (2 and 3 and 6, gene for, linkage mapping of rat)

IT 9028-86-8, Aldehyde dehydrogenase  
 RL: PRP (Properties)  
 (2, gene for, linkage mapping of rat)

IT 9014-08-8 11075-17-5, Carboxypeptidase A  
 RL: PRP (Properties)  
 (2, gene for, mapping on rat chromosome of)

IT 9031-96-3, Peptidase  
 RL: PRP (Properties)  
 (3, gene for, linkage mapping of rat)

IT 9029-97-4  
 RL: PRP (Properties)  
 (A, gene for, mapping on rat chromosome of)

IT 9004-07-3, Chymotrypsin B  
 RL: PRP (Properties)  
 (B, gene for, mapping on rat chromosome of)

IT 9024-25-3, Aconitase  
 RL: PRP (Properties)  
 (I, gene for, linkage mapping of rat)

IT 9002-07-7, Trypsin  
 RL: PRP (Properties)  
 (I, gene for, mapping on rat chromosome of)

IT 9001-59-6  
 RL: PRP (Properties)  
 (L type, gene for, mapping on rat chromosome of)

IT 9035-51-2, Cytochrome P 450, biological studies  
 RL: BIOL (Biological study)  
 (b/e, gene for, mapping on rat chromosome of)

IT 9015-83-2, Phosphoribosylpyrophosphate synthetase  
 RL: PRP (Properties)  
 (gene for subunit II of, mapping on rat chromosome of)

IT 57285-09-3, Inhibin  
 RL: PRP (Properties)  
 (gene for .alpha.-subunit of, mapping on rat chromosome of)

IT 9004-10-8, Insulin, biological studies  
 RL: BIOL (Biological study)  
 (gene for, linkage mapping of rat)

IT 9001-61-0, Leucine aminopeptidase 9001-82-5, Phosphogluconate  
 dehydrogenase 9030-88-0, Serine:pyruvate aminotransferase 9032-88-6,  
 Fumarate hydratase

RL: PRP (Properties)  
 (gene for, linkage mapping of rat)

IT 9002-62-4, Prolactin, biological studies 9002-72-6, Growth hormone  
 9015-94-5, Renin, biological studies  
 RL: BIOL (Biological study)  
 (gene for, mapping on rat chromosome of)

IT 1393-25-5, Secretin 9001-01-8, Kallikrein 9001-05-2, Catalase  
 9001-15-4 9001-36-9, Glucokinase 9013-08-5, Phosphoenolpyruvate  
 carboxykinase 9014-55-5, Tyrosine aminotransferase 9015-82-1,  
 Angiotensin I converting enzyme 9025-24-5, Carboxypeptidase B  
 9028-47-1D, malate dehydrogenase 9044-53-5, Steroid hydroxylase  
 9059-22-7, Heme oxygenase 11002-13-4, Angiotensinogen (protein renin  
 substrate) 37274-61-6, Isovaleryl-CoA dehydrogenase 51110-01-1,  
 Somatostatin 53414-68-9, Tonin 59763-91-6, Pancreatic  
**polypeptide** 67763-96-6, Insulin-like growth factor I  
 67763-97-7, Insulin-like growth factor II 73562-30-8, Acyl-peptide  
 hydrolase 78689-77-7 79747-53-8, Protein tyrosine phosphatase  
 81611-75-8 82785-45-3, Neuropeptide Y 85637-73-6, Atrial natriuretic  
 factor 103370-86-1, Humoral hypercalcemic factor 105844-41-5  
 117628-82-7, Follistatin  
 RL: PRP (Properties)  
 (gene for, mapping on rat chromosome of)

IT 102577-23-1, Neuromedin K  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (receptor, gene for, linkage mapping of rat)

IT 9061-61-4, Nerve growth factor 33507-63-0, Substance P  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (receptor, gene for, mapping on rat chromosome of)

IT 141436-78-4, Protein kinase C  
 RL: PRP (Properties)  
 (type I, gene for, mapping on rat chromosome of)

L12 ANSWER 11 OF 11 MEDLINE on STN  
 AN 93052391 MEDLINE  
 DN 93052391 PubMed ID: 1358809  
 TI Genetic map of nine polymorphic loci comprising a single linkage group on  
 rat chromosome 10: evidence for linkage conservation with human chromosome  
 17 and mouse **chromosome 11**.  
 AU Remmers E F; Goldmuntz E A; Cash J M; Crofford L J; Misiewicz-Poltorak B;  
 Zha H; Wilder R L  
 CS Arthritis and Rheumatism Branch, National Institute of Arthritis and  
 Musculoskeletal and Skin Diseases, National Institutes of Health,  
 Bethesda, Maryland 20892.  
 SO GENOMICS, (1992 Nov) 14 (3) 618-23.  
 Journal code: 8800135. ISSN: 0888-7543.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199212  
 ED Entered STN: 19930122  
 Last Updated on STN: 19950206  
 Entered Medline: 19921217  
 AB Seven genes and two anonymous markers were mapped to a single linkage  
 group on rat chromosome 10 using progeny of an F2 intercross of Fischer  
 (F344/N) and Lewis (LEW/N) inbred rats. Two genes, the neu oncogene or  
 cellular homologue of the viral oncogene erbb2 (ERBB2) and growth hormone  
 (GH) were mapped by Southern blot analysis of restriction fragment length  
 polymorphisms. Five genes, embryonic skeletal myosin heavy chain (MYH3),  
 androgen binding protein/sex hormone binding globulin (SHBG),

asialoglycoprotein receptor (hepatic lectin)-1 (ASGR1), ATP citrate lyase (CLATP), and pancreatic polypeptide (PPY), and two anonymous markers, F16F2 and F10F1, were mapped using PCR amplification techniques. The PCR-typable polymorphic markers for the five genes were also highly polymorphic in 10 other inbred rat strains (SHR/N, WKY/N, MNR/N, MR/N, LOU/MN, BN/SsN, BUF/N, WBB1/N, WBB2/N, and ACI/N). These markers should be useful in genetic analysis of traits described in inbred rat strains, as well as in genetic monitoring of such strains. The loci in this linkage group covered 50 cM of rat chromosome 10 with the following order: MYH3, SHBG/ASGR1 (no recombinants detected), F16F2, ERBB2, CLATP, PPY, GH, and F10F1. Comparative gene mapping analysis indicated that this region of rat chromosome 10 exhibits linkage conservation with regions of human chromosome 17 and mouse chromosome 11.



=> fil reg

FILE 'REGISTRY' ENTERED AT 07:46:32 ON 29 SEP 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 26 SEP 2003 HIGHEST RN 593958-55-5  
 DICTIONARY FILE UPDATES: 26 SEP 2003 HIGHEST RN 593958-55-5

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
 PROPERTIES for more information. See STNote 27, Searching Properties  
 in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d que 113

L13 4 SEA FILE=REGISTRY ABB=ON PLU=ON SS3939/BI

=> d sqide3 113 1-4

L13 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 280786-71-2 REGISTRY  
 CN 249-374-Protein ss3939 (human) (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN 6: PN: WO0039296 SEQID: 6 claimed protein  
 FS PROTEIN SEQUENCE  
 SQL 126

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2000039296
	claimed
	SEQID 6

SEQ3 1 Trp-Ile-Cys-Arg-Lys-Arg-Lys-Arg-Glu-Gln-  
 11 Pro-Asp-Pro-Ser-Thr-Lys-Lys-Gln-His-Thr-  
 21 Ile-Trp-Pro-Ser-Pro-His-Gln-Gly-Asn-Ser-  
 31 Pro-Asp-Leu-Glu-Val-Tyr-Asn-Val-Ile-Arg-  
 41 Lys-Gln-Ser-Glu-Ala-Asp-Leu-Ala-Glu-Thr-  
 51 Arg-Pro-Asp-Leu-Lys-Asn-Ile-Ser-Phe-Arg-  
 61 Val-Cys-Ser-Gly-Glu-Ala-Thr-Pro-Asp-Asp-  
 71 Met-Ser-Cys-Asp-Tyr-Asp-Asn-Met-Ala-Val-  
 81 Asn-Pro-Ser-Glu-Ser-Gly-Phe-Val-Thr-Leu-  
 91 Val-Ser-Val-Glu-Ser-Gly-Phe-Val-Thr-Asn-  
 101 Asp-Ile-Tyr-Glu-Phe-Ser-Pro-Asp-Gln-Met-  
 111 Gly-Arg-Ser-Lys-Glu-Ser-Gly-Trp-Val-Glu-

121 Asn-Glu-Ile-Tyr-Gly-Tyr

MF Unspecified  
 CI MAN  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL  
     1 REFERENCES IN FILE CA (1907 TO DATE)  
     1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 280786-69-8 REGISTRY  
 CN 22-227-Protein ss3939 (human) (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN 5: PN: WO0039296 SEQID: 5 claimed protein  
 FS PROTEIN SEQUENCE  
 SQL 206

## PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2000039296
	claimed
	SEQID 5

SEQ3 1 Ala-Thr-Gly-Arg-Leu-Leu-Ser-Gly-Gln-Pro-  
 11 Val-Cys-Arg-Gly-Gly-Thr-Gln-Arg-Pro-Cys-  
 21 Tyr-Lys-Val-Ile-Tyr-Phe-His-Asp-Thr-Ser-  
 31 Arg-Arg-Leu-Asn-Phe-Glu-Glu-Ala-Lys-Glu-  
 41 Ala-Cys-Arg-Arg-Asp-Gly-Gly-Gln-Leu-Val-  
 51 Ser-Ile-Glu-Ser-Glu-Asp-Glu-Gln-Lys-Leu-  
 61 Ile-Glu-Lys-Phe-Ile-Glu-Asn-Leu-Leu-Pro-  
 71 Ser-Asp-Gly-Asp-Phe-Trp-Ile-Gly-Leu-Arg-  
 81 Arg-Arg-Glu-Glu-Lys-Gln-Ser-Asn-Ser-Thr-  
 91 Ala-Cys-Gln-Asp-Leu-Tyr-Ala-Trp-Thr-Asp-  
 101 Gly-Ser-Ile-Ser-Gln-Phe-Arg-Asn-Trp-Tyr-  
 111 Val-Asp-Glu-Pro-Ser-Cys-Gly-Ser-Glu-Val-  
 121 Cys-Val-Val-Met-Tyr-His-Gln-Pro-Ser-Ala-  
 131 Pro-Ala-Gly-Ile-Gly-Gly-Pro-Tyr-Met-Phe-  
 141 Gln-Trp-Asn-Asp-Asp-Arg-Cys-Asn-Met-Lys-  
 151 Asn-Asn-Phe-Ile-Cys-Lys-Tyr-Ser-Asp-Glu-  
 161 Lys-Pro-Ala-Val-Pro-Ser-Arg-Glu-Ala-Glu-  
 171 Gly-Glu-Glu-Thr-Glu-Leu-Thr-Thr-Pro-Val-  
 181 Leu-Pro-Glu-Glu-Thr-Gln-Glu-Glu-Asp-Ala-  
 191 Lys-Lys-Thr-Phe-Lys-Glu-Ser-Arg-Glu-Ala-  
 201 Ala-Leu-Asn-Leu-Ala-Tyr

MF Unspecified  
 CI MAN  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL  
     1 REFERENCES IN FILE CA (1907 TO DATE)  
     1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
     1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 280786-68-7 REGISTRY  
 CN Protein ss3939 (human) (9CI) (CA INDEX NAME)  
 OTHER NAMES:

CN 1175: PN: WO0190304 SEQID: 2579 claimed protein  
 CN 15: PN: WO0142285 SEQID: 15 claimed protein  
 CN 2: PN: WO0039296 SEQID: 2 claimed protein  
 CN Protein (human clone HSLKC45)  
 CN Protein XMAD-15 (extracellular matrix and cell adhesion molecule) (human  
 Incyte clone 3143411CD1 precursor)  
 FS PROTEIN SEQUENCE  
 SQL 374

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2000039296 claimed SEQID 2
	WO2001042285 claimed SEQID 15
	WO2001090304 claimed SEQID 2579

SEQ3 1 Met-Arg-Pro-Gly-Thr-Ala-Leu-Gln-Ala-Val-  
 11 Leu-Leu-Ala-Val-Leu-Leu-Val-Gly-Leu-Arg-  
 21 Ala-Ala-Thr-Gly-Arg-Leu-Leu-Ser-Gly-Gln-  
 31 Pro-Val-Cys-Arg-Gly-Gly-Thr-Gln-Arg-Pro-  
 41 Cys-Tyr-Lys-Val-Ile-Tyr-Phe-His-Asp-Thr-  
 51 Ser-Arg-Arg-Leu-Asn-Phe-Glu-Glu-Ala-Lys-  
 61 Glu-Ala-Cys-Arg-Arg-Asp-Gly-Gly-Gln-Leu-  
 71 Val-Ser-Ile-Glu-Ser-Glu-Asp-Glu-Gln-Lys-  
 81 Leu-Ile-Glu-Lys-Phe-Ile-Glu-Asn-Leu-Leu-  
 91 Pro-Ser-Asp-Gly-Asp-Phe-Trp-Ile-Gly-Leu-  
 101 Arg-Arg-Arg-Glu-Glu-Lys-Gln-Ser-Asn-Ser-  
 111 Thr-Ala-Cys-Gln-Asp-Leu-Tyr-Ala-Trp-Thr-  
 121 Asp-Gly-Ser-Ile-Ser-Gln-Phe-Arg-Asn-Trp-  
 131 Tyr-Val-Asp-Glu-Pro-Ser-Cys-Gly-Ser-Glu-  
 141 Val-Cys-Val-Val-Met-Tyr-His-Gln-Pro-Ser-  
 151 Ala-Pro-Ala-Gly-Ile-Gly-Gly-Pro-Tyr-Met-  
 161 Phe-Gln-Trp-Asn-Asp-Asp-Arg-Cys-Asn-Met-  
 171 Lys-Asn-Asn-Phe-Ile-Cys-Lys-Tyr-Ser-Asp-  
 181 Glu-Lys-Pro-Ala-Val-Pro-Ser-Arg-Glu-Ala-  
 191 Glu-Gly-Glu-Glu-Thr-Glu-Leu-Thr-Thr-Pro-  
 201 Val-Leu-Pro-Glu-Glu-Thr-Gln-Glu-Glu-Asp-  
 211 Ala-Lys-Lys-Thr-Phe-Lys-Glu-Ser-Arg-Glu-  
 221 Ala-Ala-Leu-Asn-Leu-Ala-Tyr-Ile-Leu-Ile-  
 231 Pro-Ser-Ile-Pro-Leu-Leu-Leu-Leu-Leu-Val-  
 241 Val-Thr-Thr-Val-Val-Cys-Trp-Val-Trp-Ile-  
 251 Cys-Arg-Lys-Arg-Lys-Arg-Glu-Gln-Pro-Asp-  
 261 Pro-Ser-Thr-Lys-Lys-Gln-His-Thr-Ile-Trp-  
 271 Pro-Ser-Pro-His-Gln-Gly-Asn-Ser-Pro-Asp-  
 281 Leu-Glu-Val-Tyr-Asn-Val-Ile-Arg-Lys-Gln-  
 291 Ser-Glu-Ala-Asp-Leu-Ala-Glu-Thr-Arg-Pro-  
 301 Asp-Leu-Lys-Asn-Ile-Ser-Phe-Arg-Val-Cys-  
 311 Ser-Gly-Glu-Ala-Thr-Pro-Asp-Asp-Met-Ser-  
 321 Cys-Asp-Tyr-Asp-Asn-Met-Ala-Val-Asn-Pro-  
 331 Ser-Glu-Ser-Gly-Phe-Val-Thr-Leu-Val-Ser-

341 Val-Glu-Ser-Gly-Phe-Val-Thr-Asn-Asp-Ile-  
 351 Tyr-Glu-Phe-Ser-Pro-Asp-Gln-Met-Gly-Arg-  
 361 Ser-Lys-Glu-Ser-Gly-Trp-Val-Glu-Asn-Glu-  
 371 Ile-Tyr-Gly-Tyr

## \*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

3 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN

RN 280786-67-6 REGISTRY

CN DNA (human protein ss3939 cDNA plus flanks) (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN 1: PN: WO0039296 SEQID: 1 claimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 2005

NA 564 a 469 c 514 g 458 t

NTE doublestranded

## PATENT ANNOTATIONS (PNTE):

Sequence | Patent

Source | Reference

=====+=====

Homo sapiens | WO2000039296

| claimed

| SEQID 1

```

SEQ      1  tgtcgcgcac  gcctctgccc  gccagcccgc  tccaccgccc  tagcgcgccga
      51  gtgtcggggg  gcgcacccga  gtcggggccat  gaggccggga  accgcgctac
     101  aggccgtgct  gctggccgtg  ctgctggtgg  ggctgcgggc  cgcgacgggt
     151  cgcctgctga  gtgggcagcc  agtctgccgg  ggagggacac  agaggccttg
     201  ttataaagtc  atttacttcc  atgatacttc  tcgaagactg  aactttgagg
     251  aagccaaaga  agcctgcagg  agggatggag  gccagctagt  cagcatcgag
     301  tctgaagatg  aacagaaact  gatagaaaag  ttcattgaaa  acctcttgcc
     351  atctgatggt  gacttctgga  ttgggctcag  gaggcgtgag  gagaaacaaa
     401  gcaatagcac  agcctgccag  gacctttatg  cttggactga  tggcagcata
     451  tcacaattta  ggaactggta  tgtggatgag  ccgtcctgcg  gcagcgaggt
     501  ctgcgtggtc  atgtaccatc  agccatcggc  acccgctggc  atcggaggcc
     551  cctacatggt  ccagtggaat  gatgaccggt  gcaacatgaa  gaacaatttc
     601  atttgcaaata  attctgatga  gaaaccagca  gttccttcta  gagaagctga
     651  aggtgaggaa  acagagctga  caacacctgt  acttccagaa  gaaacacagg
     701  aagaagatgc  caaaaaaaca  tttaaagaaa  gtagagaagc  tgccttgaat
     751  ctggcctaca  tcctaatacc  cagcattccc  cttctcctcc  tccttggtgt
     801  caccacagtt  gtatgttggg  tttggatctg  tagaaaaaga  aaacgggagc
     851  agccagaccc  tagcaciaag  aagcaacaca  ccatctggcc  ctctcctcac
     901  cagggaaaca  gcccgacact  agaggtctac  aatgtcataa  gaaaacaaag
     951  cgaagctgac  ttagctgaga  cccggccaga  cctgaagaat  atttcattcc
    1001  gagtgtgttc  gggagaagcc  actcccgatg  acatgtcttg  tgactatgac
    1051  aacatggctg  tgaacccatc  agaaagtggg  tttgtgactc  tgggtgagcgt
    1101  ggagagtggg  tttgtgacca  atgacattta  tgagttctcc  ccagacccaa
    1151  tggggaggag  taaggagtct  ggatgggtgg  aaaatgaaat  atatggttat
    1201  taggacatat  aaaaaactga  aactgacaac  aatggaaaag  aatgataag
  
```

```

1251 caaaatcctc ttatttttcta taaggaaaat acacagaagg tctatgaaca
1301 agcttagatc aggtcctgtg gatgagcatg tggccccac gacctcctgt
1351 tggaccccca cgttttggct gtatccttta tcccagccag tcatccagct
1401 cgaccttatg agaaggtacc ttgcccaggt ctggcacata gtagagtctc
1451 aataaatgtc acttggttgg ttgtatctaa cttttaaggg acagagcttt
1501 acctggcagt gataaagatg ggctgtggag cttggaaaac cacctctgtt
1551 ttccttgctc tatacagcag cacatattat catacagaca gaaaatccag
1601 aatcttttca aagcccacat atggtagcac aggttggcct gtgcatcggc
1651 aattctcata tctgtttttt tcaaagaata aaatcaaata aagagcagga
1701 aacagagtgt tagtctgtgt ctacagccct tcctctgcat gtggccacag
1751 gggacctttt tttgtttctc ctgacatcca gacttggaaa tatctaacta
1801 cttgcaaaac taaaaatgag gccaggcgca gtggctgacg cctgtaatcc
1851 cagaaccttg ggagaccaag attggaggat agcttgagtt caggagtcc
1901 agaccttcct gggcaaaaata gtgagactct gactctacaa aaaatttaaa
1951 aattagcagg gcatggtggc atg'gcctgc agtcccagct actcaggagg
2001 ccgag

```

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 07:47:00 ON 29 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Sep 2003 VOL 139 ISS 14

FILE LAST UPDATED: 28 Sep 2003 (20030928/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d que 114

L13 4 SEA FILE=REGISTRY ABB=ON PLU=ON SS3939/BI

L14 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L13

=> d bib 114 1-3

L14 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:868629 HCAPLUS

DN 136:15957



TI Human nucleic acids and their encoded proteins and antibodies  
 IN Birse, Charles E.; Rosen, Craig A.  
 PA Human Genome Sciences, Inc.; USA  
 SO PCT Int. Appl., 2081 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 91

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090304	A2	20011129	WO 2001-US16450	20010518
	WO 2001090304	A3	20020510		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001041411	A5	20010820	AU 2001-41411	20010208
	AU 2001074888	A5	20011203	AU 2001-74888	20010518
PRAI	US 2000-205515P	P	20000519		
	US 2000-241221P	P	20001020		
	US 2000-241786P	P	20001020		
	WO 2001-US16450	W	20010518		

L14 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:435111 HCAPLUS

DN 135:29911

TI DNA encoding twenty-one human extracellular matrix and cell adhesion molecules

IN Yue, Henry; Tang, Y. Tom; Lal, Preeti; Burford, Neil; Azimzai, Yalda; Patterson, Chandra; Baughn, Mariah R.; Lu, Dyung Aina M.; Shah, Purvi; Au-young, Janice

PA Incyte Genomics, Inc., USA; et al.

SO PCT Int. Appl., 135 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042285	A2	20010614	WO 2000-US32990	20001205
	WO 2001042285	A3	20020307		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1244695	A2	20021002	EP 2000-989218	20001205
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2003044913	A1	20030306	US 2002-149819	20020610
PRAI	US 1999-172852P	P	19991210		

US 1999-172354P P 19991216  
WO 2000-US32990 W 20001205

L14 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN  
AN 2000:457208 HCAPLUS  
DN 133:85160  
TI Protein and cDNA sequences of human protein ss3939, which has homology to  
C-type lectins  
IN Anderson, Dirk A.  
PA Immunex Corporation, USA  
SO PCT Int. Appl., 73 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039296	A1	20000706	WO 1999-US30523	19991222
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2002058310	A1	20020516	US 2001-887855	20010622
PRAI	US 1998-113820P	P	19981223		
	WO 1999-US30523	A1	19991222		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT